Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10823093,peripheral volume of distribution,"Although isoflurane and sevoflurane have almost the same tissue/blood partition coefficients, significant differences between substances were observed for the peripheral volume of distribution (medians and ranges: desflurane, 612 (343-1850) mlvapour kgbw-1; isoflurane, 4112 (1472-9396) mlvapour kgbw-1; sevoflurane, 1634 (762-8843) mlvapour kgbw-1) and the transport clearance from the central to the peripheral compartment (desflurane, 7.0 (4.4-11.1) mlvapour kgbw-1 min-1; isoflurane, 30.7 (15.9-38.7) mlvapour kgbw-1 min-1; sevoflurane, 13.0 (9.8-22.4) mlvapour kgbw-1 min-1).","Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823093/),[mlvapour] / [kgbw],612,381,DB00753,Isoflurane
,10823093,peripheral volume of distribution,"Although isoflurane and sevoflurane have almost the same tissue/blood partition coefficients, significant differences between substances were observed for the peripheral volume of distribution (medians and ranges: desflurane, 612 (343-1850) mlvapour kgbw-1; isoflurane, 4112 (1472-9396) mlvapour kgbw-1; sevoflurane, 1634 (762-8843) mlvapour kgbw-1) and the transport clearance from the central to the peripheral compartment (desflurane, 7.0 (4.4-11.1) mlvapour kgbw-1 min-1; isoflurane, 30.7 (15.9-38.7) mlvapour kgbw-1 min-1; sevoflurane, 13.0 (9.8-22.4) mlvapour kgbw-1 min-1).","Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823093/),[mlvapour] / [kgbw],4112,382,DB00753,Isoflurane
,10823093,peripheral volume of distribution,"Although isoflurane and sevoflurane have almost the same tissue/blood partition coefficients, significant differences between substances were observed for the peripheral volume of distribution (medians and ranges: desflurane, 612 (343-1850) mlvapour kgbw-1; isoflurane, 4112 (1472-9396) mlvapour kgbw-1; sevoflurane, 1634 (762-8843) mlvapour kgbw-1) and the transport clearance from the central to the peripheral compartment (desflurane, 7.0 (4.4-11.1) mlvapour kgbw-1 min-1; isoflurane, 30.7 (15.9-38.7) mlvapour kgbw-1 min-1; sevoflurane, 13.0 (9.8-22.4) mlvapour kgbw-1 min-1).","Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823093/),[mlvapour] / [kgbw],1634,383,DB00753,Isoflurane
,10823093,transport clearance from,"Although isoflurane and sevoflurane have almost the same tissue/blood partition coefficients, significant differences between substances were observed for the peripheral volume of distribution (medians and ranges: desflurane, 612 (343-1850) mlvapour kgbw-1; isoflurane, 4112 (1472-9396) mlvapour kgbw-1; sevoflurane, 1634 (762-8843) mlvapour kgbw-1) and the transport clearance from the central to the peripheral compartment (desflurane, 7.0 (4.4-11.1) mlvapour kgbw-1 min-1; isoflurane, 30.7 (15.9-38.7) mlvapour kgbw-1 min-1; sevoflurane, 13.0 (9.8-22.4) mlvapour kgbw-1 min-1).","Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823093/),[mlvapour] / [kgbw·min],7.0,384,DB00753,Isoflurane
,10823093,transport clearance from,"Although isoflurane and sevoflurane have almost the same tissue/blood partition coefficients, significant differences between substances were observed for the peripheral volume of distribution (medians and ranges: desflurane, 612 (343-1850) mlvapour kgbw-1; isoflurane, 4112 (1472-9396) mlvapour kgbw-1; sevoflurane, 1634 (762-8843) mlvapour kgbw-1) and the transport clearance from the central to the peripheral compartment (desflurane, 7.0 (4.4-11.1) mlvapour kgbw-1 min-1; isoflurane, 30.7 (15.9-38.7) mlvapour kgbw-1 min-1; sevoflurane, 13.0 (9.8-22.4) mlvapour kgbw-1 min-1).","Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823093/),[mlvapour] / [kgbw·min],30.7,385,DB00753,Isoflurane
,10823093,transport clearance from,"Although isoflurane and sevoflurane have almost the same tissue/blood partition coefficients, significant differences between substances were observed for the peripheral volume of distribution (medians and ranges: desflurane, 612 (343-1850) mlvapour kgbw-1; isoflurane, 4112 (1472-9396) mlvapour kgbw-1; sevoflurane, 1634 (762-8843) mlvapour kgbw-1) and the transport clearance from the central to the peripheral compartment (desflurane, 7.0 (4.4-11.1) mlvapour kgbw-1 min-1; isoflurane, 30.7 (15.9-38.7) mlvapour kgbw-1 min-1; sevoflurane, 13.0 (9.8-22.4) mlvapour kgbw-1 min-1).","Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823093/),[mlvapour] / [kgbw·min],13.0,386,DB00753,Isoflurane
,3778789,volume of distribution (area),"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [kg],139,1595,DB00753,Isoflurane
,3778789,volume of distribution (area),"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [kg],152,1596,DB00753,Isoflurane
,3778789,clearance,"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [kg·min],5.1,1597,DB00753,Isoflurane
,3778789,clearance,"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [kg·min],5.3,1598,DB00753,Isoflurane
,3778789,T1/2 alpha,"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),min,2.1,1599,DB00753,Isoflurane
,3778789,T1/2 alpha,"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),min,2.0,1600,DB00753,Isoflurane
,3778789,T1/2 beta,"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),min,19.1,1601,DB00753,Isoflurane
,3778789,T1/2 beta,"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),min,20.3,1602,DB00753,Isoflurane
,3778789,volume of distribution (area),There were significant differences in volume of distribution (area) (176 v. 139 ml kg-1) and in clearance of atracurium (9.1 v.,Pharmacokinetics of atracurium in anaesthetized infants and children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [kg],176,1603,DB00753,Isoflurane
,3778789,volume of distribution (area),There were significant differences in volume of distribution (area) (176 v. 139 ml kg-1) and in clearance of atracurium (9.1 v.,Pharmacokinetics of atracurium in anaesthetized infants and children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [kg],139,1604,DB00753,Isoflurane
,3778789,clearance,There were significant differences in volume of distribution (area) (176 v. 139 ml kg-1) and in clearance of atracurium (9.1 v.,Pharmacokinetics of atracurium in anaesthetized infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),,9.1,1605,DB00753,Isoflurane
,3778789,clearance,"In infants the clearance of atracurium in ml m-2 min-1 (153 v. 133) tended to be greater and the T1/2 alpha and T1/2 beta tended to be shorter (1.0 v. 2.0 and 13.6 v. 19.1) than in children with normal excretory function; however, these trends did not reach statistical significance.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [(m)^2·min],153,1606,DB00753,Isoflurane
,3778789,clearance,"In infants the clearance of atracurium in ml m-2 min-1 (153 v. 133) tended to be greater and the T1/2 alpha and T1/2 beta tended to be shorter (1.0 v. 2.0 and 13.6 v. 19.1) than in children with normal excretory function; however, these trends did not reach statistical significance.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [(m)^2·min],133,1607,DB00753,Isoflurane
,3778789,T1/2 alpha,"In infants the clearance of atracurium in ml m-2 min-1 (153 v. 133) tended to be greater and the T1/2 alpha and T1/2 beta tended to be shorter (1.0 v. 2.0 and 13.6 v. 19.1) than in children with normal excretory function; however, these trends did not reach statistical significance.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [(m)^2·min],1.0,1608,DB00753,Isoflurane
,3778789,T1/2 beta,"In infants the clearance of atracurium in ml m-2 min-1 (153 v. 133) tended to be greater and the T1/2 alpha and T1/2 beta tended to be shorter (1.0 v. 2.0 and 13.6 v. 19.1) than in children with normal excretory function; however, these trends did not reach statistical significance.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),,2.0,1609,DB00753,Isoflurane
,3778789,T1/2 beta,"In infants the clearance of atracurium in ml m-2 min-1 (153 v. 133) tended to be greater and the T1/2 alpha and T1/2 beta tended to be shorter (1.0 v. 2.0 and 13.6 v. 19.1) than in children with normal excretory function; however, these trends did not reach statistical significance.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),,13.6,1610,DB00753,Isoflurane
,3778789,T1/2 beta,"In infants the clearance of atracurium in ml m-2 min-1 (153 v. 133) tended to be greater and the T1/2 alpha and T1/2 beta tended to be shorter (1.0 v. 2.0 and 13.6 v. 19.1) than in children with normal excretory function; however, these trends did not reach statistical significance.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),,19.1,1611,DB00753,Isoflurane
,2400116,blood/gas partition coefficient,"The blood/gas partition coefficient of desflurane (0.35 +/- 0.02) was significantly smaller (P less than 0.01) than that of sevoflurane (0.45 +/- 0.02), isoflurane (0.94 +/- 0.05), and halothane (2.54 +/- 0.21).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),,0.35,2177,DB00753,Isoflurane
,2400116,blood/gas partition coefficient,"The blood/gas partition coefficient of desflurane (0.35 +/- 0.02) was significantly smaller (P less than 0.01) than that of sevoflurane (0.45 +/- 0.02), isoflurane (0.94 +/- 0.05), and halothane (2.54 +/- 0.21).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),,0.45,2178,DB00753,Isoflurane
,2400116,blood/gas partition coefficient,"The blood/gas partition coefficient of desflurane (0.35 +/- 0.02) was significantly smaller (P less than 0.01) than that of sevoflurane (0.45 +/- 0.02), isoflurane (0.94 +/- 0.05), and halothane (2.54 +/- 0.21).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),,0.94,2179,DB00753,Isoflurane
,2400116,blood/gas partition coefficient,"The blood/gas partition coefficient of desflurane (0.35 +/- 0.02) was significantly smaller (P less than 0.01) than that of sevoflurane (0.45 +/- 0.02), isoflurane (0.94 +/- 0.05), and halothane (2.54 +/- 0.21).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),,2.54,2180,DB00753,Isoflurane
,2400116,Recovery,"Recovery (normalized to that of isoflurane) of the volume of anesthetic taken up was significantly greater (P less than 0.05) for desflurane (93% +/- 7% [mean +/- SD]) than for halothane (77% +/- 6%), was not different from that of isoflurane (100%), but was less than that for sevoflurane (111% +/- 17%).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),%,93,2181,DB00753,Isoflurane
,2400116,Recovery,"Recovery (normalized to that of isoflurane) of the volume of anesthetic taken up was significantly greater (P less than 0.05) for desflurane (93% +/- 7% [mean +/- SD]) than for halothane (77% +/- 6%), was not different from that of isoflurane (100%), but was less than that for sevoflurane (111% +/- 17%).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),%,77,2182,DB00753,Isoflurane
,2400116,Recovery,"Recovery (normalized to that of isoflurane) of the volume of anesthetic taken up was significantly greater (P less than 0.05) for desflurane (93% +/- 7% [mean +/- SD]) than for halothane (77% +/- 6%), was not different from that of isoflurane (100%), but was less than that for sevoflurane (111% +/- 17%).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),%,111,2183,DB00753,Isoflurane
,14580052,infusion rates,"In the isoflurane group, lower infusion rates were needed (3.0 +/- 1.6 versus 3.6 +/- 1.6 microg kg(-1) min(-1)) and there was a slower recovery (significant for train-of-four ratio 70%: 21.9 versus 17.9 min).",Neuromuscular block and relative concentrations of mivacurium isomers under isoflurane versus propofol anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14580052/),[μg] / [kg·min],3.0,2929,DB00753,Isoflurane
,14580052,infusion rates,"In the isoflurane group, lower infusion rates were needed (3.0 +/- 1.6 versus 3.6 +/- 1.6 microg kg(-1) min(-1)) and there was a slower recovery (significant for train-of-four ratio 70%: 21.9 versus 17.9 min).",Neuromuscular block and relative concentrations of mivacurium isomers under isoflurane versus propofol anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14580052/),[μg] / [kg·min],3.6,2930,DB00753,Isoflurane
,14580052,train-of-four ratio,"In the isoflurane group, lower infusion rates were needed (3.0 +/- 1.6 versus 3.6 +/- 1.6 microg kg(-1) min(-1)) and there was a slower recovery (significant for train-of-four ratio 70%: 21.9 versus 17.9 min).",Neuromuscular block and relative concentrations of mivacurium isomers under isoflurane versus propofol anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14580052/),min,21.9,2931,DB00753,Isoflurane
,14580052,train-of-four ratio,"In the isoflurane group, lower infusion rates were needed (3.0 +/- 1.6 versus 3.6 +/- 1.6 microg kg(-1) min(-1)) and there was a slower recovery (significant for train-of-four ratio 70%: 21.9 versus 17.9 min).",Neuromuscular block and relative concentrations of mivacurium isomers under isoflurane versus propofol anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14580052/),min,17.9,2932,DB00753,Isoflurane
,3425871,Elimination half-life,Elimination half-life ranged from 0.72 to 15.06 h.,[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),h,0.72 to 15.06,3654,DB00753,Isoflurane
,3425871,Cl,Cl ranged from 2.5 to 12.8 ml/min per kilogram.,[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),[ml] / [kg·min],2.5 to 12.8,3655,DB00753,Isoflurane
,3425871,t1/2el,Four patients (= 9%) had a t1/2el of 7-15 h; in 16 cases we found secondary concentration peaks.,[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),h,7-15,3656,DB00753,Isoflurane
up to,3425871,half-life,"In accordance with others, we found some patients with a half-life of up to 15 h, which might reflect the influence of the anesthesia itself.",[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),h,15,3657,DB00753,Isoflurane
,8624002,Onset of,"Onset of block was delayed in the elderly; values being mean 3.0 (95% confidence interval 1.75-11.4) min and 4.0 (2.4-6.5) min in the young and elderly, respectively (P < 0.01).",Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),min,3.0,4027,DB00753,Isoflurane
,8624002,Onset of,"Onset of block was delayed in the elderly; values being mean 3.0 (95% confidence interval 1.75-11.4) min and 4.0 (2.4-6.5) min in the young and elderly, respectively (P < 0.01).",Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),min,4.0,4028,DB00753,Isoflurane
,8624002,Plasma clearance,Plasma clearance was 319 (293-345) ml/min in the study population and did not differ between young and elderly patients.,Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),[ml] / [min],319,4029,DB00753,Isoflurane
,8624002,Apparent volume of distribution,"Apparent volume of distribution was 13.28 (9.9-16.7) 1 and 9.6 (7.6-11.7) 1 in the elderly and young adults, respectively (P < 0.05).",Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),1,13.28,4030,DB00753,Isoflurane
,8624002,Apparent volume of distribution,"Apparent volume of distribution was 13.28 (9.9-16.7) 1 and 9.6 (7.6-11.7) 1 in the elderly and young adults, respectively (P < 0.05).",Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),1,9.6,4031,DB00753,Isoflurane
,8624002,rate of biophase equilibration (ke0),There also were differences in pharmacodynamic parameters between the young and elderly; the predominant change being a slower rate of biophase equilibration (ke0) in the elderly (0.060 [0.052-0.068])/min compared with the young (0.071 [0.065-0.077]/min; P < 0.05).,Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),,0.060,4032,DB00753,Isoflurane
,8624002,rate of biophase equilibration (ke0),There also were differences in pharmacodynamic parameters between the young and elderly; the predominant change being a slower rate of biophase equilibration (ke0) in the elderly (0.060 [0.052-0.068])/min compared with the young (0.071 [0.065-0.077]/min; P < 0.05).,Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),1/[min],0.071,4033,DB00753,Isoflurane
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8706,DB00753,Isoflurane
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],19.4,8707,DB00753,Isoflurane
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],688,8708,DB00753,Isoflurane
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],591,8709,DB00753,Isoflurane
,8678276,peak serum IFCs,In our study 1.69 MAC-h sevoflurane produced peak serum IFCs of 34.5 mumol/l.,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8710,DB00753,Isoflurane
,21672126,E'Iso,During the second phase anaesthesia was induced in a similar manner and E'Iso was set at 0.75 × MAC for each individual.,Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),Mac,0.75,18308,DB00753,Isoflurane
,21672126,target plasma concentrations,Fentanyl was infused IV to achieve target plasma concentrations between 8 and 32 ng mL(-1).,Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),[ng] / [ml],8 and 32,18309,DB00753,Isoflurane
,21672126,plasma concentrations,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),[ng] / [ml],0,18310,DB00753,Isoflurane
,21672126,plasma concentrations,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),[ng] / [ml],8.51,18311,DB00753,Isoflurane
,21672126,plasma concentrations,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),[ng] / [ml],14.85,18312,DB00753,Isoflurane
,21672126,MACs,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),[ng] / [ml],14.85,18313,DB00753,Isoflurane
,21672126,MACs,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),[ng] / [ml],29.25,18314,DB00753,Isoflurane
,21672126,MACs,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),%,2.05,18315,DB00753,Isoflurane
,21672126,MACs,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),%,1.42,18316,DB00753,Isoflurane
,21672126,MACs,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),%,1.14,18317,DB00753,Isoflurane
,21672126,MACs,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),%,0.93,18318,DB00753,Isoflurane
,24731563,clearance,"For rFVIIa, nephrectomy resulted in a clearance and terminal half-life of 34mL/h/kg and 2.8h compared to 68mL/h/kg and1.9h in rats exposed to sham surgery (p<0.0001 for both parameters).",The kidneys play an important role in the clearance of rFVIIa in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24731563/),[ml] / [h·kg],34,18872,DB00753,Isoflurane
,24731563,clearance,"For rFVIIa, nephrectomy resulted in a clearance and terminal half-life of 34mL/h/kg and 2.8h compared to 68mL/h/kg and1.9h in rats exposed to sham surgery (p<0.0001 for both parameters).",The kidneys play an important role in the clearance of rFVIIa in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24731563/),h,2.8,18873,DB00753,Isoflurane
,24731563,clearance,"For rFVIIa, nephrectomy resulted in a clearance and terminal half-life of 34mL/h/kg and 2.8h compared to 68mL/h/kg and1.9h in rats exposed to sham surgery (p<0.0001 for both parameters).",The kidneys play an important role in the clearance of rFVIIa in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24731563/),[ml] / [h·kg],68,18874,DB00753,Isoflurane
,24731563,terminal half-life,"For rFVIIa, nephrectomy resulted in a clearance and terminal half-life of 34mL/h/kg and 2.8h compared to 68mL/h/kg and1.9h in rats exposed to sham surgery (p<0.0001 for both parameters).",The kidneys play an important role in the clearance of rFVIIa in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24731563/),h,2.8,18875,DB00753,Isoflurane
,24731563,terminal half-life,"For rFVIIa, nephrectomy resulted in a clearance and terminal half-life of 34mL/h/kg and 2.8h compared to 68mL/h/kg and1.9h in rats exposed to sham surgery (p<0.0001 for both parameters).",The kidneys play an important role in the clearance of rFVIIa in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24731563/),h,1.9,18876,DB00753,Isoflurane
,33362765,terminal half-life,"In plasma, RMD mean terminal half-life was 15.3 h.",Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33362765/),h,15.3,20845,DB00753,Isoflurane
,33362765,terminal half-life,"In comparison, RMD mean terminal half-life was much longer in tissues: 110 h in the lymph nodes (LNs) and 28 h in gastrointestinal tract.",Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33362765/),h,110,20846,DB00753,Isoflurane
,33362765,terminal half-life,"In comparison, RMD mean terminal half-life was much longer in tissues: 110 h in the lymph nodes (LNs) and 28 h in gastrointestinal tract.",Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33362765/),h,28,20847,DB00753,Isoflurane
,16379643,MAC,The MAC of isoflurane was 1.43 +/- 0.18% (mean +/- SD).,"Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379643/),%,1.43,23068,DB00753,Isoflurane
,16379643,apparent volume of distribution of the central compartment,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, and the clearance were 371.3 +/- 162 mL/kg, 4,060.3 +/- 2,405.7 mL/kg, and 58.2 +/- 17.3 mL/min/kg, respectively.","Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379643/),[ml] / [kg],371.3,23069,DB00753,Isoflurane
,16379643,apparent volume of distribution at steady state,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, and the clearance were 371.3 +/- 162 mL/kg, 4,060.3 +/- 2,405.7 mL/kg, and 58.2 +/- 17.3 mL/min/kg, respectively.","Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379643/),[ml] / [kg],"4,060.3",23070,DB00753,Isoflurane
,16379643,clearance,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, and the clearance were 371.3 +/- 162 mL/kg, 4,060.3 +/- 2,405.7 mL/kg, and 58.2 +/- 17.3 mL/min/kg, respectively.","Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379643/),[ml] / [kg·min],58.2,23071,DB00753,Isoflurane
,16379643,terminal half-life,Norketamine rapidly appeared in plasma following ketamine administration and had a terminal half-life of 63.6 +/- 23.9 minutes.,"Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379643/),min,63.6,23072,DB00753,Isoflurane
,2001020,MAC,"The MAC of desflurane in O2 was 7.25 +/- 0.0 (mean +/- SD) in the 18-30-yr age group, and 6.0 +/- 0.29 in the 31-65-yr group; the addition of 60% N2O reduced the MAC to 4.0 +/- 0.29 and 2.83 +/- 0.58, respectively.",Clinical characteristics of desflurane in surgical patients: minimum alveolar concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001020/),,7.25,26707,DB00753,Isoflurane
,2001020,MAC,"The MAC of desflurane in O2 was 7.25 +/- 0.0 (mean +/- SD) in the 18-30-yr age group, and 6.0 +/- 0.29 in the 31-65-yr group; the addition of 60% N2O reduced the MAC to 4.0 +/- 0.29 and 2.83 +/- 0.58, respectively.",Clinical characteristics of desflurane in surgical patients: minimum alveolar concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001020/),,6.0,26708,DB00753,Isoflurane
,2001020,MAC,"The MAC of desflurane in O2 was 7.25 +/- 0.0 (mean +/- SD) in the 18-30-yr age group, and 6.0 +/- 0.29 in the 31-65-yr group; the addition of 60% N2O reduced the MAC to 4.0 +/- 0.29 and 2.83 +/- 0.58, respectively.",Clinical characteristics of desflurane in surgical patients: minimum alveolar concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001020/),,4.0,26709,DB00753,Isoflurane
,2001020,MAC,"The MAC of desflurane in O2 was 7.25 +/- 0.0 (mean +/- SD) in the 18-30-yr age group, and 6.0 +/- 0.29 in the 31-65-yr group; the addition of 60% N2O reduced the MAC to 4.0 +/- 0.29 and 2.83 +/- 0.58, respectively.",Clinical characteristics of desflurane in surgical patients: minimum alveolar concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001020/),,2.83,26710,DB00753,Isoflurane
,2001020,time,The median time from discontinuation of desflurane to an appropriate response to commands was 5.25 min.,Clinical characteristics of desflurane in surgical patients: minimum alveolar concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001020/),min,5.25,26711,DB00753,Isoflurane
,16167314,LOD,The LOD for all enantiomers is 0.01 microg/mL.,Characterization of the stereoselective biotransformation of ketamine to norketamine via determination of their enantiomers in equine plasma by capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16167314/),[μg] / [ml],0.01,28989,DB00753,Isoflurane
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],39.8,32819,DB00753,Isoflurane
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],28.3,32820,DB00753,Isoflurane
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],32.6,32821,DB00753,Isoflurane
,9350366,half-life,"With isoflurane, the approximated half-life of nicardipine (14 +/- 4 min) was shorter and clearance (2.1 +/- 0.3 l.min-1) more rapid.","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),min,14,32822,DB00753,Isoflurane
,9350366,clearance,"With isoflurane, the approximated half-life of nicardipine (14 +/- 4 min) was shorter and clearance (2.1 +/- 0.3 l.min-1) more rapid.","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[l] / [min],2.1,32823,DB00753,Isoflurane
,10655905,target plasma concentrations,"Dexmedetomidine target plasma concentrations were 0.0 (placebo), 0.3 ng ml-1 (low-dex) and 0.6 ng ml-1 (high-dex).",Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10655905/),,0.0,32927,DB00753,Isoflurane
,10655905,target plasma concentrations,"Dexmedetomidine target plasma concentrations were 0.0 (placebo), 0.3 ng ml-1 (low-dex) and 0.6 ng ml-1 (high-dex).",Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10655905/),[ng] / [ml],0.3,32928,DB00753,Isoflurane
,10655905,target plasma concentrations,"Dexmedetomidine target plasma concentrations were 0.0 (placebo), 0.3 ng ml-1 (low-dex) and 0.6 ng ml-1 (high-dex).",Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10655905/),[ng] / [ml],0.6,32929,DB00753,Isoflurane
,27473996,peak remifentanil concentration,Mean peak remifentanil concentration was 7.14ηgmL(-1) at 50min after start of infusion.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[ηgml],7.14,33193,DB00753,Isoflurane
,27473996,volume of distribution,Mean volume of distribution was 268±40mLkg(-1) and mean half-life was 12.8min.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[mlkg],268,33194,DB00753,Isoflurane
,27473996,half-life,Mean volume of distribution was 268±40mLkg(-1) and mean half-life was 12.8min.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),min,12.8,33195,DB00753,Isoflurane
,27473996,Limit of quantification,Limit of quantification was 0.2ηgmL(-1).,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[ηgml],0.2,33196,DB00753,Isoflurane
,32166760,Elimination half-lives,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),min,62.7,37893,DB00753,Isoflurane
,32166760,Elimination half-lives,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),min,30.1,37894,DB00753,Isoflurane
,32166760,steady-state volumes of distribution,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),[ml] / [kg],215,37895,DB00753,Isoflurane
,32166760,steady-state volumes of distribution,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),[ml] / [kg],744,37896,DB00753,Isoflurane
,32166760,clearances,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),[ml] / [kg·min],21.1,37897,DB00753,Isoflurane
,32166760,clearances,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),[ml] / [kg·min],48.6,37898,DB00753,Isoflurane
,32166760,times to stand,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),min,47,37899,DB00753,Isoflurane
,32166760,times to stand,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),min,53,37900,DB00753,Isoflurane
,32166760,recovery quality,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),mm,51,37901,DB00753,Isoflurane
,32166760,recovery quality,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),mm,61,37902,DB00753,Isoflurane
,7482686,initial distribution phase t1/2 pi,"The pharmacokinetic parameters were as follows: The mean (SD) of the initial distribution phase t1/2 pi, intermediate distribution phase t1/2 alpha, and elimination phase t1/2 beta were 2.22 (1.04) min, 42.9 (16.4) min, and 370 (138) min, respectively.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),min,2.22,39406,DB00753,Isoflurane
,7482686,intermediate distribution phase t1/2 alpha,"The pharmacokinetic parameters were as follows: The mean (SD) of the initial distribution phase t1/2 pi, intermediate distribution phase t1/2 alpha, and elimination phase t1/2 beta were 2.22 (1.04) min, 42.9 (16.4) min, and 370 (138) min, respectively.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),min,42.9,39407,DB00753,Isoflurane
,7482686,elimination phase t1/2 beta,"The pharmacokinetic parameters were as follows: The mean (SD) of the initial distribution phase t1/2 pi, intermediate distribution phase t1/2 alpha, and elimination phase t1/2 beta were 2.22 (1.04) min, 42.9 (16.4) min, and 370 (138) min, respectively.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),min,370,39408,DB00753,Isoflurane
,7482686,clearance,"The mean clearance of 1.31 (0.50) L/min was lower than those reported from other studies, whereas the mean blood concentration of 2.2 (1.0) mg/L at the 1-h infusion period was higher.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),[l] / [min],1.31,39409,DB00753,Isoflurane
,7482686,blood concentration,"The mean clearance of 1.31 (0.50) L/min was lower than those reported from other studies, whereas the mean blood concentration of 2.2 (1.0) mg/L at the 1-h infusion period was higher.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),mg,2.2,39410,DB00753,Isoflurane
,7482686,apparent Css,The mean calculated apparent Css was 3.9 (1.5) mg/L.,Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),[mg] / [l],3.9,39411,DB00753,Isoflurane
,30085853,apparent volume of the central compartment,"Median apparent volume of the central compartment and volume of distribution at steady state were 222 mL/kg and 987 mL/kg, respectively, for the red-tailed hawks and 5,108 mL/kg and 13,079 mL/kg, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),[ml] / [kg],222,40661,DB00753,Isoflurane
,30085853,apparent volume of the central compartment,"Median apparent volume of the central compartment and volume of distribution at steady state were 222 mL/kg and 987 mL/kg, respectively, for the red-tailed hawks and 5,108 mL/kg and 13,079 mL/kg, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),[ml] / [kg],"5,108",40662,DB00753,Isoflurane
,30085853,volume of distribution at steady state,"Median apparent volume of the central compartment and volume of distribution at steady state were 222 mL/kg and 987 mL/kg, respectively, for the red-tailed hawks and 5,108 mL/kg and 13,079 mL/kg, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),[ml] / [kg],987,40663,DB00753,Isoflurane
,30085853,volume of distribution at steady state,"Median apparent volume of the central compartment and volume of distribution at steady state were 222 mL/kg and 987 mL/kg, respectively, for the red-tailed hawks and 5,108 mL/kg and 13,079 mL/kg, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),[ml] / [kg],"13,079",40664,DB00753,Isoflurane
,30085853,clearance,"Median clearance and elimination half-life were 8.9 mL/min/kg and 90.22 minutes, respectively, for the red-tailed hawks and 198.8 mL/min/kg and 51.18 minutes, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),[ml] / [kg·min],8.9,40665,DB00753,Isoflurane
,30085853,clearance,"Median clearance and elimination half-life were 8.9 mL/min/kg and 90.22 minutes, respectively, for the red-tailed hawks and 198.8 mL/min/kg and 51.18 minutes, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),[ml] / [kg·min],198.8,40666,DB00753,Isoflurane
,30085853,elimination half-life,"Median clearance and elimination half-life were 8.9 mL/min/kg and 90.22 minutes, respectively, for the red-tailed hawks and 198.8 mL/min/kg and 51.18 minutes, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),min,90.22,40667,DB00753,Isoflurane
,30085853,elimination half-life,"Median clearance and elimination half-life were 8.9 mL/min/kg and 90.22 minutes, respectively, for the red-tailed hawks and 198.8 mL/min/kg and 51.18 minutes, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),min,51.18,40668,DB00753,Isoflurane
,27227503,Maximum bupivacaine plasma concentration,"Maximum bupivacaine plasma concentration was 1,030 ± 497.5 ng/mL at a mean ± SD value of 30 ± 24 minutes after administration.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[ng] / [ml],"1,030",40903,DB00753,Isoflurane
,27227503,elimination half-life,Mean elimination half-life was 4.79 ± 2.7 hours.,Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),h,4.79,40904,DB00753,Isoflurane
,27227503,clearance,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[h·l] / [kg],0.35,40905,DB00753,Isoflurane
,27227503,volume of distribution,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[h·l] / [kg],0.35,40906,DB00753,Isoflurane
,27227503,volume of distribution,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[l] / [kg],2.10,40907,DB00753,Isoflurane
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1155,48784,DB00753,Isoflurane
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1678,48785,DB00753,Isoflurane
,29755192,Tmax,"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),min,67,48786,DB00753,Isoflurane
,2145783,Maximum twitch depression,Maximum twitch depression was similar in older patients (96.4% +/- 1.3%) to that in the young patients (96.6% +/- 1.8%).,Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),%,96.4,49161,DB00753,Isoflurane
,2145783,Maximum twitch depression,Maximum twitch depression was similar in older patients (96.4% +/- 1.3%) to that in the young patients (96.6% +/- 1.8%).,Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),%,96.6,49162,DB00753,Isoflurane
,2145783,time to achieve this level,"The time to achieve this level of block was significantly longer in the elderly than in the young (11.2 +/- 1.1 min versus 7.7 +/- 1.0 min, respectively).",Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),min,11.2,49163,DB00753,Isoflurane
,2145783,time to achieve this level,"The time to achieve this level of block was significantly longer in the elderly than in the young (11.2 +/- 1.1 min versus 7.7 +/- 1.0 min, respectively).",Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),min,7.7,49164,DB00753,Isoflurane
,2145783,Recovery times to twitch heights,"Recovery times to twitch heights of 5% and 25% of control tended to be prolonged and were more variable in the elderly (82.6 +/- 17.2 and 97.1 +/- 20.1 min, respectively) than in the young (54.8 +/- 9 and 67.5 +/- 8.2 min, respectively).",Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),min,5,49165,DB00753,Isoflurane
,2145783,Recovery times to twitch heights,"Recovery times to twitch heights of 5% and 25% of control tended to be prolonged and were more variable in the elderly (82.6 +/- 17.2 and 97.1 +/- 20.1 min, respectively) than in the young (54.8 +/- 9 and 67.5 +/- 8.2 min, respectively).",Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),min,25,49166,DB00753,Isoflurane
,2145783,Recovery times to twitch heights,"Recovery times to twitch heights of 5% and 25% of control tended to be prolonged and were more variable in the elderly (82.6 +/- 17.2 and 97.1 +/- 20.1 min, respectively) than in the young (54.8 +/- 9 and 67.5 +/- 8.2 min, respectively).",Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),min,82.6,49167,DB00753,Isoflurane
,2145783,Recovery times to twitch heights,"Recovery times to twitch heights of 5% and 25% of control tended to be prolonged and were more variable in the elderly (82.6 +/- 17.2 and 97.1 +/- 20.1 min, respectively) than in the young (54.8 +/- 9 and 67.5 +/- 8.2 min, respectively).",Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),min,97.1,49168,DB00753,Isoflurane
,2145783,Recovery times to twitch heights,"Recovery times to twitch heights of 5% and 25% of control tended to be prolonged and were more variable in the elderly (82.6 +/- 17.2 and 97.1 +/- 20.1 min, respectively) than in the young (54.8 +/- 9 and 67.5 +/- 8.2 min, respectively).",Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),min,54.8,49169,DB00753,Isoflurane
,2145783,Recovery times to twitch heights,"Recovery times to twitch heights of 5% and 25% of control tended to be prolonged and were more variable in the elderly (82.6 +/- 17.2 and 97.1 +/- 20.1 min, respectively) than in the young (54.8 +/- 9 and 67.5 +/- 8.2 min, respectively).",Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),min,67.5,49170,DB00753,Isoflurane
,2145783,Elimination half-life,Elimination half-life (96 +/- 20 min) and clearance (2.47 +/- 0.69 mL.kg-1.min-1) in the elderly patients were not statistically different from values found in the younger group.,Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),min,96,49171,DB00753,Isoflurane
,2145783,clearance,Elimination half-life (96 +/- 20 min) and clearance (2.47 +/- 0.69 mL.kg-1.min-1) in the elderly patients were not statistically different from values found in the younger group.,Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),[ml] / [kg·min],2.47,49172,DB00753,Isoflurane
,2145783,Volume of distribution at steady state,Volume of distribution at steady state in the elderly (220 +/- 80.2 mL/kg) was significantly larger than in the young (150 +/- 40.0 mL/kg).,Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),[ml] / [kg],220,49173,DB00753,Isoflurane
,2145783,Volume of distribution at steady state,Volume of distribution at steady state in the elderly (220 +/- 80.2 mL/kg) was significantly larger than in the young (150 +/- 40.0 mL/kg).,Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145783/),[ml] / [kg],150,49174,DB00753,Isoflurane
,8659778,Onset to 90% paralysis,Onset to 90% paralysis (mean +/- SD) was delayed in the elderly (3.4 +/- 1.0 vs. 2.5 +/- 0.6 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,3.4,51558,DB00753,Isoflurane
,8659778,Onset to 90% paralysis,Onset to 90% paralysis (mean +/- SD) was delayed in the elderly (3.4 +/- 1.0 vs. 2.5 +/- 0.6 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,2.5,51559,DB00753,Isoflurane
,8659778,Elimination half-life,Elimination half-life was minimally prolonged in the elderly (25.5 +/- 3.7 vs. 21.5 +/- 2.4 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,25.5,51560,DB00753,Isoflurane
,8659778,Elimination half-life,Elimination half-life was minimally prolonged in the elderly (25.5 +/- 3.7 vs. 21.5 +/- 2.4 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,21.5,51561,DB00753,Isoflurane
,8659778,Vss,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg],126,51562,DB00753,Isoflurane
,8659778,Vss,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg],108,51563,DB00753,Isoflurane
,8659778,clearances,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg·min],5.0,51564,DB00753,Isoflurane
,8659778,clearances,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg·min],4.6,51565,DB00753,Isoflurane
,8659778,time to onset,"These differences are not associated with changes in recovery profile after a single bolus dose, although the mean time to onset was approximately 1 min longer in elderly patients.",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,1,51566,DB00753,Isoflurane
,11500261,F(A),"The F(A) values were close to 1, and the F(G) values ranged from 0.449 to 0.461.",First-pass of GTS-21 on canine gut wall and liver determined by portal-systemic concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11500261/),,1,53732,DB00753,Isoflurane
,11500261,F(G),"The F(A) values were close to 1, and the F(G) values ranged from 0.449 to 0.461.",First-pass of GTS-21 on canine gut wall and liver determined by portal-systemic concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11500261/),,0.449 to 0.461,53733,DB00753,Isoflurane
,11500261,F(H),"Accordingly, the F(H) values were estimated at 0.170, 0.047, and 0.083.",First-pass of GTS-21 on canine gut wall and liver determined by portal-systemic concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11500261/),,0.170,53734,DB00753,Isoflurane
,11500261,F(H),"Accordingly, the F(H) values were estimated at 0.170, 0.047, and 0.083.",First-pass of GTS-21 on canine gut wall and liver determined by portal-systemic concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11500261/),,0.047,53735,DB00753,Isoflurane
,11500261,F(H),"Accordingly, the F(H) values were estimated at 0.170, 0.047, and 0.083.",First-pass of GTS-21 on canine gut wall and liver determined by portal-systemic concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11500261/),,0.083,53736,DB00753,Isoflurane
,19821842,peak half-clearance,"Moreover, the clearance of [(11)C]cocaine from the brain was faster for ISO (peak half-clearance 15.8 +/- 2.8 min) than for alpha-CHLOR (27.5 +/- 0.6 min), and the ratio of specific to non-specific binding of [(11)C]cocaine in the brain was higher for ISO- (3.37 +/- 0.32) than for alpha-CHLOR-anesthetized rats (2.24 +/- 0.4).",Differential effects of anesthetics on cocaine's pharmacokinetic and pharmacodynamic effects in brain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19821842/),min,15.8,56096,DB00753,Isoflurane
,19821842,peak half-clearance,"Moreover, the clearance of [(11)C]cocaine from the brain was faster for ISO (peak half-clearance 15.8 +/- 2.8 min) than for alpha-CHLOR (27.5 +/- 0.6 min), and the ratio of specific to non-specific binding of [(11)C]cocaine in the brain was higher for ISO- (3.37 +/- 0.32) than for alpha-CHLOR-anesthetized rats (2.24 +/- 0.4).",Differential effects of anesthetics on cocaine's pharmacokinetic and pharmacodynamic effects in brain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19821842/),min,27.5,56097,DB00753,Isoflurane
,3598907,cardiac output,"Awake, nicardipine produced a decrease in mean arterial pressure (-12 +/- 2 mm Hg) associated with an increase in cardiac output (1.63 +/- 0.2 liters/min), heart rate (75 +/- 9 beats/min), dP/dt (741 +/- 202 mm Hg/sec) and carotid (41 +/- 11 ml/min) and coronary blood flows (39 +/- 6 ml/min).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),[l] / [min],1.63,65217,DB00753,Isoflurane
,3598907,heart rate,"Awake, nicardipine produced a decrease in mean arterial pressure (-12 +/- 2 mm Hg) associated with an increase in cardiac output (1.63 +/- 0.2 liters/min), heart rate (75 +/- 9 beats/min), dP/dt (741 +/- 202 mm Hg/sec) and carotid (41 +/- 11 ml/min) and coronary blood flows (39 +/- 6 ml/min).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),[beats] / [min],75,65218,DB00753,Isoflurane
,3598907,dP/dt,"Awake, nicardipine produced a decrease in mean arterial pressure (-12 +/- 2 mm Hg) associated with an increase in cardiac output (1.63 +/- 0.2 liters/min), heart rate (75 +/- 9 beats/min), dP/dt (741 +/- 202 mm Hg/sec) and carotid (41 +/- 11 ml/min) and coronary blood flows (39 +/- 6 ml/min).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),[hg·mm] / [s],741,65219,DB00753,Isoflurane
,3598907,blood flows,"Awake, nicardipine produced a decrease in mean arterial pressure (-12 +/- 2 mm Hg) associated with an increase in cardiac output (1.63 +/- 0.2 liters/min), heart rate (75 +/- 9 beats/min), dP/dt (741 +/- 202 mm Hg/sec) and carotid (41 +/- 11 ml/min) and coronary blood flows (39 +/- 6 ml/min).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),[ml] / [min],39,65220,DB00753,Isoflurane
,3598907,initial volume of distribution,"Isoflurane reduced nicardipine initial volume of distribution (11.6 +/- 1.2 vs. 8.9 +/- 0.8 liters), total clearance (28.5 +/- 2.9 vs. 19.2 +/- 2.1 liters/hr) and volume of distribution at steady state (50.0 +/- 11.3 vs. 29.2 +/- 3.7 liters, P less than .05).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),l,11.6,65221,DB00753,Isoflurane
,3598907,initial volume of distribution,"Isoflurane reduced nicardipine initial volume of distribution (11.6 +/- 1.2 vs. 8.9 +/- 0.8 liters), total clearance (28.5 +/- 2.9 vs. 19.2 +/- 2.1 liters/hr) and volume of distribution at steady state (50.0 +/- 11.3 vs. 29.2 +/- 3.7 liters, P less than .05).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),l,8.9,65222,DB00753,Isoflurane
,3598907,total clearance,"Isoflurane reduced nicardipine initial volume of distribution (11.6 +/- 1.2 vs. 8.9 +/- 0.8 liters), total clearance (28.5 +/- 2.9 vs. 19.2 +/- 2.1 liters/hr) and volume of distribution at steady state (50.0 +/- 11.3 vs. 29.2 +/- 3.7 liters, P less than .05).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),[l] / [h],28.5,65223,DB00753,Isoflurane
,3598907,total clearance,"Isoflurane reduced nicardipine initial volume of distribution (11.6 +/- 1.2 vs. 8.9 +/- 0.8 liters), total clearance (28.5 +/- 2.9 vs. 19.2 +/- 2.1 liters/hr) and volume of distribution at steady state (50.0 +/- 11.3 vs. 29.2 +/- 3.7 liters, P less than .05).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),[l] / [h],19.2,65224,DB00753,Isoflurane
,3598907,volume of distribution at steady state,"Isoflurane reduced nicardipine initial volume of distribution (11.6 +/- 1.2 vs. 8.9 +/- 0.8 liters), total clearance (28.5 +/- 2.9 vs. 19.2 +/- 2.1 liters/hr) and volume of distribution at steady state (50.0 +/- 11.3 vs. 29.2 +/- 3.7 liters, P less than .05).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),l,50.0,65225,DB00753,Isoflurane
,3598907,volume of distribution at steady state,"Isoflurane reduced nicardipine initial volume of distribution (11.6 +/- 1.2 vs. 8.9 +/- 0.8 liters), total clearance (28.5 +/- 2.9 vs. 19.2 +/- 2.1 liters/hr) and volume of distribution at steady state (50.0 +/- 11.3 vs. 29.2 +/- 3.7 liters, P less than .05).",Role of isoflurane on hemodynamic properties and disposition of nicardipine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598907/),l,29.2,65226,DB00753,Isoflurane
,26440992,wash-in time to P50,"The uptake and elimination of desflurane in arterial blood was delayed by nebulization of MCh, as determined by Micropore Membrane Inlet Mass Spectrometry (wash-in time to P50, healthy vs. inhalation: 0.5 min vs. 1.1 min, to P90: 4.0 min vs. 14.8 min).",Bronchoconstriction induced by inhaled methacholine delays desflurane uptake and elimination in a piglet model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26440992/),min,0.5,65752,DB00753,Isoflurane
,26440992,wash-in time to P50,"The uptake and elimination of desflurane in arterial blood was delayed by nebulization of MCh, as determined by Micropore Membrane Inlet Mass Spectrometry (wash-in time to P50, healthy vs. inhalation: 0.5 min vs. 1.1 min, to P90: 4.0 min vs. 14.8 min).",Bronchoconstriction induced by inhaled methacholine delays desflurane uptake and elimination in a piglet model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26440992/),min,1.1,65753,DB00753,Isoflurane
,26440992,P90,"The uptake and elimination of desflurane in arterial blood was delayed by nebulization of MCh, as determined by Micropore Membrane Inlet Mass Spectrometry (wash-in time to P50, healthy vs. inhalation: 0.5 min vs. 1.1 min, to P90: 4.0 min vs. 14.8 min).",Bronchoconstriction induced by inhaled methacholine delays desflurane uptake and elimination in a piglet model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26440992/),min,4.0,65754,DB00753,Isoflurane
,26440992,P90,"The uptake and elimination of desflurane in arterial blood was delayed by nebulization of MCh, as determined by Micropore Membrane Inlet Mass Spectrometry (wash-in time to P50, healthy vs. inhalation: 0.5 min vs. 1.1 min, to P90: 4.0 min vs. 14.8 min).",Bronchoconstriction induced by inhaled methacholine delays desflurane uptake and elimination in a piglet model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26440992/),min,14.8,65755,DB00753,Isoflurane
,8866454,Maximum concentration,"Maximum concentration of butorphanol and time to obtain this concentration were 42.28 ng/mL at 13.88 min in blood, and 18.03 ng/mL at 30 min in CSF.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),[ng] / [ml],42.28,67698,DB00753,Isoflurane
,8866454,Volume of distribution,"Volume of distribution, clearance, mean distribution and elimination half-lives were respectively 4.39 L/kg, 2.02 L/h.kg, 16.5 min and 189.1 min.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),[l] / [kg],4.39,67699,DB00753,Isoflurane
,8866454,clearance,"Volume of distribution, clearance, mean distribution and elimination half-lives were respectively 4.39 L/kg, 2.02 L/h.kg, 16.5 min and 189.1 min.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),[l] / [h·kg],2.02,67700,DB00753,Isoflurane
,8866454,clearance,"Volume of distribution, clearance, mean distribution and elimination half-lives were respectively 4.39 L/kg, 2.02 L/h.kg, 16.5 min and 189.1 min.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),min,16.5,67701,DB00753,Isoflurane
,8866454,distribution,"Volume of distribution, clearance, mean distribution and elimination half-lives were respectively 4.39 L/kg, 2.02 L/h.kg, 16.5 min and 189.1 min.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),[l] / [h·kg],2.02,67702,DB00753,Isoflurane
,8866454,distribution,"Volume of distribution, clearance, mean distribution and elimination half-lives were respectively 4.39 L/kg, 2.02 L/h.kg, 16.5 min and 189.1 min.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),min,16.5,67703,DB00753,Isoflurane
,8866454,elimination half-lives,"Volume of distribution, clearance, mean distribution and elimination half-lives were respectively 4.39 L/kg, 2.02 L/h.kg, 16.5 min and 189.1 min.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),min,189.1,67704,DB00753,Isoflurane
,18052733,MAC,Isoflurane MAC was 1.32 +/- 0.14%.,Effects of perzinfotel on the minimum alveolar concentration of isoflurane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18052733/),%,1.32,69482,DB00753,Isoflurane
,17529920,effect site concentration,Obese patients were intubated using a flexible fiberoptic bronchoscopic technique facilitated by a target controlled effect site concentration of remifentanil set at 2.5 ng/mL.,Effect of morbid obesity on kinetic of desflurane: wash-in wash-out curves and recovery times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529920/),[ng] / [ml],2.5,69936,DB00753,Isoflurane
below,19247757,Total plasma concentrations,Total plasma concentrations of lidocaine remained below 4 microg ml(-1) throughout the study period.,Intranasal lidocaine plus naphazoline nitrate improves surgical conditions and perioperative analgesia in septorhinoplasty surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19247757/),[μg] / [ml],4,71699,DB00753,Isoflurane
,10608210,F(I)O2,"After an initial 90 min period of propofol infusion, rabbits were randomly allocated to one of three groups: hypoxia (F(I)O2 = 0.1), normoxia (F(I)O2 = 0.21), and hyperoxia (F(I)O2 = 1.0).",The influence of hypoxia and hyperoxia on the kinetics of propofol emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10608210/),,0,71925,DB00753,Isoflurane
,10608210,F(I)O2,"After an initial 90 min period of propofol infusion, rabbits were randomly allocated to one of three groups: hypoxia (F(I)O2 = 0.1), normoxia (F(I)O2 = 0.21), and hyperoxia (F(I)O2 = 1.0).",The influence of hypoxia and hyperoxia on the kinetics of propofol emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10608210/),,1.0,71926,DB00753,Isoflurane
,10608210,arterial propofol concentration,"The mean arterial propofol concentration at the end of infusion was higher in the hypoxia group (15.2 +/- 2.8 microg x mL(-1), mean +/- SD) than in the normoxia (7.4 +/- 1.7) and hyperoxia (8.0 +/- 1.9) groups (P < 0.05).",The influence of hypoxia and hyperoxia on the kinetics of propofol emulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10608210/),[μg] / [ml],15.2,71927,DB00753,Isoflurane
,10608210,arterial propofol concentration,"The mean arterial propofol concentration at the end of infusion was higher in the hypoxia group (15.2 +/- 2.8 microg x mL(-1), mean +/- SD) than in the normoxia (7.4 +/- 1.7) and hyperoxia (8.0 +/- 1.9) groups (P < 0.05).",The influence of hypoxia and hyperoxia on the kinetics of propofol emulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10608210/),[μg] / [ml],7.4,71928,DB00753,Isoflurane
,10608210,arterial propofol concentration,"The mean arterial propofol concentration at the end of infusion was higher in the hypoxia group (15.2 +/- 2.8 microg x mL(-1), mean +/- SD) than in the normoxia (7.4 +/- 1.7) and hyperoxia (8.0 +/- 1.9) groups (P < 0.05).",The influence of hypoxia and hyperoxia on the kinetics of propofol emulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10608210/),[μg] / [ml],8.0,71929,DB00753,Isoflurane
,8789701,IC50,Isoflurane increased the potency of metocurine significantly; IC50 (the concentration in the effect compartment at 50% paralysis) was 70 +/- 15 ng/mL during isoflurane anaesthesia and 129 +/- 42 ng/mL during barbiturate-opiate anaesthesia (P < 0.03).,Metocurine pharmacokinetics and pharmacodynamics in goats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789701/),[ng] / [ml],70,75095,DB00753,Isoflurane
,8789701,IC50,Isoflurane increased the potency of metocurine significantly; IC50 (the concentration in the effect compartment at 50% paralysis) was 70 +/- 15 ng/mL during isoflurane anaesthesia and 129 +/- 42 ng/mL during barbiturate-opiate anaesthesia (P < 0.03).,Metocurine pharmacokinetics and pharmacodynamics in goats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789701/),[ng] / [ml],129,75096,DB00753,Isoflurane
,8789701,Volume of distribution,"Volume of distribution (63 +/- 18 mL/kg), clearance (1.6 +/- 0.4 mL/min.kg) and elimination half-life (99 +/- 9 min) during barbiturate-opiate anaesthesia were not significantly different during isoflurane anaesthesia: 64 +/- 25 mL/kg, 1.5 +/- 0.7 mL/kg.min, 116 +/- 16 min respectively.",Metocurine pharmacokinetics and pharmacodynamics in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789701/),[ml] / [kg],63,75097,DB00753,Isoflurane
,8789701,clearance,"Volume of distribution (63 +/- 18 mL/kg), clearance (1.6 +/- 0.4 mL/min.kg) and elimination half-life (99 +/- 9 min) during barbiturate-opiate anaesthesia were not significantly different during isoflurane anaesthesia: 64 +/- 25 mL/kg, 1.5 +/- 0.7 mL/kg.min, 116 +/- 16 min respectively.",Metocurine pharmacokinetics and pharmacodynamics in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789701/),[ml] / [kg·min],1.6,75098,DB00753,Isoflurane
,8789701,clearance,"Volume of distribution (63 +/- 18 mL/kg), clearance (1.6 +/- 0.4 mL/min.kg) and elimination half-life (99 +/- 9 min) during barbiturate-opiate anaesthesia were not significantly different during isoflurane anaesthesia: 64 +/- 25 mL/kg, 1.5 +/- 0.7 mL/kg.min, 116 +/- 16 min respectively.",Metocurine pharmacokinetics and pharmacodynamics in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789701/),[ml] / [kg],64,75099,DB00753,Isoflurane
,8789701,elimination half-life,"Volume of distribution (63 +/- 18 mL/kg), clearance (1.6 +/- 0.4 mL/min.kg) and elimination half-life (99 +/- 9 min) during barbiturate-opiate anaesthesia were not significantly different during isoflurane anaesthesia: 64 +/- 25 mL/kg, 1.5 +/- 0.7 mL/kg.min, 116 +/- 16 min respectively.",Metocurine pharmacokinetics and pharmacodynamics in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789701/),min,99,75100,DB00753,Isoflurane
,8557005,Onset time for maximum block,"Onset time for maximum block and duration of clinical relaxation (DUR25) were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min, respectively, for patients with and without renal failure.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),s,61,76032,DB00753,Isoflurane
,8557005,duration of clinical relaxation (DUR25),"Onset time for maximum block and duration of clinical relaxation (DUR25) were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min, respectively, for patients with and without renal failure.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),s,65,76033,DB00753,Isoflurane
,8557005,duration of clinical relaxation (DUR25),"Onset time for maximum block and duration of clinical relaxation (DUR25) were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min, respectively, for patients with and without renal failure.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,42,76034,DB00753,Isoflurane
,8557005,time for,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,0,76035,DB00753,Isoflurane
,8557005,time for,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,99,76036,DB00753,Isoflurane
,8557005,time for,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,73,76037,DB00753,Isoflurane
,8557005,train-of-four ratio to return spontaneously,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,0,76038,DB00753,Isoflurane
,8557005,train-of-four ratio to return spontaneously,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,99,76039,DB00753,Isoflurane
,8557005,train-of-four ratio to return spontaneously,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,73,76040,DB00753,Isoflurane
,8557005,rates of clearance,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) mL kg-1 min-1 and 3.7 (1.4) mL kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) (P < 0.05).",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),[ml] / [kg·min],2.5,76041,DB00753,Isoflurane
,8557005,rates of clearance,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) mL kg-1 min-1 and 3.7 (1.4) mL kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) (P < 0.05).",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),[ml] / [kg·min],3.7,76042,DB00753,Isoflurane
,8557005,mean residence times,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) mL kg-1 min-1 and 3.7 (1.4) mL kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) (P < 0.05).",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,97.1,76043,DB00753,Isoflurane
,8557005,mean residence times,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) mL kg-1 min-1 and 3.7 (1.4) mL kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) (P < 0.05).",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,58.3,76044,DB00753,Isoflurane
,34281773,Fe',Anaesthesia was maintained with isoflurane in 50% oxygen (Fe'Iso 1.3-1.5%).,Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),%,1.3-1.5,81318,DB00753,Isoflurane
,34281773,volume of distribution,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [kg],1.41,81319,DB00753,Isoflurane
,34281773,volume of distribution,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [kg],1.72,81320,DB00753,Isoflurane
,34281773,clearance,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [h·kg],1.52,81321,DB00753,Isoflurane
,34281773,clearance,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [h·kg],1.60,81322,DB00753,Isoflurane
,34281773,terminal elimination half-life,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),h,2.45,81323,DB00753,Isoflurane
,34281773,terminal elimination half-life,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),h,3.57,81324,DB00753,Isoflurane
,7880508,Plasma concentration,"Plasma concentration of sufentanil at the different time points varied from 0.021 to 0.142 ng/ml, with a mean maximal peak concentration of 0.103 ng/ml.",Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: an open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880508/),[ng] / [ml],0.021 to 0.142,82353,DB00753,Isoflurane
,7880508,maximal peak concentration,"Plasma concentration of sufentanil at the different time points varied from 0.021 to 0.142 ng/ml, with a mean maximal peak concentration of 0.103 ng/ml.",Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: an open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880508/),[ng] / [ml],0.103,82354,DB00753,Isoflurane
,7880508,plasma concentration,The plasma concentration 48 hours after injection varied from 0.026 to 0.074 ng/ml.,Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: an open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880508/),[ng] / [ml],0.026 to 0.074,82355,DB00753,Isoflurane
,9989340,blood/gas partition coefficient,The more rapid pharmacokinetics are a result of the low blood/gas partition coefficient of 0.69.,Clinical pharmacokinetics of sevoflurane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989340/),,0.69,82479,DB00753,Isoflurane
,9989340,oil/gas partition coefficient,"With an oil/gas partition coefficient of 47.2, the minimum alveolar concentration (MAC) of sevoflurane is 2.05%.",Clinical pharmacokinetics of sevoflurane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989340/),,47.2,82480,DB00753,Isoflurane
,9989340,minimum alveolar concentration (MAC),"With an oil/gas partition coefficient of 47.2, the minimum alveolar concentration (MAC) of sevoflurane is 2.05%.",Clinical pharmacokinetics of sevoflurane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989340/),%,2.05,82481,DB00753,Isoflurane
,16169890,Apparent systemic clearances,"Apparent systemic clearances in the dissection, anhepatic and reperfusion phases were 1.89 (sd 0.48) litre min(-1), 1.08 (0.25) litre min(-1) and 1.53 (0.51) litre min(-1), respectively.",Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169890/),[l] / [min],1.89,85040,DB00753,Isoflurane
,16169890,Apparent systemic clearances,"Apparent systemic clearances in the dissection, anhepatic and reperfusion phases were 1.89 (sd 0.48) litre min(-1), 1.08 (0.25) litre min(-1) and 1.53 (0.51) litre min(-1), respectively.",Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169890/),[l] / [min],1.08,85041,DB00753,Isoflurane
,16169890,Apparent systemic clearances,"Apparent systemic clearances in the dissection, anhepatic and reperfusion phases were 1.89 (sd 0.48) litre min(-1), 1.08 (0.25) litre min(-1) and 1.53 (0.51) litre min(-1), respectively.",Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169890/),[l] / [min],1.53,85042,DB00753,Isoflurane
,16169890,intestinal extraction ratio,The intestinal extraction ratio calculated from the concentration in the radial artery and portal vein was 0.24 (0.12).,Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169890/),,0.24,85043,DB00753,Isoflurane
,17666353,FGF rate,"Sixty female patients (ASA class I-II, age range of 18-49 years) scheduled for gynecological laparoscopic surgery were randomly divided into groups I, II, and III (n=20) for isoflurane inhalation with FGF rate of 1, 2, and 3 L/min, respectively.",[Effect of fresh gas flow on isoflurane pharmacokinetics during anesthesia induction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666353/),[l] / [min],1,86236,DB00753,Isoflurane
,17666353,FGF rate,"Sixty female patients (ASA class I-II, age range of 18-49 years) scheduled for gynecological laparoscopic surgery were randomly divided into groups I, II, and III (n=20) for isoflurane inhalation with FGF rate of 1, 2, and 3 L/min, respectively.",[Effect of fresh gas flow on isoflurane pharmacokinetics during anesthesia induction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666353/),[l] / [min],2,86237,DB00753,Isoflurane
,17666353,FGF rate,"Sixty female patients (ASA class I-II, age range of 18-49 years) scheduled for gynecological laparoscopic surgery were randomly divided into groups I, II, and III (n=20) for isoflurane inhalation with FGF rate of 1, 2, and 3 L/min, respectively.",[Effect of fresh gas flow on isoflurane pharmacokinetics during anesthesia induction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666353/),[l] / [min],3,86238,DB00753,Isoflurane
,10951986,Arterial pH,"Arterial pH, Paco2, and Pao2 ranged from 7.46 +/- 0.04 to 751 +/- 0.05 units, 29.2 +/- 3 to 34.6 +/- 4.4 mm Hg, and 412.6 +/- 105.3 to 482.9 +/- 71.2 mm Hg, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),units,7.46,88942,DB00753,Isoflurane
,10951986,Paco2,"Arterial pH, Paco2, and Pao2 ranged from 7.46 +/- 0.04 to 751 +/- 0.05 units, 29.2 +/- 3 to 34.6 +/- 4.4 mm Hg, and 412.6 +/- 105.3 to 482.9 +/- 71.2 mm Hg, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),units,751,88943,DB00753,Isoflurane
,10951986,Paco2,"Arterial pH, Paco2, and Pao2 ranged from 7.46 +/- 0.04 to 751 +/- 0.05 units, 29.2 +/- 3 to 34.6 +/- 4.4 mm Hg, and 412.6 +/- 105.3 to 482.9 +/- 71.2 mm Hg, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),hg·mm,29.2,88944,DB00753,Isoflurane
,10951986,Pao2,"Arterial pH, Paco2, and Pao2 ranged from 7.46 +/- 0.04 to 751 +/- 0.05 units, 29.2 +/- 3 to 34.6 +/- 4.4 mm Hg, and 412.6 +/- 105.3 to 482.9 +/- 71.2 mm Hg, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),hg·mm,34.6,88945,DB00753,Isoflurane
,10951986,Pao2,"Arterial pH, Paco2, and Pao2 ranged from 7.46 +/- 0.04 to 751 +/- 0.05 units, 29.2 +/- 3 to 34.6 +/- 4.4 mm Hg, and 412.6 +/- 105.3 to 482.9 +/- 71.2 mm Hg, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),hg·mm,412.6,88946,DB00753,Isoflurane
,10951986,Pao2,"Arterial pH, Paco2, and Pao2 ranged from 7.46 +/- 0.04 to 751 +/- 0.05 units, 29.2 +/- 3 to 34.6 +/- 4.4 mm Hg, and 412.6 +/- 105.3 to 482.9 +/- 71.2 mm Hg, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),hg·mm,482.9,88947,DB00753,Isoflurane
,10951986,clearance,"The clearance, volume of distribution area, volume of distribution steady state, mean residence time, area under the curve, elimination rate constant, and half-life were 32.5 +/- 2.48 ml/kg/min, 9.04 +/- 1.91 L/kg, 70 +/- 1.2 L/kg, 218.5 +/- 35.5 min, 0.247 +/- 0.019 mg/ml/min, 0.004 + 0.001/min, and 192.0 +/- 33.5 min, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),[ml] / [kg·min],32.5,88948,DB00753,Isoflurane
,10951986,half-life,"The clearance, volume of distribution area, volume of distribution steady state, mean residence time, area under the curve, elimination rate constant, and half-life were 32.5 +/- 2.48 ml/kg/min, 9.04 +/- 1.91 L/kg, 70 +/- 1.2 L/kg, 218.5 +/- 35.5 min, 0.247 +/- 0.019 mg/ml/min, 0.004 + 0.001/min, and 192.0 +/- 33.5 min, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),1/[min],0.004,88949,DB00753,Isoflurane
,10951986,half-life,"The clearance, volume of distribution area, volume of distribution steady state, mean residence time, area under the curve, elimination rate constant, and half-life were 32.5 +/- 2.48 ml/kg/min, 9.04 +/- 1.91 L/kg, 70 +/- 1.2 L/kg, 218.5 +/- 35.5 min, 0.247 +/- 0.019 mg/ml/min, 0.004 + 0.001/min, and 192.0 +/- 33.5 min, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),min,192.0,88950,DB00753,Isoflurane
,16175313,MIC,"Using a fixed MIC of 2 microg ml(-1) against potentially encountered bacteria, it was concluded that the recommended dosing schedule was suitable in all tested populations, including obese patients, although prolongation of the interval between injections appeared advisable for renal insufficiency patients.",Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175313/),[μg] / [ml],2,92912,DB00753,Isoflurane
,16175313,MIC,"Furthermore, when a MIC of 3 microg ml(-1) was considered, the recommended cefazolin-dosing regimen failed to maintain sufficient free cefazolin concentrations in the interstitial fluids during surgery in all tested populations except renal insufficiency patients (GFR < 50 ml min(-1)).",Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175313/),[μg] / [ml],3,92913,DB00753,Isoflurane
,27027704,MACBAR,"Mean ± SD isoflurane MACBAR of the fentanyl and control treatments was 1.70 ± 0.28% and 1.79 ± 0.35%, respectively; no significant difference was found between the 2 treatments.",Determination of the minimum alveolar concentration of isoflurane that blunts adrenergic responses in sheep and evaluation of the effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27027704/),%,1.70,94698,DB00753,Isoflurane
,27027704,MACBAR,"Mean ± SD isoflurane MACBAR of the fentanyl and control treatments was 1.70 ± 0.28% and 1.79 ± 0.35%, respectively; no significant difference was found between the 2 treatments.",Determination of the minimum alveolar concentration of isoflurane that blunts adrenergic responses in sheep and evaluation of the effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27027704/),%,1.79,94699,DB00753,Isoflurane
,27027704,steady-state concentration,"Plasma concentration of fentanyl reached a median steady-state concentration of 1.69 ng/mL (interquartile range [25th to 75th percentile], 1.47 to 1.79 ng/mL), which was maintained throughout the study.",Determination of the minimum alveolar concentration of isoflurane that blunts adrenergic responses in sheep and evaluation of the effects of fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27027704/),[ng] / [ml],1.69,94700,DB00753,Isoflurane
,1731542,total gas flow,"Sevoflurane or isoflurane was administered with a semiclosed (total gas flow, 2 L/min O2) circle absorption system for durations of 1.0 to greater than 7.0 minimal alveolar concentration (MAC) hours for surgical anesthesia (sevoflurane MAC, 2.05%; isoflurane MAC, 1.15%).",Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1731542/),[l] / [min·o2],2,95779,DB00753,Isoflurane
,1731542,peak plasma inorganic fluoride concentration,"Sevoflurane biotransformation produced a mean peak plasma inorganic fluoride concentration of 29.3 +/- 1.8 mumol/L, 2 h after anesthesia, which decreased to 18 mumol/L concentration by 8 h after anesthesia.",Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1731542/),[μM] / [l],29.3,95780,DB00753,Isoflurane
,1731542,peak plasma inorganic fluoride concentration,"Sevoflurane biotransformation produced a mean peak plasma inorganic fluoride concentration of 29.3 +/- 1.8 mumol/L, 2 h after anesthesia, which decreased to 18 mumol/L concentration by 8 h after anesthesia.",Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1731542/),[μM] / [l],18,95781,DB00753,Isoflurane
exceeding,1731542,peak levels,"Five patients given sevoflurane had peak levels transiently exceeding 50 mumol/L, and one of these had a history of ingesting drugs potentially producing hepatic enzyme induction.",Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1731542/),[μM] / [l],50,95782,DB00753,Isoflurane
,23895731,volume of distribution at steady-state,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.06,95847,DB00753,Isoflurane
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.25,95848,DB00753,Isoflurane
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,2.18,95849,DB00753,Isoflurane
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,18.6,95850,DB00753,Isoflurane
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,151,95851,DB00753,Isoflurane
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.10,95852,DB00753,Isoflurane
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.89,95853,DB00753,Isoflurane
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,11.6,95854,DB00753,Isoflurane
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,144,95855,DB00753,Isoflurane
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.06,95856,DB00753,Isoflurane
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.77,95857,DB00753,Isoflurane
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,17.6,95858,DB00753,Isoflurane
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,151,95859,DB00753,Isoflurane
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.10,95860,DB00753,Isoflurane
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.89,95861,DB00753,Isoflurane
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,11.6,95862,DB00753,Isoflurane
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,144,95863,DB00753,Isoflurane
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.06,95864,DB00753,Isoflurane
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.77,95865,DB00753,Isoflurane
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,17.6,95866,DB00753,Isoflurane
,8624003,ED50,ED50 of the initial dose was 144 micrograms.,Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),μg,144,96082,DB00753,Isoflurane
,8624003,initial volume of distribution,"kg-1 in control subjects, related to a higher initial volume of distribution (cirrhotic 78.5 +/- 31.7 ml.kg-1, control 29.8 +/- 17.3 ml.kg-1).",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),[ml] / [kg],78.5,96083,DB00753,Isoflurane
,8624003,initial volume of distribution,"kg-1 in control subjects, related to a higher initial volume of distribution (cirrhotic 78.5 +/- 31.7 ml.kg-1, control 29.8 +/- 17.3 ml.kg-1).",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),[ml] / [kg],29.8,96084,DB00753,Isoflurane
,8624003,Time from complementary dose to 25% recovery,"Time from complementary dose to 25% recovery was longer in cirrhotic patients (41.0 +/- 20.7 min vs 30.2 +/- 9.7 min), but time course of action during maintenance was not statistically different in the two groups.",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),min,41.0,96085,DB00753,Isoflurane
,8624003,Time from complementary dose to 25% recovery,"Time from complementary dose to 25% recovery was longer in cirrhotic patients (41.0 +/- 20.7 min vs 30.2 +/- 9.7 min), but time course of action during maintenance was not statistically different in the two groups.",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),min,30.2,96086,DB00753,Isoflurane
,8624003,volume of distribution at steady-state,"Spontaneous recovery was delayed in cirrhotic patients, because of impaired elimination processes: greater volume of distribution at steady-state (264 +/- 92 vs. 151 +/- 59 ml.kg-1); trend toward a lower clearance (189 +/- 60 vs. 296 +/- 169 ml.min-1).",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),[ml] / [kg],264,96087,DB00753,Isoflurane
,8624003,volume of distribution at steady-state,"Spontaneous recovery was delayed in cirrhotic patients, because of impaired elimination processes: greater volume of distribution at steady-state (264 +/- 92 vs. 151 +/- 59 ml.kg-1); trend toward a lower clearance (189 +/- 60 vs. 296 +/- 169 ml.min-1).",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),[ml] / [kg],151,96088,DB00753,Isoflurane
,8624003,clearance,"Spontaneous recovery was delayed in cirrhotic patients, because of impaired elimination processes: greater volume of distribution at steady-state (264 +/- 92 vs. 151 +/- 59 ml.kg-1); trend toward a lower clearance (189 +/- 60 vs. 296 +/- 169 ml.min-1).",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),[ml] / [min],189,96089,DB00753,Isoflurane
,8624003,clearance,"Spontaneous recovery was delayed in cirrhotic patients, because of impaired elimination processes: greater volume of distribution at steady-state (264 +/- 92 vs. 151 +/- 59 ml.kg-1); trend toward a lower clearance (189 +/- 60 vs. 296 +/- 169 ml.min-1).",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),[ml] / [min],296,96090,DB00753,Isoflurane
,17228596,elimination half-life,"The fentanyl elimination half-life, in awake and anaesthetised horses, was 1 h and volume of distribution at steady state was 0.37 and 0.26 l/kg bwt, respectively.",Influence of general anaesthesia on the pharmacokinetics of intravenous fentanyl and its primary metabolite in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17228596/),h,1,97416,DB00753,Isoflurane
,17228596,volume of distribution at steady state,"The fentanyl elimination half-life, in awake and anaesthetised horses, was 1 h and volume of distribution at steady state was 0.37 and 0.26 l/kg bwt, respectively.",Influence of general anaesthesia on the pharmacokinetics of intravenous fentanyl and its primary metabolite in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17228596/),[l] / [bwt·kg],0.37,97417,DB00753,Isoflurane
,17228596,volume of distribution at steady state,"The fentanyl elimination half-life, in awake and anaesthetised horses, was 1 h and volume of distribution at steady state was 0.37 and 0.26 l/kg bwt, respectively.",Influence of general anaesthesia on the pharmacokinetics of intravenous fentanyl and its primary metabolite in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17228596/),[l] / [bwt·kg],0.26,97418,DB00753,Isoflurane
,17228596,elimination half-life,"The elimination half-life of PMA was 2 and 1.5 h in awake and anaesthetised horses, respectively.",Influence of general anaesthesia on the pharmacokinetics of intravenous fentanyl and its primary metabolite in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17228596/),h,2,97419,DB00753,Isoflurane
,17228596,elimination half-life,"The elimination half-life of PMA was 2 and 1.5 h in awake and anaesthetised horses, respectively.",Influence of general anaesthesia on the pharmacokinetics of intravenous fentanyl and its primary metabolite in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17228596/),h,1.5,97420,DB00753,Isoflurane
,16720675,plasma concentrations,"Following determination of baseline MAC of isoflurane, fentanyl was administered i.v. to target plasma concentrations of 1, 8 and 16 ng ml(-1).",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],1,98342,DB00753,Isoflurane
,16720675,plasma concentrations,"Following determination of baseline MAC of isoflurane, fentanyl was administered i.v. to target plasma concentrations of 1, 8 and 16 ng ml(-1).",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],8,98343,DB00753,Isoflurane
,16720675,plasma concentrations,"Following determination of baseline MAC of isoflurane, fentanyl was administered i.v. to target plasma concentrations of 1, 8 and 16 ng ml(-1).",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],16,98344,DB00753,Isoflurane
,16720675,plasma concentrations,"Mean actual fentanyl plasma concentrations were 0 (baseline), and 0.72 (SD 0.26), 8.43 (3.22), and 13.31 (6.66) ng ml(-1) for the target concentrations of 1, 8 and 16 ng ml(-1), respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],0,98345,DB00753,Isoflurane
,16720675,plasma concentrations,"Mean actual fentanyl plasma concentrations were 0 (baseline), and 0.72 (SD 0.26), 8.43 (3.22), and 13.31 (6.66) ng ml(-1) for the target concentrations of 1, 8 and 16 ng ml(-1), respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],0.72,98346,DB00753,Isoflurane
,16720675,plasma concentrations,"Mean actual fentanyl plasma concentrations were 0 (baseline), and 0.72 (SD 0.26), 8.43 (3.22), and 13.31 (6.66) ng ml(-1) for the target concentrations of 1, 8 and 16 ng ml(-1), respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],8.43,98347,DB00753,Isoflurane
,16720675,plasma concentrations,"Mean actual fentanyl plasma concentrations were 0 (baseline), and 0.72 (SD 0.26), 8.43 (3.22), and 13.31 (6.66) ng ml(-1) for the target concentrations of 1, 8 and 16 ng ml(-1), respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],13.31,98348,DB00753,Isoflurane
,16720675,plasma concentrations,"Mean actual fentanyl plasma concentrations were 0 (baseline), and 0.72 (SD 0.26), 8.43 (3.22), and 13.31 (6.66) ng ml(-1) for the target concentrations of 1, 8 and 16 ng ml(-1), respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),,8,98349,DB00753,Isoflurane
,16720675,MAC,"The corresponding isoflurane MAC values were a baseline of 1.57 (0.23), and 1.51 (0.24), 1.41 (0.23) and 1.37 (0.09)%, respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),%,1.57,98350,DB00753,Isoflurane
,16720675,MAC,"The corresponding isoflurane MAC values were a baseline of 1.57 (0.23), and 1.51 (0.24), 1.41 (0.23) and 1.37 (0.09)%, respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),%,1.51,98351,DB00753,Isoflurane
,16720675,MAC,"The corresponding isoflurane MAC values were a baseline of 1.57 (0.23), and 1.51 (0.24), 1.41 (0.23) and 1.37 (0.09)%, respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),%,1.41,98352,DB00753,Isoflurane
,16720675,MAC,"The corresponding isoflurane MAC values were a baseline of 1.57 (0.23), and 1.51 (0.24), 1.41 (0.23) and 1.37 (0.09)%, respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),%,1.37,98353,DB00753,Isoflurane
,9103501,terminal half-life,"Remifentanil was rapidly eliminated, with a terminal half-life of 6 min, compared with 19 min for GR90291 and alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,6,101227,DB00753,Isoflurane
,9103501,terminal half-life,"Remifentanil was rapidly eliminated, with a terminal half-life of 6 min, compared with 19 min for GR90291 and alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,19,101228,DB00753,Isoflurane
,9103501,blood-brain,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,2.3 to 5.2,101229,DB00753,Isoflurane
,9103501,blood-brain,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,0.39 to 0.41,101230,DB00753,Isoflurane
,9103501,blood-brain,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,3.1 to 3.7,101231,DB00753,Isoflurane
,9103501,half-life,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,2.3 to 5.2,101232,DB00753,Isoflurane
,9103501,half-life,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,0.39 to 0.41,101233,DB00753,Isoflurane
,9103501,half-life,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,3.1 to 3.7,101234,DB00753,Isoflurane
,8453853,elimination half-life,"In the elderly group, doxacurium elimination half-life was prolonged (119.7 versus 75.9 minutes) and plasma clearance was significantly reduced (1.75 versus 2.54 ml/min/kg) without any change in volume of distribution.",Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453853/),min,119.7,101416,DB00753,Isoflurane
,8453853,elimination half-life,"In the elderly group, doxacurium elimination half-life was prolonged (119.7 versus 75.9 minutes) and plasma clearance was significantly reduced (1.75 versus 2.54 ml/min/kg) without any change in volume of distribution.",Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453853/),min,75.9,101417,DB00753,Isoflurane
,8453853,plasma clearance,"In the elderly group, doxacurium elimination half-life was prolonged (119.7 versus 75.9 minutes) and plasma clearance was significantly reduced (1.75 versus 2.54 ml/min/kg) without any change in volume of distribution.",Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453853/),[ml] / [kg·min],1.75,101418,DB00753,Isoflurane
,8453853,plasma clearance,"In the elderly group, doxacurium elimination half-life was prolonged (119.7 versus 75.9 minutes) and plasma clearance was significantly reduced (1.75 versus 2.54 ml/min/kg) without any change in volume of distribution.",Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453853/),[ml] / [kg·min],2.54,101419,DB00753,Isoflurane
,8453853,Onset,Onset (12.9 versus 8.9 minutes) and recovery times (113.4 versus 48.1 minutes) were longer in the elderly group.,Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453853/),min,12.9,101420,DB00753,Isoflurane
,8453853,Onset,Onset (12.9 versus 8.9 minutes) and recovery times (113.4 versus 48.1 minutes) were longer in the elderly group.,Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453853/),min,8.9,101421,DB00753,Isoflurane
,8453853,recovery times,Onset (12.9 versus 8.9 minutes) and recovery times (113.4 versus 48.1 minutes) were longer in the elderly group.,Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453853/),min,113.4,101422,DB00753,Isoflurane
,8453853,recovery times,Onset (12.9 versus 8.9 minutes) and recovery times (113.4 versus 48.1 minutes) were longer in the elderly group.,Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453853/),min,48.1,101423,DB00753,Isoflurane
,8453853,equilibrium rate constant to the effect compartment (kco),"The equilibrium rate constant to the effect compartment (kco) was decreased in the elderly (0.039 versus 0.051 min-1), whereas the effect compartment concentration at 50% block was similar in both groups (44.7 versus 54.1 ng/ml).",Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453853/),1/[min],0.039,101424,DB00753,Isoflurane
,8453853,equilibrium rate constant to the effect compartment (kco),"The equilibrium rate constant to the effect compartment (kco) was decreased in the elderly (0.039 versus 0.051 min-1), whereas the effect compartment concentration at 50% block was similar in both groups (44.7 versus 54.1 ng/ml).",Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453853/),1/[min],0.051,101425,DB00753,Isoflurane
,8453853,effect compartment concentration at 50% block,"The equilibrium rate constant to the effect compartment (kco) was decreased in the elderly (0.039 versus 0.051 min-1), whereas the effect compartment concentration at 50% block was similar in both groups (44.7 versus 54.1 ng/ml).",Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453853/),[ng] / [ml],44.7,101426,DB00753,Isoflurane
,8453853,effect compartment concentration at 50% block,"The equilibrium rate constant to the effect compartment (kco) was decreased in the elderly (0.039 versus 0.051 min-1), whereas the effect compartment concentration at 50% block was similar in both groups (44.7 versus 54.1 ng/ml).",Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453853/),[ng] / [ml],54.1,101427,DB00753,Isoflurane
,7574009,plasma clearance,"Pharmacokinetic analysis revealed that plasma clearance in the elderly group was significantly decreased compared to that in the younger group (6.7 +/- 2.2 vs 9.5 +/- 2.7 mL.kg-1.min-1, P < 0.05).",Aging alters the pharmacokinetics of pyridostigmine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574009/),[ml] / [kg·min],6.7,107246,DB00753,Isoflurane
,7574009,plasma clearance,"Pharmacokinetic analysis revealed that plasma clearance in the elderly group was significantly decreased compared to that in the younger group (6.7 +/- 2.2 vs 9.5 +/- 2.7 mL.kg-1.min-1, P < 0.05).",Aging alters the pharmacokinetics of pyridostigmine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574009/),[ml] / [kg·min],9.5,107247,DB00753,Isoflurane
,2031815,volume of distribution,Mean (SEM) volume of distribution was slightly greater with previous suxamethonium (143 (13) ml kg-1) than without (109 (5) ml kg-1) (P less than 0.04).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ml] / [kg],143,109862,DB00753,Isoflurane
,2031815,volume of distribution,Mean (SEM) volume of distribution was slightly greater with previous suxamethonium (143 (13) ml kg-1) than without (109 (5) ml kg-1) (P less than 0.04).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ml] / [kg],109,109863,DB00753,Isoflurane
,2031815,elimination half-life,"Mean elimination half-life was unaffected (20.3 (0.8) min and 20.4 (1.6) min, respectively).",Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),min,20.3,109864,DB00753,Isoflurane
,2031815,elimination half-life,"Mean elimination half-life was unaffected (20.3 (0.8) min and 20.4 (1.6) min, respectively).",Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),min,20.4,109865,DB00753,Isoflurane
,2031815,concentration at 50% block (Cpss50),Atracurium concentration at 50% block (Cpss50) was 305 (30) ng ml-1 with and 454 (25) ng ml-1 without previous suxamethonium (P less than 0.01).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ng] / [ml],305,109866,DB00753,Isoflurane
,2031815,concentration at 50% block (Cpss50),Atracurium concentration at 50% block (Cpss50) was 305 (30) ng ml-1 with and 454 (25) ng ml-1 without previous suxamethonium (P less than 0.01).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ng] / [ml],454,109867,DB00753,Isoflurane
,31353195,Clearance (CL,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg·min],33.2,110008,DB00753,Isoflurane
,31353195,Clearance (CL,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg·min],61.3,110009,DB00753,Isoflurane
,31353195,maximum concentration,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ng] / [ml],33.6,110010,DB00753,Isoflurane
,31353195,maximum concentration,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ng] / [ml],20.0,110011,DB00753,Isoflurane
,31353195,apparent volume of the rapid peripheral compartment,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],436,110012,DB00753,Isoflurane
,31353195,apparent volume of the rapid peripheral compartment,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],925,110013,DB00753,Isoflurane
,31353195,apparent volume at steady state,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],4064,110014,DB00753,Isoflurane
,31353195,apparent volume at steady state,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],7195,110015,DB00753,Isoflurane
,1744940,elimination half-life (t1/2 beta),The elimination half-life (t1/2 beta) was 21.65 +/- 3.99 min and the clearance (Cl) was 14.1 +/- 0.7 ml/kg/min.,The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,21.65,110196,DB00753,Isoflurane
,1744940,clearance (Cl),The elimination half-life (t1/2 beta) was 21.65 +/- 3.99 min and the clearance (Cl) was 14.1 +/- 0.7 ml/kg/min.,The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],14.1,110197,DB00753,Isoflurane
,1744940,t1/2 beta,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,55.95,110198,DB00753,Isoflurane
,1744940,t1/2 beta,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,68.03,110199,DB00753,Isoflurane
,1744940,Cl,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],14,110200,DB00753,Isoflurane
,1744940,Cl,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],13.6,110201,DB00753,Isoflurane
,12224866,maximum plasma concentration,"In the other 4 cats, the median maximum plasma concentration was 149.5 ng/ml, the median time to maximum plasma concentration was 2 hours, and the median area under the concentration versus time curve from zero to infinity was 1014.5 ng.h/ml.",Transdermal absorption of a liposome-encapsulated formulation of lidocaine following topical administration in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12224866/),[ng] / [ml],149.5,112915,DB00753,Isoflurane
,12224866,time to maximum plasma concentration,"In the other 4 cats, the median maximum plasma concentration was 149.5 ng/ml, the median time to maximum plasma concentration was 2 hours, and the median area under the concentration versus time curve from zero to infinity was 1014.5 ng.h/ml.",Transdermal absorption of a liposome-encapsulated formulation of lidocaine following topical administration in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12224866/),h,2,112916,DB00753,Isoflurane
,12224866,area under the concentration versus time curve from zero to infinity,"In the other 4 cats, the median maximum plasma concentration was 149.5 ng/ml, the median time to maximum plasma concentration was 2 hours, and the median area under the concentration versus time curve from zero to infinity was 1014.5 ng.h/ml.",Transdermal absorption of a liposome-encapsulated formulation of lidocaine following topical administration in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12224866/),[h·ng] / [ml],1014.5,112917,DB00753,Isoflurane
,2001028,FA/FI,"FA/FI values at 30 min of administration were: (mean +/- SD) nitrous oxide 0.99 +/- 0.01, desflurane 0.90 +/- 0.01, isoflurane 0.73 +/- 0.03, and halothane 0.58 +/- 0.04.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.99,113473,DB00753,Isoflurane
,2001028,FA/FI,"FA/FI values at 30 min of administration were: (mean +/- SD) nitrous oxide 0.99 +/- 0.01, desflurane 0.90 +/- 0.01, isoflurane 0.73 +/- 0.03, and halothane 0.58 +/- 0.04.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.90,113474,DB00753,Isoflurane
,2001028,FA/FI,"FA/FI values at 30 min of administration were: (mean +/- SD) nitrous oxide 0.99 +/- 0.01, desflurane 0.90 +/- 0.01, isoflurane 0.73 +/- 0.03, and halothane 0.58 +/- 0.04.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.73,113475,DB00753,Isoflurane
,2001028,FA/FI,"FA/FI values at 30 min of administration were: (mean +/- SD) nitrous oxide 0.99 +/- 0.01, desflurane 0.90 +/- 0.01, isoflurane 0.73 +/- 0.03, and halothane 0.58 +/- 0.04.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.58,113476,DB00753,Isoflurane
,2001028,FA/FA0,"FA/FA0 values after 5 min of elimination were: desflurane 0.14 +/- 0.02, isoflurane 0.22 +/- 0.02, and halothane 0.25 +/- 0.02.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.14,113477,DB00753,Isoflurane
,2001028,FA/FA0,"FA/FA0 values after 5 min of elimination were: desflurane 0.14 +/- 0.02, isoflurane 0.22 +/- 0.02, and halothane 0.25 +/- 0.02.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.22,113478,DB00753,Isoflurane
,2001028,FA/FA0,"FA/FA0 values after 5 min of elimination were: desflurane 0.14 +/- 0.02, isoflurane 0.22 +/- 0.02, and halothane 0.25 +/- 0.02.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.25,113479,DB00753,Isoflurane
,2001028,Recovery,Recovery (volume of anesthetic recovered during elimination per volume taken up) of desflurane (105 +/- 25%) equalled recovery of isoflurane (102 +/- 13%) and exceeded recovery of halothane (64 +/- 9%).,"Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),%,105,113480,DB00753,Isoflurane
,2001028,Recovery,Recovery (volume of anesthetic recovered during elimination per volume taken up) of desflurane (105 +/- 25%) equalled recovery of isoflurane (102 +/- 13%) and exceeded recovery of halothane (64 +/- 9%).,"Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),%,102,113481,DB00753,Isoflurane
,2001028,Recovery,Recovery (volume of anesthetic recovered during elimination per volume taken up) of desflurane (105 +/- 25%) equalled recovery of isoflurane (102 +/- 13%) and exceeded recovery of halothane (64 +/- 9%).,"Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),%,64,113482,DB00753,Isoflurane
,2001028,volume of,Recovery (volume of anesthetic recovered during elimination per volume taken up) of desflurane (105 +/- 25%) equalled recovery of isoflurane (102 +/- 13%) and exceeded recovery of halothane (64 +/- 9%).,"Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),%,105,113483,DB00753,Isoflurane
,9547698,times to peak concentration,The mean +/- S.D. times to peak concentration of propranolol in aqueous humor were 86.6 +/- 47.6 min in the dog and 54.1 +/- 20.4 min in the rabbit.,Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547698/),min,86.6,114326,DB00753,Isoflurane
,9547698,times to peak concentration,The mean +/- S.D. times to peak concentration of propranolol in aqueous humor were 86.6 +/- 47.6 min in the dog and 54.1 +/- 20.4 min in the rabbit.,Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547698/),min,54.1,114327,DB00753,Isoflurane
,9547698,terminal rate constant,The terminal rate constant was 0.0189 +/- 0.00429 min-1 in the dog vs. 0.00983 +/- 0.00546 min-1 in the rabbit.,Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547698/),1/[min],0.0189,114328,DB00753,Isoflurane
,9547698,terminal rate constant,The terminal rate constant was 0.0189 +/- 0.00429 min-1 in the dog vs. 0.00983 +/- 0.00546 min-1 in the rabbit.,Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547698/),1/[min],0.00983,114329,DB00753,Isoflurane
,9547698,Intraocular tissue availability,Intraocular tissue availability of propranolol differed markedly between the dog (n = 3) and rabbit (n = 3) (approximately 0.056 in the dog vs. approximately 0.55 in the rabbit).,Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547698/),,0.056,114330,DB00753,Isoflurane
,9547698,Intraocular tissue availability,Intraocular tissue availability of propranolol differed markedly between the dog (n = 3) and rabbit (n = 3) (approximately 0.056 in the dog vs. approximately 0.55 in the rabbit).,Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547698/),,0.55,114331,DB00753,Isoflurane
,33303396,initial plasma concentration,The initial plasma concentration of IV carprofen was estimated at 54.57 ± 3.92 μg mL-1 and decreased to 8.26 ± 1.07 μg mL-1 24 hours later.,Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),[μg] / [ml],54.57,117443,DB00753,Isoflurane
,33303396,initial plasma concentration,The initial plasma concentration of IV carprofen was estimated at 54.57 ± 3.92 μg mL-1 and decreased to 8.26 ± 1.07 μg mL-1 24 hours later.,Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),[μg] / [ml],8.26,117444,DB00753,Isoflurane
,33303396,distribution half-life,The plasma elimination curve showed a bi-exponential decline: a rapid distribution phase with a distribution half-life of 0.21 ± 0.03 hours and a slower elimination phase with an elimination half-life of 17.31 ± 3.78 hours.,Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),h,0.21,117445,DB00753,Isoflurane
,33303396,elimination half-life,The plasma elimination curve showed a bi-exponential decline: a rapid distribution phase with a distribution half-life of 0.21 ± 0.03 hours and a slower elimination phase with an elimination half-life of 17.31 ± 3.78 hours.,Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),h,17.31,117446,DB00753,Isoflurane
,33303396,area under the plasma concentration-time curve,"The calculated pharmacokinetic parameters were as follows: the area under the plasma concentration-time curve was 357.3 ± 16.73 μg mL-1 hour, volume of distribution was 0.28 ± 0.07 L kg-1 and plasma clearance rate was 0.19 ± 0.009 mL minute-1 kg-1.",Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),[h·μg] / [ml],357.3,117447,DB00753,Isoflurane
,33303396,volume of distribution,"The calculated pharmacokinetic parameters were as follows: the area under the plasma concentration-time curve was 357.3 ± 16.73 μg mL-1 hour, volume of distribution was 0.28 ± 0.07 L kg-1 and plasma clearance rate was 0.19 ± 0.009 mL minute-1 kg-1.",Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),[l] / [kg],0.28,117448,DB00753,Isoflurane
,33303396,plasma clearance rate,"The calculated pharmacokinetic parameters were as follows: the area under the plasma concentration-time curve was 357.3 ± 16.73 μg mL-1 hour, volume of distribution was 0.28 ± 0.07 L kg-1 and plasma clearance rate was 0.19 ± 0.009 mL minute-1 kg-1.",Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),[ml] / [kg·min],0.19,117449,DB00753,Isoflurane
,25523103,end tidal isoflurane concentration,"During surgery, mean end tidal isoflurane concentration was 1.63 (SD 0.24)% and normocapnia and spontaneous ventilation were maintained in all animals.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),%,1.63,119249,DB00753,Isoflurane
,25523103,distribution,"The distribution and elimination half-lives were 0.09 (SD 0.06) and 4.14 (SD 1.18) hours, respectively.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),h,0.09,119250,DB00753,Isoflurane
,25523103,elimination half-lives,"The distribution and elimination half-lives were 0.09 (SD 0.06) and 4.14 (SD 1.18) hours, respectively.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),h,4.14,119251,DB00753,Isoflurane
,25523103,body clearance,The body clearance was 56.8 (SD 33.1) mL/h/kg.,Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),[ml] / [h·kg],56.8,119252,DB00753,Isoflurane
,25523103,volume of distribution at steady-state,"The volume of distribution at steady-state and the mean residence time were 323.9 (SD 115.7) mL/kg and 6.47 (SD 2.86) hours, respectively.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),[ml] / [kg],323.9,119253,DB00753,Isoflurane
,25523103,mean residence time,"The volume of distribution at steady-state and the mean residence time were 323.9 (SD 115.7) mL/kg and 6.47 (SD 2.86) hours, respectively.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),h,6.47,119254,DB00753,Isoflurane
,2905588,isoflurane,The mean isoflurane concentration in group 1 was 0.8 vol% combined with an average alfentanil bolus of 6.8 mg and three additional doses of 1.1-1.4 mg.,[Clinical experiences with alfentanil for balanced anesthesia in upper abdominal surgery]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905588/),vol%,0.8,120712,DB00753,Isoflurane
,2905588,concentration,The mean isoflurane concentration in group 1 was 0.8 vol% combined with an average alfentanil bolus of 6.8 mg and three additional doses of 1.1-1.4 mg.,[Clinical experiences with alfentanil for balanced anesthesia in upper abdominal surgery]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905588/),vol%,0.8,120713,DB00753,Isoflurane
,17973935,clearance,"3. The systemic kinetics of indomethacin could be described by a two-compartment model, with small distribution volumes and a clearance of 0.68 L/min.",Pharmacokinetics and pharmacodynamics of indomethacin: effects on cerebral blood flow in anaesthetized sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973935/),[l] / [min],0.68,121513,DB00753,Isoflurane
,17973935,cerebral distribution volume,"The cerebral kinetics of indomethacin could be described using a model with a cerebral distribution volume between 5 and 8 mL and a loss term of 3.3 mL/min, the latter probably representing slow diffusion across the blood-brain barrier.",Pharmacokinetics and pharmacodynamics of indomethacin: effects on cerebral blood flow in anaesthetized sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973935/),ml,5 and 8,121514,DB00753,Isoflurane
,17973935,loss term,"The cerebral kinetics of indomethacin could be described using a model with a cerebral distribution volume between 5 and 8 mL and a loss term of 3.3 mL/min, the latter probably representing slow diffusion across the blood-brain barrier.",Pharmacokinetics and pharmacodynamics of indomethacin: effects on cerebral blood flow in anaesthetized sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973935/),[ml] / [min],3.3,121515,DB00753,Isoflurane
,17973935,turnover times,Indirect response models with turnover times of 1.70-4.08 min were generally better able to describe the effect of indomethacin on CBF than effect compartment models.,Pharmacokinetics and pharmacodynamics of indomethacin: effects on cerebral blood flow in anaesthetized sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973935/),min,1.70-4.08,121516,DB00753,Isoflurane
,22280391,apparent volume of distribution of the central compartment,"Weighted mean ± SEM apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state were 402 ± 47 mL/kg and 1,701 ± 200 mL/kg, respectively; clearance and terminal half-life (harmonic mean ± jackknife pseudo-SD) were 6.3 ± 2.8 mL/min/kg and 198 ± 75 minutes, respectively.",Pharmacokinetics of dexmedetomidine administered intravenously in isoflurane-anesthetized cats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280391/),[ml] / [kg],402,121821,DB00753,Isoflurane
,22280391,apparent volume of distribution at steady-state,"Weighted mean ± SEM apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state were 402 ± 47 mL/kg and 1,701 ± 200 mL/kg, respectively; clearance and terminal half-life (harmonic mean ± jackknife pseudo-SD) were 6.3 ± 2.8 mL/min/kg and 198 ± 75 minutes, respectively.",Pharmacokinetics of dexmedetomidine administered intravenously in isoflurane-anesthetized cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280391/),[ml] / [kg],"1,701",121822,DB00753,Isoflurane
,22280391,clearance,"Weighted mean ± SEM apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state were 402 ± 47 mL/kg and 1,701 ± 200 mL/kg, respectively; clearance and terminal half-life (harmonic mean ± jackknife pseudo-SD) were 6.3 ± 2.8 mL/min/kg and 198 ± 75 minutes, respectively.",Pharmacokinetics of dexmedetomidine administered intravenously in isoflurane-anesthetized cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280391/),[ml] / [kg·min],6.3,121823,DB00753,Isoflurane
,22280391,terminal half-life,"Weighted mean ± SEM apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state were 402 ± 47 mL/kg and 1,701 ± 200 mL/kg, respectively; clearance and terminal half-life (harmonic mean ± jackknife pseudo-SD) were 6.3 ± 2.8 mL/min/kg and 198 ± 75 minutes, respectively.",Pharmacokinetics of dexmedetomidine administered intravenously in isoflurane-anesthetized cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280391/),min,198,121824,DB00753,Isoflurane
,22280391,area under the plasma concentration curve,"The area under the plasma concentration curve and maximal plasma concentration were 1,061 ± 292 min•ng/mL and 17.6 ± 1.8 ng/mL, respectively.",Pharmacokinetics of dexmedetomidine administered intravenously in isoflurane-anesthetized cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280391/),[min·ng] / [ml],"1,061",121825,DB00753,Isoflurane
,22280391,maximal plasma concentration,"The area under the plasma concentration curve and maximal plasma concentration were 1,061 ± 292 min•ng/mL and 17.6 ± 1.8 ng/mL, respectively.",Pharmacokinetics of dexmedetomidine administered intravenously in isoflurane-anesthetized cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280391/),[ng] / [ml],17.6,121826,DB00753,Isoflurane
,18672959,half-life,Mean +/- SD half-life of tramadol after administration was 145.4 +/- 81.0 minutes; mean +/- SD maximum plasma concentration was 135.3 +/- 89.1 ng/mL.,Pharmacokinetics of orally administered tramadol in domestic rabbits (Oryctolagus cuniculus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18672959/),min,145.4,121851,DB00753,Isoflurane
,18672959,maximum plasma concentration,Mean +/- SD half-life of tramadol after administration was 145.4 +/- 81.0 minutes; mean +/- SD maximum plasma concentration was 135.3 +/- 89.1 ng/mL.,Pharmacokinetics of orally administered tramadol in domestic rabbits (Oryctolagus cuniculus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18672959/),[ng] / [ml],135.3,121852,DB00753,Isoflurane
,1990898,peak plasma concentration,Intranasal midazolam achieved its peak plasma concentration of 72.2 +/- 27.3 ng/ml in 10.2 +/- 2 min.,Plasma concentrations of midazolam in children following intranasal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1990898/),[ng] / [ml],72.2,121885,DB00753,Isoflurane
,2295106,elimination,"After surgery the times to awakening and extubation, and alfentanil elimination half-life (t1/2B = 0.693/-k) were determined for each patient.",Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),,0.693,122218,DB00753,Isoflurane
,2295106,times to awakening,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,3.2,122219,DB00753,Isoflurane
,2295106,extubation,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,8.8,122220,DB00753,Isoflurane
,2295106,elimination half-life,The elimination half-life for all patients was 5.1 +/- 1.0 hr (mean +/- SEM).,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,5.1,122221,DB00753,Isoflurane
,10638903,rate constant,"Decreasing core temperature over 38.0-34.0 degrees C decreases the plasma clearance of vecuronium (11.3% per degrees C), decreases the rate constant for drug equilibration between plasma and effect site (0.023 min(-1) per degrees C), and increases the slope of the concentration-response relationship (0.43 per degrees C).",Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638903/),1/[c·degrees·min],0.023,128475,DB00753,Isoflurane
,33423953,terminal half-life,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),min,44.3,130142,DB00753,Isoflurane
,33423953,volume of distribution,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),[l] / [kg],0.43,130143,DB00753,Isoflurane
,33423953,plasma clearance,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),[ml] / [kg·min],7.77,130144,DB00753,Isoflurane
,10526823,end-tidal concentration (FA,"Mean end-tidal concentration (FA = FA0) at the end of anesthesia was 6.34 +/- 1.15% after desflurane, 1.85 +/- 0.42% after sevoflurane, and 1.10 +/- 0.24% after isoflurane.","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),%,6.34,133161,DB00753,Isoflurane
,10526823,end-tidal concentration (FA,"Mean end-tidal concentration (FA = FA0) at the end of anesthesia was 6.34 +/- 1.15% after desflurane, 1.85 +/- 0.42% after sevoflurane, and 1.10 +/- 0.24% after isoflurane.","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),%,1.85,133162,DB00753,Isoflurane
,10526823,end-tidal concentration (FA,"Mean end-tidal concentration (FA = FA0) at the end of anesthesia was 6.34 +/- 1.15% after desflurane, 1.85 +/- 0.42% after sevoflurane, and 1.10 +/- 0.24% after isoflurane.","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),%,1.10,133163,DB00753,Isoflurane
,10526823,terminal half-life (t1/2),"As for the terminal half-life (t1/2), there were no differences among the groups (8.16 +/- 3.15 min after desflurane, 9.47 +/- 4.46 min after sevoflurane, and 10.0 +/- 5.57 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,8.16,133164,DB00753,Isoflurane
,10526823,terminal half-life (t1/2),"As for the terminal half-life (t1/2), there were no differences among the groups (8.16 +/- 3.15 min after desflurane, 9.47 +/- 4.46 min after sevoflurane, and 10.0 +/- 5.57 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,9.47,133165,DB00753,Isoflurane
,10526823,terminal half-life (t1/2),"As for the terminal half-life (t1/2), there were no differences among the groups (8.16 +/- 3.15 min after desflurane, 9.47 +/- 4.46 min after sevoflurane, and 10.0 +/- 5.57 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,10.0,133166,DB00753,Isoflurane
,10526823,time until a command was followed,"The time until a command was followed for the first time was the same in all three groups (13.0 +/- 4.7 min after desflurane, 13.4 +/- 4.4 min after sevoflurane, and 13.6 +/- 3.4 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,13.0,133167,DB00753,Isoflurane
,10526823,time until a command was followed,"The time until a command was followed for the first time was the same in all three groups (13.0 +/- 4.7 min after desflurane, 13.4 +/- 4.4 min after sevoflurane, and 13.6 +/- 3.4 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,13.4,133168,DB00753,Isoflurane
,10526823,time until a command was followed,"The time until a command was followed for the first time was the same in all three groups (13.0 +/- 4.7 min after desflurane, 13.4 +/- 4.4 min after sevoflurane, and 13.6 +/- 3.4 min after isoflurane).","Recovery and pharmacokinetic parameters of desflurane, sevoflurane, and isoflurane in patients undergoing urologic procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526823/),min,13.6,133169,DB00753,Isoflurane
,3407970,peak values,"The mean peak values of fluoride ions were 3.8 +/- 1.1, 3.9 +/- 1.4, and 4.2 +/- 0.9 mumole/1 (M +/- SD) in patients in groups I, II, and III, respectively.",Biotransformation of isoflurane: urinary and serum fluoride ion and organic fluorine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407970/),mumole,3.8,133954,DB00753,Isoflurane
,3407970,peak values,"The mean peak values of fluoride ions were 3.8 +/- 1.1, 3.9 +/- 1.4, and 4.2 +/- 0.9 mumole/1 (M +/- SD) in patients in groups I, II, and III, respectively.",Biotransformation of isoflurane: urinary and serum fluoride ion and organic fluorine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407970/),mumole,3.9,133955,DB00753,Isoflurane
,3407970,peak values,"The mean peak values of fluoride ions were 3.8 +/- 1.1, 3.9 +/- 1.4, and 4.2 +/- 0.9 mumole/1 (M +/- SD) in patients in groups I, II, and III, respectively.",Biotransformation of isoflurane: urinary and serum fluoride ion and organic fluorine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407970/),mumole,4.2,133956,DB00753,Isoflurane
,3407970,half-lives,"The half-lives of fluoride ion and of organic fluorine as metabolites of isoflurane, calculated from the amounts excreted in urine, were 36 h and 41 h, respectively.",Biotransformation of isoflurane: urinary and serum fluoride ion and organic fluorine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407970/),h,36,133957,DB00753,Isoflurane
,3407970,half-lives,"The half-lives of fluoride ion and of organic fluorine as metabolites of isoflurane, calculated from the amounts excreted in urine, were 36 h and 41 h, respectively.",Biotransformation of isoflurane: urinary and serum fluoride ion and organic fluorine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407970/),h,41,133958,DB00753,Isoflurane
,7853456,half-life,"In plasma, a very short initial distribution phase in both horses and ponies, half-life 1.4 +/- 1.2 min (mean +/- SD) and 1.3 +/- 0.7 min, respectively, was obtained, which was followed by a second comparatively slower redistribution phase, half-life 16 +/- 12 min and 11 +/- 5 min, respectively.",Pharmacokinetics of thiopentone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,1.4,135041,DB00753,Isoflurane
,7853456,half-life,"In plasma, a very short initial distribution phase in both horses and ponies, half-life 1.4 +/- 1.2 min (mean +/- SD) and 1.3 +/- 0.7 min, respectively, was obtained, which was followed by a second comparatively slower redistribution phase, half-life 16 +/- 12 min and 11 +/- 5 min, respectively.",Pharmacokinetics of thiopentone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,1.3,135042,DB00753,Isoflurane
,7853456,half-life,"In plasma, a very short initial distribution phase in both horses and ponies, half-life 1.4 +/- 1.2 min (mean +/- SD) and 1.3 +/- 0.7 min, respectively, was obtained, which was followed by a second comparatively slower redistribution phase, half-life 16 +/- 12 min and 11 +/- 5 min, respectively.",Pharmacokinetics of thiopentone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,16,135043,DB00753,Isoflurane
,7853456,half-life,"In plasma, a very short initial distribution phase in both horses and ponies, half-life 1.4 +/- 1.2 min (mean +/- SD) and 1.3 +/- 0.7 min, respectively, was obtained, which was followed by a second comparatively slower redistribution phase, half-life 16 +/- 12 min and 11 +/- 5 min, respectively.",Pharmacokinetics of thiopentone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,11,135044,DB00753,Isoflurane
,7853456,volume of distribution,"The volume of distribution for the drug was large, especially in the ponies which received isoflurane (1127 +/- 86 ml/kg), compared to the horses which received halothane (742 +/- 89 ml/kg).",Pharmacokinetics of thiopentone in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),[ml] / [kg],1127,135045,DB00753,Isoflurane
,7853456,volume of distribution,"The volume of distribution for the drug was large, especially in the ponies which received isoflurane (1127 +/- 86 ml/kg), compared to the horses which received halothane (742 +/- 89 ml/kg).",Pharmacokinetics of thiopentone in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),[ml] / [kg],742,135046,DB00753,Isoflurane
,7853456,elimination half-life,"The drug had a somewhat shorter elimination half-life in the horses (147 +/- 21 min) than in than ponies (222 +/- 44 min), but no obvious difference in clearance of the drug was observed between the horses (3.5 +/- 0.5 ml/min/kg) and ponies (3.6 +/- 0.8 ml/min/kg).",Pharmacokinetics of thiopentone in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,147,135047,DB00753,Isoflurane
,7853456,elimination half-life,"The drug had a somewhat shorter elimination half-life in the horses (147 +/- 21 min) than in than ponies (222 +/- 44 min), but no obvious difference in clearance of the drug was observed between the horses (3.5 +/- 0.5 ml/min/kg) and ponies (3.6 +/- 0.8 ml/min/kg).",Pharmacokinetics of thiopentone in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,222,135048,DB00753,Isoflurane
,7853456,clearance,"The drug had a somewhat shorter elimination half-life in the horses (147 +/- 21 min) than in than ponies (222 +/- 44 min), but no obvious difference in clearance of the drug was observed between the horses (3.5 +/- 0.5 ml/min/kg) and ponies (3.6 +/- 0.8 ml/min/kg).",Pharmacokinetics of thiopentone in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),[ml] / [kg·min],3.5,135049,DB00753,Isoflurane
,7853456,clearance,"The drug had a somewhat shorter elimination half-life in the horses (147 +/- 21 min) than in than ponies (222 +/- 44 min), but no obvious difference in clearance of the drug was observed between the horses (3.5 +/- 0.5 ml/min/kg) and ponies (3.6 +/- 0.8 ml/min/kg).",Pharmacokinetics of thiopentone in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),[ml] / [kg·min],3.6,135050,DB00753,Isoflurane
,2889403,initial rate,"Thirty healthy surgical patients were given an initial 0.1 mg/kg bolus of vecuronium, followed by an infusion of vecuronium at an initial rate of 1.0 microgram .",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),,1,138618,DB00753,Isoflurane
,2889403,infusion rates,"Vecuronium infusion rates (mean +/- SD) were similar for patients given enflurane (0.28 +/- 0.13 microgram . kg-1 . min-1) and isoflurane (0.30 +/- 0.13 microgram . kg-1 . min-1), but significantly higher in patients given fentanyl (0.92 +/- 0.37 microgram . kg-1 . min-1).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[μg] / [kg·min],0.28,138619,DB00753,Isoflurane
,2889403,infusion rates,"Vecuronium infusion rates (mean +/- SD) were similar for patients given enflurane (0.28 +/- 0.13 microgram . kg-1 . min-1) and isoflurane (0.30 +/- 0.13 microgram . kg-1 . min-1), but significantly higher in patients given fentanyl (0.92 +/- 0.37 microgram . kg-1 . min-1).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[μg] / [kg·min],0.30,138620,DB00753,Isoflurane
,2889403,infusion rates,"Vecuronium infusion rates (mean +/- SD) were similar for patients given enflurane (0.28 +/- 0.13 microgram . kg-1 . min-1) and isoflurane (0.30 +/- 0.13 microgram . kg-1 . min-1), but significantly higher in patients given fentanyl (0.92 +/- 0.37 microgram . kg-1 . min-1).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[μg] / [kg·min],0.92,138621,DB00753,Isoflurane
,2889403,Css90,"Values for Css90 in the patients receiving enflurane and isoflurane were similar (71 +/- 34 and 72 +/- 44 ng/ml, respectively), but significantly higher in those receiving fentanyl (165 +/- 48 ng/ml).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ng] / [ml],71,138622,DB00753,Isoflurane
,2889403,Css90,"Values for Css90 in the patients receiving enflurane and isoflurane were similar (71 +/- 34 and 72 +/- 44 ng/ml, respectively), but significantly higher in those receiving fentanyl (165 +/- 48 ng/ml).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ng] / [ml],72,138623,DB00753,Isoflurane
,2889403,Css90,"Values for Css90 in the patients receiving enflurane and isoflurane were similar (71 +/- 34 and 72 +/- 44 ng/ml, respectively), but significantly higher in those receiving fentanyl (165 +/- 48 ng/ml).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ng] / [ml],165,138624,DB00753,Isoflurane
,2889403,Total plasma clearance,"Total plasma clearance was similar during enflurane, isoflurane, and fentanyl anesthesia (4.4 +/- 2.6, 4.6 +/- 1.2, and 5.6 +/- 1.9 ml X kg-1 min-1, respectively).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ml] / [kg·min],4.4,138625,DB00753,Isoflurane
,2889403,Total plasma clearance,"Total plasma clearance was similar during enflurane, isoflurane, and fentanyl anesthesia (4.4 +/- 2.6, 4.6 +/- 1.2, and 5.6 +/- 1.9 ml X kg-1 min-1, respectively).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ml] / [kg·min],4.6,138626,DB00753,Isoflurane
,2889403,Total plasma clearance,"Total plasma clearance was similar during enflurane, isoflurane, and fentanyl anesthesia (4.4 +/- 2.6, 4.6 +/- 1.2, and 5.6 +/- 1.9 ml X kg-1 min-1, respectively).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ml] / [kg·min],5.6,138627,DB00753,Isoflurane
,28655497,volume of distribution at steady state,"Median volume of distribution at steady state and terminal half-life were 3169 mL kg-1 (range, 2182-3859 mL kg-1) and 80 minutes (range, 72-88 minutes), respectively.",Pharmacokinetics of dexmedetomidine in isoflurane-anesthetized New Zealand White rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28655497/),[ml] / [kg],3169,139801,DB00753,Isoflurane
,28655497,terminal half-life,"Median volume of distribution at steady state and terminal half-life were 3169 mL kg-1 (range, 2182-3859 mL kg-1) and 80 minutes (range, 72-88 minutes), respectively.",Pharmacokinetics of dexmedetomidine in isoflurane-anesthetized New Zealand White rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28655497/),min,80,139802,DB00753,Isoflurane
,1642933,plasma clearance,Patients with non-alcoholic liver disease had lesser plasma clearance (114.8 (range 66.8-213.5) ml min-1) than the alcoholic group (158.8 (100.0-220.7) ml min-1) or controls (187.4 (125.2-269.5) ml min-1).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),[ml] / [min],114.8,140727,DB00753,Isoflurane
,1642933,plasma clearance,Patients with non-alcoholic liver disease had lesser plasma clearance (114.8 (range 66.8-213.5) ml min-1) than the alcoholic group (158.8 (100.0-220.7) ml min-1) or controls (187.4 (125.2-269.5) ml min-1).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),[ml] / [min],158.8,140728,DB00753,Isoflurane
,1642933,plasma clearance,Patients with non-alcoholic liver disease had lesser plasma clearance (114.8 (range 66.8-213.5) ml min-1) than the alcoholic group (158.8 (100.0-220.7) ml min-1) or controls (187.4 (125.2-269.5) ml min-1).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),[ml] / [min],187.4,140729,DB00753,Isoflurane
,1642933,Mean residence time,Mean residence time was prolonged in the alcoholic group compared with controls (284.9 (217.8-362.2) min vs 226.8 (201.2-250) min).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),min,284.9,140730,DB00753,Isoflurane
,1642933,Mean residence time,Mean residence time was prolonged in the alcoholic group compared with controls (284.9 (217.8-362.2) min vs 226.8 (201.2-250) min).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),min,226.8,140731,DB00753,Isoflurane
,25943714,plasma concentrations,Mean fentanyl plasma concentrations were 1.6-4.5 ng mL(-1) during isoflurane anesthesia and 1.6-2.0 ng mL(-1) during recovery from anesthesia.,Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[ng] / [ml],1.6-4.5,140789,DB00753,Isoflurane
,25943714,plasma concentrations,Mean fentanyl plasma concentrations were 1.6-4.5 ng mL(-1) during isoflurane anesthesia and 1.6-2.0 ng mL(-1) during recovery from anesthesia.,Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[ng] / [ml],1.6-2.0,140790,DB00753,Isoflurane
,25943714,volume of the central compartment,Recovery from isoflurane anesthesia without sedation was associated with an increase in the volume of the central compartment from 0.80 to 1.02 L kg(-1).,Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[l] / [kg],0.80,140791,DB00753,Isoflurane
,25943714,volume of the central compartment,Recovery from isoflurane anesthesia without sedation was associated with an increase in the volume of the central compartment from 0.80 to 1.02 L kg(-1).,Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[l] / [kg],1.02,140792,DB00753,Isoflurane
,25943714,systemic clearance,"After administration of acepromazine, systemic clearance of fentanyl increased from 31.5 to 40.3 mL minute(-1) kg(-1) and the volume of the central compartment increased from 0.70 to 0.94 L kg(-1).",Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[ml] / [kg·minute],31.5 to 40.3,140793,DB00753,Isoflurane
,25943714,volume of the central compartment,"After administration of acepromazine, systemic clearance of fentanyl increased from 31.5 to 40.3 mL minute(-1) kg(-1) and the volume of the central compartment increased from 0.70 to 0.94 L kg(-1).",Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[l] / [kg],0,140794,DB00753,Isoflurane
,7913801,recovery time,"Atracurium's recovery time increased 2.4 +/- 2.2 min (mean +/- SD) with the larger dose, less than the increase with vecuronium (8.2 +/- 3.8 min).",Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,2.4,144052,DB00753,Isoflurane
,7913801,recovery time,"Atracurium's recovery time increased 2.4 +/- 2.2 min (mean +/- SD) with the larger dose, less than the increase with vecuronium (8.2 +/- 3.8 min).",Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,8.2,144053,DB00753,Isoflurane
,7913801,recovery phase half-life,Atracurium's recovery phase half-life was 14.6 +/- 1.7 and 20.1 +/- 2.3 min with the small and large doses (P < 0.05); vecuronium's recovery phase half-life increased similarly from 13.5 +/- 2.3 to 18.5 +/- 5.0 min (P < 0.05).,Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,14.6,144054,DB00753,Isoflurane
,7913801,recovery phase half-life,Atracurium's recovery phase half-life was 14.6 +/- 1.7 and 20.1 +/- 2.3 min with the small and large doses (P < 0.05); vecuronium's recovery phase half-life increased similarly from 13.5 +/- 2.3 to 18.5 +/- 5.0 min (P < 0.05).,Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,20.1,144055,DB00753,Isoflurane
,7913801,recovery phase half-life,Atracurium's recovery phase half-life was 14.6 +/- 1.7 and 20.1 +/- 2.3 min with the small and large doses (P < 0.05); vecuronium's recovery phase half-life increased similarly from 13.5 +/- 2.3 to 18.5 +/- 5.0 min (P < 0.05).,Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,13.5,144056,DB00753,Isoflurane
,7913801,recovery phase half-life,Atracurium's recovery phase half-life was 14.6 +/- 1.7 and 20.1 +/- 2.3 min with the small and large doses (P < 0.05); vecuronium's recovery phase half-life increased similarly from 13.5 +/- 2.3 to 18.5 +/- 5.0 min (P < 0.05).,Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,18.5,144057,DB00753,Isoflurane
,7913801,Ce,"At 75% recovery, vecuronium's Ce decreased from 65 +/- 18 ng/ml with the small dose to 55 +/- 15 ng/ml with the large dose (P < 0.05).",Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),[ng] / [ml],65,144058,DB00753,Isoflurane
,7913801,Ce,"At 75% recovery, vecuronium's Ce decreased from 65 +/- 18 ng/ml with the small dose to 55 +/- 15 ng/ml with the large dose (P < 0.05).",Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),[ng] / [ml],55,144059,DB00753,Isoflurane
,9806701,elimination rate constant,The elimination rate constant from the peripheral compartment was fixed to the in vitro rate of degradation of cisatracurium in human plasma (0.0237 min(-1)).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.0237,145684,DB00753,Isoflurane
,9806701,rate of degradation,The elimination rate constant from the peripheral compartment was fixed to the in vitro rate of degradation of cisatracurium in human plasma (0.0237 min(-1)).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.0237,145685,DB00753,Isoflurane
,9806701,terminal half-life,"The mean terminal half-life of cisatracurium was 23.9+/-3.3 min, and its total clearance averaged 3.7+/-0.8 mL x min(-1) x kg(-1).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),min,23.9,145686,DB00753,Isoflurane
,9806701,total clearance,"The mean terminal half-life of cisatracurium was 23.9+/-3.3 min, and its total clearance averaged 3.7+/-0.8 mL x min(-1) x kg(-1).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[ml] / [kg·min],3.7,145687,DB00753,Isoflurane
,9806701,volume of distribution at steady state,"Using this model, the volume of distribution at steady state was significantly increased compared with that obtained when central elimination only was assumed (0.118+/-0.027 vs 0.089+/-0.017 L/kg).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[l] / [kg],0.118,145688,DB00753,Isoflurane
,9806701,volume of distribution at steady state,"Using this model, the volume of distribution at steady state was significantly increased compared with that obtained when central elimination only was assumed (0.118+/-0.027 vs 0.089+/-0.017 L/kg).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[l] / [kg],0.089,145689,DB00753,Isoflurane
,9806701,rate constant,The effect-plasma equilibration rate constant was 0.054+/-0.013 min(-1).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.054,145690,DB00753,Isoflurane
,9806701,50% effective concentration,"The 50% effective concentration (153+/-33 ng/mL) was 56% higher than that reported in patients anesthetized with volatile anesthetics, which suggests that, compared with inhaled anesthetics, a cisatracurium neuromuscular block is less enhanced by propofol.",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[ng] / [ml],153,145691,DB00753,Isoflurane
,12928584,C(I)iso,"Sixteen patients (aged 43-76 years) undergoing colorectal surgery were enrolled, and anesthesia was maintained with a constant C(I)iso of either 1% (group 1, n = 8) or 2% (group 2, n = 8) during the 1st hour of isoflurane anesthesia.",Pharmacokinetics of isoflurane: uptake in the brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12928584/),%,1,149329,DB00753,Isoflurane
,12928584,C(I)iso,"Sixteen patients (aged 43-76 years) undergoing colorectal surgery were enrolled, and anesthesia was maintained with a constant C(I)iso of either 1% (group 1, n = 8) or 2% (group 2, n = 8) during the 1st hour of isoflurane anesthesia.",Pharmacokinetics of isoflurane: uptake in the brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12928584/),%,2,149330,DB00753,Isoflurane
,8544280,clinical duration,"The clinical duration of vecuronium, defined as recovery to 25% of the control first twitch in the train-of-four sequence, was significantly longer in the clonidine group (51.2 +/- 7.5 minutes compared with 40.5 +/- 5.1 minutes in the control group, P < 0.01).",[The effect of clonidine on the duration of vecuronium-induced neuromuscular blockade in humans]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8544280/),min,51.2,152868,DB00753,Isoflurane
,8544280,clinical duration,"The clinical duration of vecuronium, defined as recovery to 25% of the control first twitch in the train-of-four sequence, was significantly longer in the clonidine group (51.2 +/- 7.5 minutes compared with 40.5 +/- 5.1 minutes in the control group, P < 0.01).",[The effect of clonidine on the duration of vecuronium-induced neuromuscular blockade in humans]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8544280/),min,40.5,152869,DB00753,Isoflurane
,18380586,apparent volume of distribution of the central compartment,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),[ml] / [kg],"1,596",153299,DB00753,Isoflurane
,18380586,apparent volume of distribution at steady state,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),[ml] / [kg],567,153300,DB00753,Isoflurane
,18380586,apparent volume of distribution at steady state,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),[ml] / [kg],"7,632",153301,DB00753,Isoflurane
,18380586,clearance,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),[ml] / [kg],"7,632",153302,DB00753,Isoflurane
,18380586,terminal half-life,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),[ml] / [kg],"1,651",153303,DB00753,Isoflurane
,18380586,terminal half-life,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),[ml] / [kg·min],371,153304,DB00753,Isoflurane
,18380586,terminal half-life,"The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, the clearance, and the terminal half-life (median [range]) were 1,596 (1,164 to 2,111) and 567 (278 to 641) mL/kg, 7,632 (2,284 to 76,039) and 1,651 (446 to 29,229) mL/kg, 766 (408 to 1,473) and 371 (197 to 472) mL/min/kg, and 17.4 (5.5 to 920.3) and 15.7 (3.8 to 410.3) minutes in conscious and anesthetized cats, respectively.",Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18380586/),min,17.4,153305,DB00753,Isoflurane
,11312475,CPB time,"CPB time was 116 +/- 10 minutes, and ischemic time was 81 +/- 6 minutes.",Desflurane pharmacokinetics during cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11312475/),min,116,154299,DB00753,Isoflurane
,11312475,ischemic time,"CPB time was 116 +/- 10 minutes, and ischemic time was 81 +/- 6 minutes.",Desflurane pharmacokinetics during cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11312475/),min,81,154300,DB00753,Isoflurane
,11312475,pump flow,"Mean pump flow was 4.49 +/- 0.03 L/min, and mean arterial pressure was 70.1 +/- 1 mmHg during the study period.",Desflurane pharmacokinetics during cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11312475/),[l] / [min],4.49,154301,DB00753,Isoflurane
,15509291,Minimum alveolar concentration,Minimum alveolar concentration of I was 1.34 +/- 0.11 (%; mean +/- SD) for both types of stimulus.,Effect of lidocaine on the minimum alveolar concentration of isoflurane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509291/),%,1.34,156139,DB00753,Isoflurane
,15509291,Plasma concentrations,"Plasma concentrations (ng mL(-1), median; value below and above MAC, respectively) for LCRI were: lidocaine, 1465 and 1537; glycinexylidide (GX), 111 and 181; monoethylglycinexylidide (MEGX), 180 and 471 and for HCRI were: lidocaine, 4350 and 4691; GX, 784 and 862; MEGX, 714 and 710.",Effect of lidocaine on the minimum alveolar concentration of isoflurane in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509291/),[ng] / [ml],146,156140,DB00753,Isoflurane
,15509291,Plasma concentrations,"Plasma concentrations (ng mL(-1), median; value below and above MAC, respectively) for LCRI were: lidocaine, 1465 and 1537; glycinexylidide (GX), 111 and 181; monoethylglycinexylidide (MEGX), 180 and 471 and for HCRI were: lidocaine, 4350 and 4691; GX, 784 and 862; MEGX, 714 and 710.",Effect of lidocaine on the minimum alveolar concentration of isoflurane in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509291/),[ng] / [ml],435,156141,DB00753,Isoflurane
,31806431,distribution clearances,"Typical value (% interindividual variability) for the three volumes (mL kg-1), the metabolic clearance and two distribution clearances (mL minute-1 kg-1) were 34 (55), 151 (35), 306 (18), 2.3 (34), 42.6 (25) and 5.6 (0), respectively.",Pharmacokinetics of vatinoxan in male neutered cats anesthetized with isoflurane. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806431/),[ml] / [kg·min],2.3,159800,DB00753,Isoflurane
,31806431,distribution clearances,"Typical value (% interindividual variability) for the three volumes (mL kg-1), the metabolic clearance and two distribution clearances (mL minute-1 kg-1) were 34 (55), 151 (35), 306 (18), 2.3 (34), 42.6 (25) and 5.6 (0), respectively.",Pharmacokinetics of vatinoxan in male neutered cats anesthetized with isoflurane. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806431/),[ml] / [kg·min],42.6,159801,DB00753,Isoflurane
,31806431,distribution clearances,"Typical value (% interindividual variability) for the three volumes (mL kg-1), the metabolic clearance and two distribution clearances (mL minute-1 kg-1) were 34 (55), 151 (35), 306 (18), 2.3 (34), 42.6 (25) and 5.6 (0), respectively.",Pharmacokinetics of vatinoxan in male neutered cats anesthetized with isoflurane. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806431/),[ml] / [kg·min],5.6,159802,DB00753,Isoflurane
,31806431,second distribution clearance,Hypotension increased the second distribution clearance to 10.6.,Pharmacokinetics of vatinoxan in male neutered cats anesthetized with isoflurane. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806431/),,10.6,159803,DB00753,Isoflurane
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],0.16,160504,DB00753,Isoflurane
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],0.31,160505,DB00753,Isoflurane
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],0.63,160506,DB00753,Isoflurane
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],1.25,160507,DB00753,Isoflurane
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],2.5,160508,DB00753,Isoflurane
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],5,160509,DB00753,Isoflurane
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],10,160510,DB00753,Isoflurane
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],20,160511,DB00753,Isoflurane
,21521237,MAC,"Mean ± SE MAC(iso.0), determined in a previous study conducted under conditions identical to those in this study, was 2.07 ± 0.04.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),,2.07,160512,DB00753,Isoflurane
,21521237,I(max),"Weighted mean ± SE I(max), and IC(50) estimated by the model were 1.76 ± 0.07%, and 1.05 ± 0.08 ng/mL, respectively.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),%,1.76,160513,DB00753,Isoflurane
,21521237,IC(50),"Weighted mean ± SE I(max), and IC(50) estimated by the model were 1.76 ± 0.07%, and 1.05 ± 0.08 ng/mL, respectively.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],1.05,160514,DB00753,Isoflurane
,21521237,MAC(iso),"The lowest MAC(iso) predicted by the model was 0.38 ± 0.08%, illustrating that dexmedetomidine alone is not expected to result in immobility in response to noxious stimulation in cats at any plasma concentration.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),%,0.38,160515,DB00753,Isoflurane
,11748515,effect-site concentrations,"Sufentanil was administered by target-controlled infusion, with target effect-site concentrations ranging from 0.4 to 4.5 ng/mL.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[ng] / [ml],0.4 to 4.5,161310,DB00753,Isoflurane
,11748515,V(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,5.7,161311,DB00753,Isoflurane
,11748515,V(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,18.1,161312,DB00753,Isoflurane
,11748515,V(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,225,161313,DB00753,Isoflurane
,11748515,Cl(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],0.69,161314,DB00753,Isoflurane
,11748515,Cl(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],3.1,161315,DB00753,Isoflurane
,11748515,Cl(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],1.4,161316,DB00753,Isoflurane
,19608809,effect,Hemorrhagic shock decreased the effect-site concentration that produced 50% of the maximal BIS effect from 11.6 +/- 3.8 to 9.1 +/- 1.7 microg/mL and that producing a 50% probability of movement from 26.8 +/- 1.0 to 20.6 +/- 1.0 microg/mL.,The influence of hemorrhagic shock on the electroencephalographic and immobilizing effects of propofol in a swine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19608809/),[μg] / [ml],11.6,161493,DB00753,Isoflurane
,19608809,effect,Hemorrhagic shock decreased the effect-site concentration that produced 50% of the maximal BIS effect from 11.6 +/- 3.8 to 9.1 +/- 1.7 microg/mL and that producing a 50% probability of movement from 26.8 +/- 1.0 to 20.6 +/- 1.0 microg/mL.,The influence of hemorrhagic shock on the electroencephalographic and immobilizing effects of propofol in a swine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19608809/),[μg] / [ml],9.1,161494,DB00753,Isoflurane
,19608809,50% probability of movement,Hemorrhagic shock decreased the effect-site concentration that produced 50% of the maximal BIS effect from 11.6 +/- 3.8 to 9.1 +/- 1.7 microg/mL and that producing a 50% probability of movement from 26.8 +/- 1.0 to 20.6 +/- 1.0 microg/mL.,The influence of hemorrhagic shock on the electroencephalographic and immobilizing effects of propofol in a swine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19608809/),[μg] / [ml],26.8,161495,DB00753,Isoflurane
,19608809,50% probability of movement,Hemorrhagic shock decreased the effect-site concentration that produced 50% of the maximal BIS effect from 11.6 +/- 3.8 to 9.1 +/- 1.7 microg/mL and that producing a 50% probability of movement from 26.8 +/- 1.0 to 20.6 +/- 1.0 microg/mL.,The influence of hemorrhagic shock on the electroencephalographic and immobilizing effects of propofol in a swine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19608809/),[μg] / [ml],20.6,161496,DB00753,Isoflurane
,9669003,Systemic temperature,Systemic temperature for patients in the normothermic and hypothermic groups was maintained at 33-36 C and 26-30 C respectively.,Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),c,33-36,161929,DB00753,Isoflurane
,9669003,Systemic temperature,Systemic temperature for patients in the normothermic and hypothermic groups was maintained at 33-36 C and 26-30 C respectively.,Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),c,26-30,161930,DB00753,Isoflurane
,9669003,terminal elimination half-life (t1/2 beta),"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,100.1,161931,DB00753,Isoflurane
,9669003,terminal elimination half-life (t1/2 beta),"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,183.8,161932,DB00753,Isoflurane
,9669003,elimination half-life during the CPB phase (T1/2 CPB,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,114.5,161933,DB00753,Isoflurane
,9669003,elimination half-life during the CPB phase (T1/2 CPB,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,183.8,161934,DB00753,Isoflurane
,9669003,mean residence time,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,108.8,161935,DB00753,Isoflurane
,9669003,mean residence time,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,164.8,161936,DB00753,Isoflurane
,9669003,apparent volume of distribution at steady state,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[l] / [kg],0.20,161937,DB00753,Isoflurane
,9669003,apparent volume of distribution at steady state,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[l] / [kg],0.26,161938,DB00753,Isoflurane
,9669003,rate of renal clearance,"Compared with the hypothermic group, the normothermic group had a higher rate of renal clearance (1.40 +/- 0.4 vs 0.93 +/- 0.3 ml.min-1.kg-1; P < 0.05) and a higher value for renal clearance as a percentage of the total clearance (76.2 +/- 10 vs 58.3 +/- 20%).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[ml] / [kg·min],1.40,161939,DB00753,Isoflurane
,9669003,rate of renal clearance,"Compared with the hypothermic group, the normothermic group had a higher rate of renal clearance (1.40 +/- 0.4 vs 0.93 +/- 0.3 ml.min-1.kg-1; P < 0.05) and a higher value for renal clearance as a percentage of the total clearance (76.2 +/- 10 vs 58.3 +/- 20%).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[ml] / [kg·min],0.93,161940,DB00753,Isoflurane
,8915441,T1,The infusion was discontinued and 50 to 75% T1 recovery time was recorded.,"Pharmacokinetics, effects on renal function, and potentiation of atracurium-induced neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8915441/),%,50 to 75,162130,DB00753,Isoflurane
,8915441,volume of distribution,"Mean values for volume of distribution and clearance were 0.263 L/kg and 2.0 ml/min/kg, respectively.","Pharmacokinetics, effects on renal function, and potentiation of atracurium-induced neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8915441/),[l] / [kg],0.263,162131,DB00753,Isoflurane
,8915441,clearance,"Mean values for volume of distribution and clearance were 0.263 L/kg and 2.0 ml/min/kg, respectively.","Pharmacokinetics, effects on renal function, and potentiation of atracurium-induced neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8915441/),[ml] / [kg·min],2.0,162132,DB00753,Isoflurane
,8915441,maximal serum concentration,Mean maximal serum concentration of gentamicin was 46.4 micrograms/ml.,"Pharmacokinetics, effects on renal function, and potentiation of atracurium-induced neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8915441/),[μg] / [ml],46.4,162133,DB00753,Isoflurane
,23473380,minimal alveolar concentration,"During surgery, mean minimal alveolar concentration of isoflurane was 1.69 ± 0.11%, and normocapnia and spontaneous ventilation were maintained in all animals.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),%,1.69,163499,DB00753,Isoflurane
,23473380,elimination half-life (t½λz ),"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),h,10.95,163500,DB00753,Isoflurane
,23473380,ClB,"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[ml] / [h·kg],92.66,163501,DB00753,Isoflurane
,23473380,Vdss,"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[ml] / [kg],1030.09,163502,DB00753,Isoflurane
,23473380,Vz,"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[ml] / [kg],1512.25,163503,DB00753,Isoflurane
,23473380,AUC(0→last),"AUC(0→last) and MRT(0→last) were 6.08 ± 3.28 h × μg/mL and 5.59 ± 2.12 h, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[h·μg] / [ml],6.08,163504,DB00753,Isoflurane
,23473380,MRT(0→last),"AUC(0→last) and MRT(0→last) were 6.08 ± 3.28 h × μg/mL and 5.59 ± 2.12 h, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),h,5.59,163505,DB00753,Isoflurane
,16426207,target plasma concentrations,"Actual mean +/- SD plasma ketamine concentrations were 1.07 +/- 0.42 microg/mL, 1.62 +/- 0.98 microg/mL, 3.32 +/- 0.59 microg/mL, 4.92 +/- 2.64 microg/mL, 13.03 +/- 10.49 microg/mL, and 22.80 +/- 25.56 microg/mL for target plasma concentrations of 0.5, 1, 2, 5, 8, and 11 microg/mL, respectively.",Effect of intravenous administration of ketamine on the minimum alveolar concentration of isoflurane in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426207/),[μg] / [ml],0.5,169768,DB00753,Isoflurane
,16426207,target plasma concentrations,"Actual mean +/- SD plasma ketamine concentrations were 1.07 +/- 0.42 microg/mL, 1.62 +/- 0.98 microg/mL, 3.32 +/- 0.59 microg/mL, 4.92 +/- 2.64 microg/mL, 13.03 +/- 10.49 microg/mL, and 22.80 +/- 25.56 microg/mL for target plasma concentrations of 0.5, 1, 2, 5, 8, and 11 microg/mL, respectively.",Effect of intravenous administration of ketamine on the minimum alveolar concentration of isoflurane in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426207/),[μg] / [ml],1,169769,DB00753,Isoflurane
,16426207,target plasma concentrations,"Actual mean +/- SD plasma ketamine concentrations were 1.07 +/- 0.42 microg/mL, 1.62 +/- 0.98 microg/mL, 3.32 +/- 0.59 microg/mL, 4.92 +/- 2.64 microg/mL, 13.03 +/- 10.49 microg/mL, and 22.80 +/- 25.56 microg/mL for target plasma concentrations of 0.5, 1, 2, 5, 8, and 11 microg/mL, respectively.",Effect of intravenous administration of ketamine on the minimum alveolar concentration of isoflurane in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426207/),[μg] / [ml],2,169770,DB00753,Isoflurane
,16426207,target plasma concentrations,"Actual mean +/- SD plasma ketamine concentrations were 1.07 +/- 0.42 microg/mL, 1.62 +/- 0.98 microg/mL, 3.32 +/- 0.59 microg/mL, 4.92 +/- 2.64 microg/mL, 13.03 +/- 10.49 microg/mL, and 22.80 +/- 25.56 microg/mL for target plasma concentrations of 0.5, 1, 2, 5, 8, and 11 microg/mL, respectively.",Effect of intravenous administration of ketamine on the minimum alveolar concentration of isoflurane in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426207/),[μg] / [ml],5,169771,DB00753,Isoflurane
,16426207,target plasma concentrations,"Actual mean +/- SD plasma ketamine concentrations were 1.07 +/- 0.42 microg/mL, 1.62 +/- 0.98 microg/mL, 3.32 +/- 0.59 microg/mL, 4.92 +/- 2.64 microg/mL, 13.03 +/- 10.49 microg/mL, and 22.80 +/- 25.56 microg/mL for target plasma concentrations of 0.5, 1, 2, 5, 8, and 11 microg/mL, respectively.",Effect of intravenous administration of ketamine on the minimum alveolar concentration of isoflurane in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426207/),[μg] / [ml],8,169772,DB00753,Isoflurane
,16426207,target plasma concentrations,"Actual mean +/- SD plasma ketamine concentrations were 1.07 +/- 0.42 microg/mL, 1.62 +/- 0.98 microg/mL, 3.32 +/- 0.59 microg/mL, 4.92 +/- 2.64 microg/mL, 13.03 +/- 10.49 microg/mL, and 22.80 +/- 25.56 microg/mL for target plasma concentrations of 0.5, 1, 2, 5, 8, and 11 microg/mL, respectively.",Effect of intravenous administration of ketamine on the minimum alveolar concentration of isoflurane in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426207/),[μg] / [ml],11,169773,DB00753,Isoflurane
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],6.8,171104,DB00753,Isoflurane
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],9.56,171105,DB00753,Isoflurane
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],9.30,171106,DB00753,Isoflurane
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],18.99,171107,DB00753,Isoflurane
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,6,171264,DB00753,Isoflurane
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,2,171265,DB00753,Isoflurane
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,1.15,171266,DB00753,Isoflurane
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,1.7,171267,DB00753,Isoflurane
,11038831,fractional end tidal alveolar concentration (Fa),The fractional end tidal alveolar concentration (Fa) was adjusted to 1MAC during the maintenance of anesthsia.,"[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),,1,171268,DB00753,Isoflurane
,1824669,volume of distribution at steady state,"The pharmacokinetic variables were (normal vs hepatic failure vs renal failure, respectively): volume of distribution at steady state (220 +/- 110 vs 290 +/- 60 vs 270 +/- 130 mL/kg [mean +/- SD]), plasma clearance (2.7 +/- 1.6 vs 2.3 +/- 0.4 vs 1.2 +/- 0.7 mL.kg-1.min-1), mean residence time (95.2 +/- 57 vs 129.4 +/- 30 vs 270 +/- 210 min), and elimination half-life (99 +/- 54 vs 115 +/- 31 vs 221 +/- 156 min).",Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824669/),[ml] / [kg],220,172498,DB00753,Isoflurane
,1824669,volume of distribution at steady state,"The pharmacokinetic variables were (normal vs hepatic failure vs renal failure, respectively): volume of distribution at steady state (220 +/- 110 vs 290 +/- 60 vs 270 +/- 130 mL/kg [mean +/- SD]), plasma clearance (2.7 +/- 1.6 vs 2.3 +/- 0.4 vs 1.2 +/- 0.7 mL.kg-1.min-1), mean residence time (95.2 +/- 57 vs 129.4 +/- 30 vs 270 +/- 210 min), and elimination half-life (99 +/- 54 vs 115 +/- 31 vs 221 +/- 156 min).",Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824669/),[ml] / [kg],290,172499,DB00753,Isoflurane
,1824669,volume of distribution at steady state,"The pharmacokinetic variables were (normal vs hepatic failure vs renal failure, respectively): volume of distribution at steady state (220 +/- 110 vs 290 +/- 60 vs 270 +/- 130 mL/kg [mean +/- SD]), plasma clearance (2.7 +/- 1.6 vs 2.3 +/- 0.4 vs 1.2 +/- 0.7 mL.kg-1.min-1), mean residence time (95.2 +/- 57 vs 129.4 +/- 30 vs 270 +/- 210 min), and elimination half-life (99 +/- 54 vs 115 +/- 31 vs 221 +/- 156 min).",Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824669/),[ml] / [kg],270,172500,DB00753,Isoflurane
,1824669,plasma clearance,"The pharmacokinetic variables were (normal vs hepatic failure vs renal failure, respectively): volume of distribution at steady state (220 +/- 110 vs 290 +/- 60 vs 270 +/- 130 mL/kg [mean +/- SD]), plasma clearance (2.7 +/- 1.6 vs 2.3 +/- 0.4 vs 1.2 +/- 0.7 mL.kg-1.min-1), mean residence time (95.2 +/- 57 vs 129.4 +/- 30 vs 270 +/- 210 min), and elimination half-life (99 +/- 54 vs 115 +/- 31 vs 221 +/- 156 min).",Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824669/),[ml] / [kg·min],2.7,172501,DB00753,Isoflurane
,1824669,plasma clearance,"The pharmacokinetic variables were (normal vs hepatic failure vs renal failure, respectively): volume of distribution at steady state (220 +/- 110 vs 290 +/- 60 vs 270 +/- 130 mL/kg [mean +/- SD]), plasma clearance (2.7 +/- 1.6 vs 2.3 +/- 0.4 vs 1.2 +/- 0.7 mL.kg-1.min-1), mean residence time (95.2 +/- 57 vs 129.4 +/- 30 vs 270 +/- 210 min), and elimination half-life (99 +/- 54 vs 115 +/- 31 vs 221 +/- 156 min).",Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824669/),[ml] / [kg·min],2.3,172502,DB00753,Isoflurane
,1824669,plasma clearance,"The pharmacokinetic variables were (normal vs hepatic failure vs renal failure, respectively): volume of distribution at steady state (220 +/- 110 vs 290 +/- 60 vs 270 +/- 130 mL/kg [mean +/- SD]), plasma clearance (2.7 +/- 1.6 vs 2.3 +/- 0.4 vs 1.2 +/- 0.7 mL.kg-1.min-1), mean residence time (95.2 +/- 57 vs 129.4 +/- 30 vs 270 +/- 210 min), and elimination half-life (99 +/- 54 vs 115 +/- 31 vs 221 +/- 156 min).",Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824669/),[ml] / [kg·min],1.2,172503,DB00753,Isoflurane
,1824669,mean residence time,"The pharmacokinetic variables were (normal vs hepatic failure vs renal failure, respectively): volume of distribution at steady state (220 +/- 110 vs 290 +/- 60 vs 270 +/- 130 mL/kg [mean +/- SD]), plasma clearance (2.7 +/- 1.6 vs 2.3 +/- 0.4 vs 1.2 +/- 0.7 mL.kg-1.min-1), mean residence time (95.2 +/- 57 vs 129.4 +/- 30 vs 270 +/- 210 min), and elimination half-life (99 +/- 54 vs 115 +/- 31 vs 221 +/- 156 min).",Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824669/),min,95.2,172504,DB00753,Isoflurane
,1824669,mean residence time,"The pharmacokinetic variables were (normal vs hepatic failure vs renal failure, respectively): volume of distribution at steady state (220 +/- 110 vs 290 +/- 60 vs 270 +/- 130 mL/kg [mean +/- SD]), plasma clearance (2.7 +/- 1.6 vs 2.3 +/- 0.4 vs 1.2 +/- 0.7 mL.kg-1.min-1), mean residence time (95.2 +/- 57 vs 129.4 +/- 30 vs 270 +/- 210 min), and elimination half-life (99 +/- 54 vs 115 +/- 31 vs 221 +/- 156 min).",Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824669/),min,129.4,172505,DB00753,Isoflurane
,1824669,mean residence time,"The pharmacokinetic variables were (normal vs hepatic failure vs renal failure, respectively): volume of distribution at steady state (220 +/- 110 vs 290 +/- 60 vs 270 +/- 130 mL/kg [mean +/- SD]), plasma clearance (2.7 +/- 1.6 vs 2.3 +/- 0.4 vs 1.2 +/- 0.7 mL.kg-1.min-1), mean residence time (95.2 +/- 57 vs 129.4 +/- 30 vs 270 +/- 210 min), and elimination half-life (99 +/- 54 vs 115 +/- 31 vs 221 +/- 156 min).",Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824669/),min,270,172506,DB00753,Isoflurane
,1824669,elimination half-life,"The pharmacokinetic variables were (normal vs hepatic failure vs renal failure, respectively): volume of distribution at steady state (220 +/- 110 vs 290 +/- 60 vs 270 +/- 130 mL/kg [mean +/- SD]), plasma clearance (2.7 +/- 1.6 vs 2.3 +/- 0.4 vs 1.2 +/- 0.7 mL.kg-1.min-1), mean residence time (95.2 +/- 57 vs 129.4 +/- 30 vs 270 +/- 210 min), and elimination half-life (99 +/- 54 vs 115 +/- 31 vs 221 +/- 156 min).",Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824669/),min,99,172507,DB00753,Isoflurane
,1824669,elimination half-life,"The pharmacokinetic variables were (normal vs hepatic failure vs renal failure, respectively): volume of distribution at steady state (220 +/- 110 vs 290 +/- 60 vs 270 +/- 130 mL/kg [mean +/- SD]), plasma clearance (2.7 +/- 1.6 vs 2.3 +/- 0.4 vs 1.2 +/- 0.7 mL.kg-1.min-1), mean residence time (95.2 +/- 57 vs 129.4 +/- 30 vs 270 +/- 210 min), and elimination half-life (99 +/- 54 vs 115 +/- 31 vs 221 +/- 156 min).",Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824669/),min,115,172508,DB00753,Isoflurane
,1824669,elimination half-life,"The pharmacokinetic variables were (normal vs hepatic failure vs renal failure, respectively): volume of distribution at steady state (220 +/- 110 vs 290 +/- 60 vs 270 +/- 130 mL/kg [mean +/- SD]), plasma clearance (2.7 +/- 1.6 vs 2.3 +/- 0.4 vs 1.2 +/- 0.7 mL.kg-1.min-1), mean residence time (95.2 +/- 57 vs 129.4 +/- 30 vs 270 +/- 210 min), and elimination half-life (99 +/- 54 vs 115 +/- 31 vs 221 +/- 156 min).",Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824669/),min,221,172509,DB00753,Isoflurane
,9209610,half-life of elimination,"The mean half-life of elimination was 47 s with a 95% confidence interval of 24 to 70 s; that of effect compartment equilibration, 211 s with a 95% confidence range of 139 to 282 s.",Pharmacokinetics and pharmacodynamics of suxamethonium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209610/),s,47,172779,DB00753,Isoflurane
,9209610,half-life of elimination,"The mean half-life of elimination was 47 s with a 95% confidence interval of 24 to 70 s; that of effect compartment equilibration, 211 s with a 95% confidence range of 139 to 282 s.",Pharmacokinetics and pharmacodynamics of suxamethonium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209610/),s,211,172780,DB00753,Isoflurane
,15616060,plasma concentrations,"Actual lidocaine plasma concentrations were 1.06 +/- 0.12, 2.83 +/- 0.39, 4.93 +/- 0.64, 6.86 +/- 0.97, 8.86 +/- 2.10, and 9.84 +/- 1.34 microg/mL for the target concentrations of 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),[μg] / [ml],1.06,176933,DB00753,Isoflurane
,15616060,plasma concentrations,"Actual lidocaine plasma concentrations were 1.06 +/- 0.12, 2.83 +/- 0.39, 4.93 +/- 0.64, 6.86 +/- 0.97, 8.86 +/- 2.10, and 9.84 +/- 1.34 microg/mL for the target concentrations of 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),[μg] / [ml],2.83,176934,DB00753,Isoflurane
,15616060,plasma concentrations,"Actual lidocaine plasma concentrations were 1.06 +/- 0.12, 2.83 +/- 0.39, 4.93 +/- 0.64, 6.86 +/- 0.97, 8.86 +/- 2.10, and 9.84 +/- 1.34 microg/mL for the target concentrations of 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),[μg] / [ml],4.93,176935,DB00753,Isoflurane
,15616060,plasma concentrations,"Actual lidocaine plasma concentrations were 1.06 +/- 0.12, 2.83 +/- 0.39, 4.93 +/- 0.64, 6.86 +/- 0.97, 8.86 +/- 2.10, and 9.84 +/- 1.34 microg/mL for the target concentrations of 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),[μg] / [ml],6.86,176936,DB00753,Isoflurane
,15616060,plasma concentrations,"Actual lidocaine plasma concentrations were 1.06 +/- 0.12, 2.83 +/- 0.39, 4.93 +/- 0.64, 6.86 +/- 0.97, 8.86 +/- 2.10, and 9.84 +/- 1.34 microg/mL for the target concentrations of 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),[μg] / [ml],8.86,176937,DB00753,Isoflurane
,15616060,plasma concentrations,"Actual lidocaine plasma concentrations were 1.06 +/- 0.12, 2.83 +/- 0.39, 4.93 +/- 0.64, 6.86 +/- 0.97, 8.86 +/- 2.10, and 9.84 +/- 1.34 microg/mL for the target concentrations of 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),[μg] / [ml],9.84,176938,DB00753,Isoflurane
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,2.21,176939,DB00753,Isoflurane
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,2.14,176940,DB00753,Isoflurane
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,1.88,176941,DB00753,Isoflurane
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,1.66,176942,DB00753,Isoflurane
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,1.47,176943,DB00753,Isoflurane
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,1.33,176944,DB00753,Isoflurane
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,1.06,176945,DB00753,Isoflurane
,8346837,systemic clearance,"Except for systemic clearance of morphine during halothane and isoflurane (40.1 +/- 6.1 and 53.7 +/- 5.6 mL.min-1.kg-1, respectively), there were no differences in disposition kinetics of free morphine associated with the two inhaled anesthetics.",Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),[ml] / [kg·min],40.1,177182,DB00753,Isoflurane
,8346837,systemic clearance,"Except for systemic clearance of morphine during halothane and isoflurane (40.1 +/- 6.1 and 53.7 +/- 5.6 mL.min-1.kg-1, respectively), there were no differences in disposition kinetics of free morphine associated with the two inhaled anesthetics.",Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),[ml] / [kg·min],53.7,177183,DB00753,Isoflurane
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),hg·mm,42.2,177184,DB00753,Isoflurane
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),mm,55.6,177185,DB00753,Isoflurane
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),h·mm,46.2,177186,DB00753,Isoflurane
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),mm,55.3,177187,DB00753,Isoflurane
,8572357,heart rate,"Without propofol pretreatment, the increase to 8% desflurane transiently increased heart rate (from 63 +/- 3 beats/min to 108 +/- 5 beats/min, mean +/- SEM; P < 0.01), mean arterial pressure (from 73 +/- 1 mmHg to 118 +/- 6 mmHg; P < 0.01), and epinephrine concentration (from 14 +/- 1 pg.ml-1 to 279 +/- 51 pg.ml-1; P < 0.05).",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[beats] / [min],63,177505,DB00753,Isoflurane
,8572357,heart rate,"Without propofol pretreatment, the increase to 8% desflurane transiently increased heart rate (from 63 +/- 3 beats/min to 108 +/- 5 beats/min, mean +/- SEM; P < 0.01), mean arterial pressure (from 73 +/- 1 mmHg to 118 +/- 6 mmHg; P < 0.01), and epinephrine concentration (from 14 +/- 1 pg.ml-1 to 279 +/- 51 pg.ml-1; P < 0.05).",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[beats] / [min],108,177506,DB00753,Isoflurane
,8572357,peak plasma epinephrine concentration,"The peak plasma epinephrine concentration was attenuated by each propofol pretreatment (158 +/- 35 pg.ml-1, propofol given 2 min before, and 146 + 41 pg.ml-1, propofol given 5 min before; P < 0.05), but neither propofol pretreatment modified the cardiovascular or norepinephrine responses.",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[pg] / [ml],158,177507,DB00753,Isoflurane
,8572357,peak plasma epinephrine concentration,"The peak plasma epinephrine concentration was attenuated by each propofol pretreatment (158 +/- 35 pg.ml-1, propofol given 2 min before, and 146 + 41 pg.ml-1, propofol given 5 min before; P < 0.05), but neither propofol pretreatment modified the cardiovascular or norepinephrine responses.",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[pg] / [ml],146,177508,DB00753,Isoflurane
,8602663,recovery times to T(1),"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,28.1,180814,DB00753,Isoflurane
,8602663,recovery times to T(1),"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,47.3,180815,DB00753,Isoflurane
,8602663,T(1) 25% to T(1) 75% recovery index,"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,7.6,180816,DB00753,Isoflurane
,8602663,T(1) 25% to T(1) 75% recovery index,"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,21.9,180817,DB00753,Isoflurane
,8602663,Clearance,"Clearance was 9.0 +/- 1.2 ml x kg-1 x min-1 versus 3.8 +/- 0.3 in the control group (P=0.003), whereas no changes in volumes of distribution at steady-state were observed.",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),[ml] / [kg·min],9.0,180818,DB00753,Isoflurane
,8602663,Clearance,"Clearance was 9.0 +/- 1.2 ml x kg-1 x min-1 versus 3.8 +/- 0.3 in the control group (P=0.003), whereas no changes in volumes of distribution at steady-state were observed.",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),,3.8,180819,DB00753,Isoflurane
,8602663,mean residence time,"Therefore, the mean residence time was halved (17.8 +/- 2.5 vs. 31.9 +/- 2.5 min in control subjects; P=0.001).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,17.8,180820,DB00753,Isoflurane
,8602663,mean residence time,"Therefore, the mean residence time was halved (17.8 +/- 2.5 vs. 31.9 +/- 2.5 min in control subjects; P=0.001).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,31.9,180821,DB00753,Isoflurane
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],0.3 to 97.3,181080,DB00753,Isoflurane
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],6.7,181081,DB00753,Isoflurane
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],402.8,181082,DB00753,Isoflurane
,8541435,total dose,Over a period of 69.2 +/- 39.8 min during resection of the tumor the total dose was 7017 +/- 12433 micrograms.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),μg,7017,181083,DB00753,Isoflurane
more,28455212,elimination half-life,Plasma concentrations of tramadol rapidly decreased in the first 2 hours for both doses with an elimination half-life of more than 40 minutes.,Cardiovascular effects and intraoperative pharmacokinetics of tramadol in sheep undergoing spinal surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28455212/),min,40,183661,DB00753,Isoflurane
,1334687,"time to recovery of 25% neuromuscular transmission, T25","The mean time to recovery of 25% neuromuscular transmission, T25, was greater in the patients with liver failure (57.2 min) than in control patients (18.7 min).",Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1334687/),min,57.2,185052,DB00753,Isoflurane
,1334687,"time to recovery of 25% neuromuscular transmission, T25","The mean time to recovery of 25% neuromuscular transmission, T25, was greater in the patients with liver failure (57.2 min) than in control patients (18.7 min).",Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1334687/),min,18.7,185053,DB00753,Isoflurane
,16415090,pseudo steady-state C,"Under isoflurane anesthesia, male Sprague-Dawley rats were administered i.v. CsA to achieve pseudo steady-state CsA blood concentrations ranging from 0 to approximately 12 microM.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),μM,0 to,185380,DB00753,Isoflurane
,16415090,blood concentrations,"Under isoflurane anesthesia, male Sprague-Dawley rats were administered i.v. CsA to achieve pseudo steady-state CsA blood concentrations ranging from 0 to approximately 12 microM.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),μM,0 to,185381,DB00753,Isoflurane
,16415090,E(max),"The percentage increase in the brain/blood (3)H radioactivity (relative to 0 microM CsA) was described by the Hill equation with E(max), 1290%; EC(50), 7.2 microM; and gamma, 3.8.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),%,1290,185382,DB00753,Isoflurane
,16415090,EC(50),"The percentage increase in the brain/blood (3)H radioactivity (relative to 0 microM CsA) was described by the Hill equation with E(max), 1290%; EC(50), 7.2 microM; and gamma, 3.8.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),μM,7.2,185383,DB00753,Isoflurane
,16415090,gamma,"The percentage increase in the brain/blood (3)H radioactivity (relative to 0 microM CsA) was described by the Hill equation with E(max), 1290%; EC(50), 7.2 microM; and gamma, 3.8.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),,3.8,185384,DB00753,Isoflurane
,15268689,MAC,The baseline isoflurane MAC was 1.51 +/- 0.21% (mean +/- SD).,Effect of transdermally administered fentanyl on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15268689/),%,1.51,189985,DB00753,Isoflurane
,15268689,MAC,Isoflurane MAC determined during administration of fentanyl 25 micro g hour(-1) and naloxone (1.44 +/- 0.16%) and fentanyl 50 micro g hour(-1) and naloxone (1.51 +/- 0.19%) was not significantly different from baseline MAC (1.51 +/- 0.21%).,Effect of transdermally administered fentanyl on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15268689/),%,1,189986,DB00753,Isoflurane
,1443743,end-tidal concentrations,"All patients were anesthetized with nitrous oxide (50-70% in oxygen) and isoflurane (end-tidal concentrations of 1.2 +/- 0.5% and 0.8 +/- 0.2%, mean +/- SD, for control and transplant groups, respectively).",Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),,1,190405,DB00753,Isoflurane
,1443743,end-tidal concentrations,"All patients were anesthetized with nitrous oxide (50-70% in oxygen) and isoflurane (end-tidal concentrations of 1.2 +/- 0.5% and 0.8 +/- 0.2%, mean +/- SD, for control and transplant groups, respectively).",Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),%,0,190406,DB00753,Isoflurane
,1443743,Total plasma clearance,"Total plasma clearance (2.89 +/- 0.25 ml.kg-1.min-1, mean +/- SE) and volume of the central compartment (76.9 +/- 10.6 ml/kg) did not differ between control and renal transplant patients, whereas volume of distribution at steady state was greater in renal transplant patients (264 +/- 19 ml/kg) than in control patients (207 +/- 14 ml/kg).",Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),[ml] / [kg·min],2.89,190407,DB00753,Isoflurane
,1443743,volume of the central compartment,"Total plasma clearance (2.89 +/- 0.25 ml.kg-1.min-1, mean +/- SE) and volume of the central compartment (76.9 +/- 10.6 ml/kg) did not differ between control and renal transplant patients, whereas volume of distribution at steady state was greater in renal transplant patients (264 +/- 19 ml/kg) than in control patients (207 +/- 14 ml/kg).",Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),[ml] / [kg],76.9,190408,DB00753,Isoflurane
,1443743,volume of distribution at steady state,"Total plasma clearance (2.89 +/- 0.25 ml.kg-1.min-1, mean +/- SE) and volume of the central compartment (76.9 +/- 10.6 ml/kg) did not differ between control and renal transplant patients, whereas volume of distribution at steady state was greater in renal transplant patients (264 +/- 19 ml/kg) than in control patients (207 +/- 14 ml/kg).",Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),[ml] / [kg],264,190409,DB00753,Isoflurane
,1443743,volume of distribution at steady state,"Total plasma clearance (2.89 +/- 0.25 ml.kg-1.min-1, mean +/- SE) and volume of the central compartment (76.9 +/- 10.6 ml/kg) did not differ between control and renal transplant patients, whereas volume of distribution at steady state was greater in renal transplant patients (264 +/- 19 ml/kg) than in control patients (207 +/- 14 ml/kg).",Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),[ml] / [kg],207,190410,DB00753,Isoflurane
,1443743,elimination half life,This resulted in a longer elimination half life in renal transplant patients (97.2 +/- 17.3 min) compared to controls (70.9 +/- 4.7 min).,Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),min,97.2,190411,DB00753,Isoflurane
,1443743,elimination half life,This resulted in a longer elimination half life in renal transplant patients (97.2 +/- 17.3 min) compared to controls (70.9 +/- 4.7 min).,Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),min,70.9,190412,DB00753,Isoflurane
,31806432,target plasma concentration (TPC),"Dogs were allocated to group fTCI [target plasma concentration (TPC) 1 ng mL-1] or group PNB (nerve stimulator-guided femoral-sciatic block using 0.2 and 0.1 mL kg-1 of levobupivacaine 0.5%, respectively).",Peripheral nerve block versus systemic analgesia in dogs undergoing tibial plateau levelling osteotomy: Analgesic efficacy and pharmacoeconomics comparison. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806432/),[ng] / [ml],1,190829,DB00753,Isoflurane
,12131108,onset time of maximum effect,"With hypothermia, the central volume of distribution of neostigmine decreased by 38%, and onset time of maximum effect increased (4.6 vs. 5.6 min).",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),min,4.6,192750,DB00753,Isoflurane
,12131108,onset time of maximum effect,"With hypothermia, the central volume of distribution of neostigmine decreased by 38%, and onset time of maximum effect increased (4.6 vs. 5.6 min).",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),min,5.6,192751,DB00753,Isoflurane
,12131108,clearance,"Hypothermia did not change the clearance (696 ml/min), maximum effect, or duration of action of neostigmine.",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),[ml] / [min],696,192752,DB00753,Isoflurane
,7739943,Plasma clearance,Plasma clearance was greater during isoflurane than during balanced anesthesia (4.48 vs 3.49 ml/kg/min).,The effect of isoflurane versus balanced anesthesia on rocuronium's pharmacokinetics and infusion requirement. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7739943/),[ml] / [kg·min],4.48,199576,DB00753,Isoflurane
,7739943,Plasma clearance,Plasma clearance was greater during isoflurane than during balanced anesthesia (4.48 vs 3.49 ml/kg/min).,The effect of isoflurane versus balanced anesthesia on rocuronium's pharmacokinetics and infusion requirement. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7739943/),[ml] / [kg·min],3.49,199577,DB00753,Isoflurane
,18179652,plasma concentration,Mean DMED plasma concentration ranged from 0.23 to 0.47 ng mL(-1) for both groups during the 24-hour CRI with a mean elimination half-life of approximately 0.46 hour.,Dexmedetomidine constant rate infusion for 24 hours during and after propofol or isoflurane anaesthesia in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18179652/),[ng] / [ml],0.23 to 0.47,199977,DB00753,Isoflurane
,18179652,elimination half-life,Mean DMED plasma concentration ranged from 0.23 to 0.47 ng mL(-1) for both groups during the 24-hour CRI with a mean elimination half-life of approximately 0.46 hour.,Dexmedetomidine constant rate infusion for 24 hours during and after propofol or isoflurane anaesthesia in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18179652/),h,0.46,199978,DB00753,Isoflurane
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.29,200615,DB00753,Isoflurane
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.65,200616,DB00753,Isoflurane
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.40,200617,DB00753,Isoflurane
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],6.8,200618,DB00753,Isoflurane
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],14.2,200619,DB00753,Isoflurane
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],40.1,200620,DB00753,Isoflurane
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,3.7,200621,DB00753,Isoflurane
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,5.7,200622,DB00753,Isoflurane
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,22,200623,DB00753,Isoflurane
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],15.7,200624,DB00753,Isoflurane
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],12.4,200625,DB00753,Isoflurane
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],16.4,200626,DB00753,Isoflurane
,32448336,Bioavailability,"Bioavailability for IM and SC was 62.6 and 40%, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),%,62.6,200627,DB00753,Isoflurane
,32448336,Bioavailability,"Bioavailability for IM and SC was 62.6 and 40%, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),%,40,200628,DB00753,Isoflurane
,32448336,Maximum plasma concentrations,"Maximum plasma concentrations of buprenorphine were 6.2 and 1.3 ng/mL at 0.14 and 0.33 h after IM and SC administration, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [ml],6.2,200629,DB00753,Isoflurane
,32448336,Maximum plasma concentrations,"Maximum plasma concentrations of buprenorphine were 6.2 and 1.3 ng/mL at 0.14 and 0.33 h after IM and SC administration, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [ml],1.3,200630,DB00753,Isoflurane
,2897176,time to attain 100% twitch depression (onset time),Only the time to attain 100% twitch depression (onset time) was prolonged in liver disease patients (2.8 +/- 0.7 min; mean +/- SD) as compared to control patients (1.9 +/- 0.4 min).,Vecuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897176/),min,2.8,205186,DB00753,Isoflurane
,2897176,time to attain 100% twitch depression (onset time),Only the time to attain 100% twitch depression (onset time) was prolonged in liver disease patients (2.8 +/- 0.7 min; mean +/- SD) as compared to control patients (1.9 +/- 0.4 min).,Vecuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897176/),min,1.9,205187,DB00753,Isoflurane
,2897176,time to the reappearance of twitch response,The time to the reappearance of twitch response was 32.7 +/- 9.7 min in patients with liver disease and 36.8 +/- 15.5 min in controls.,Vecuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897176/),min,32.7,205188,DB00753,Isoflurane
,2897176,time to the reappearance of twitch response,The time to the reappearance of twitch response was 32.7 +/- 9.7 min in patients with liver disease and 36.8 +/- 15.5 min in controls.,Vecuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897176/),min,36.8,205189,DB00753,Isoflurane
,17238960,PaCO2,PaCO2 was maintained between 29 and 41 mmHg (3.9-5.5 kPa) and body temperature was kept between 37.8 and 39.3 degrees C.,The effects of ketamine on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17238960/),mmhg,29 and 41,206489,DB00753,Isoflurane
,17238960,plasma concentrations,"These infusion rates corresponded to ketamine plasma concentrations of 1.75 +/- 0.21, 2.69 +/- 0.40, and 5.36 +/- 1.19 microg mL(-1).",The effects of ketamine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17238960/),[μg] / [ml],1.75,206490,DB00753,Isoflurane
,17238960,plasma concentrations,"These infusion rates corresponded to ketamine plasma concentrations of 1.75 +/- 0.21, 2.69 +/- 0.40, and 5.36 +/- 1.19 microg mL(-1).",The effects of ketamine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17238960/),[μg] / [ml],2.69,206491,DB00753,Isoflurane
,17238960,plasma concentrations,"These infusion rates corresponded to ketamine plasma concentrations of 1.75 +/- 0.21, 2.69 +/- 0.40, and 5.36 +/- 1.19 microg mL(-1).",The effects of ketamine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17238960/),[μg] / [ml],5.36,206492,DB00753,Isoflurane
,7978186,peak plasma concentrations,The peak plasma concentrations were P 10.6 +/- 1.5 micrograms.,[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),μg,10.6,207603,DB00753,Isoflurane
,7978186,M,ml-1 and M 12.4 +/- 2.6 micrograms.,[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),μg,12.4,207604,DB00753,Isoflurane
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,15,207605,DB00753,Isoflurane
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,50,207606,DB00753,Isoflurane
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,25,207607,DB00753,Isoflurane
,1608154,elimination half-life,"However, the mean elimination half-life of bupivacaine was significantly longer in patients with TMP [5.0 +/- 1.7 (SD) hr] compared with those with PGE1 (3.1 +/- 1.4 hr).",[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),h,5.0,208111,DB00753,Isoflurane
,1608154,elimination half-life,"However, the mean elimination half-life of bupivacaine was significantly longer in patients with TMP [5.0 +/- 1.7 (SD) hr] compared with those with PGE1 (3.1 +/- 1.4 hr).",[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),h,3.1,208112,DB00753,Isoflurane
,1608154,total clearance,The total clearance of bupivacaine was greater in patients with PGE1 (345 +/- 150 ml.min-1) compared with those with TMP (248 +/- 66 ml.min-1).,[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),[ml] / [min],345,208113,DB00753,Isoflurane
,1608154,total clearance,The total clearance of bupivacaine was greater in patients with PGE1 (345 +/- 150 ml.min-1) compared with those with TMP (248 +/- 66 ml.min-1).,[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),[ml] / [min],248,208114,DB00753,Isoflurane
,15717705,k(ip),"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),1/[min],0.374,211082,DB00753,Isoflurane
,15717705,k(ei),"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),1/[min],0.151,211083,DB00753,Isoflurane
,15717705,EC50,"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),[μg] / [l],98,211084,DB00753,Isoflurane
,15717705,gamma,"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),,3.7,211085,DB00753,Isoflurane
,23015620,half-lives of distribution [t(1/2α),"The half-lives of distribution [t(1/2α): 1.77 (0.57) min] and elimination [t(1/2β): 17.66 (5.56) min] in the bolus group were shorter than those in the infusion group [14.12 (4.04) min, 58.21 (11.39) min, P<0.01].",Pharmacokinetics of intravenous emulsified isoflurane in beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23015620/),min,1.77,212997,DB00753,Isoflurane
,23015620,elimination [t(1/2β),"The half-lives of distribution [t(1/2α): 1.77 (0.57) min] and elimination [t(1/2β): 17.66 (5.56) min] in the bolus group were shorter than those in the infusion group [14.12 (4.04) min, 58.21 (11.39) min, P<0.01].",Pharmacokinetics of intravenous emulsified isoflurane in beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23015620/),min,17.66,212998,DB00753,Isoflurane
,23015620,elimination [t(1/2β),"The half-lives of distribution [t(1/2α): 1.77 (0.57) min] and elimination [t(1/2β): 17.66 (5.56) min] in the bolus group were shorter than those in the infusion group [14.12 (4.04) min, 58.21 (11.39) min, P<0.01].",Pharmacokinetics of intravenous emulsified isoflurane in beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23015620/),min,14.12,212999,DB00753,Isoflurane
,23015620,elimination [t(1/2β),"The half-lives of distribution [t(1/2α): 1.77 (0.57) min] and elimination [t(1/2β): 17.66 (5.56) min] in the bolus group were shorter than those in the infusion group [14.12 (4.04) min, 58.21 (11.39) min, P<0.01].",Pharmacokinetics of intravenous emulsified isoflurane in beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23015620/),min,58.21,213000,DB00753,Isoflurane
,23015620,apparent volume of the central compartment [V(1),"The apparent volume of the central compartment [V(1), 0.377 (0.138) litre kg(-1)] in the bolus group was less than that in the infusion group [0.809 (0.077) litre kg(-1), P<0.01].",Pharmacokinetics of intravenous emulsified isoflurane in beagle dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23015620/),[l] / [kg],0.377,213001,DB00753,Isoflurane
,23015620,apparent volume of the central compartment [V(1),"The apparent volume of the central compartment [V(1), 0.377 (0.138) litre kg(-1)] in the bolus group was less than that in the infusion group [0.809 (0.077) litre kg(-1), P<0.01].",Pharmacokinetics of intravenous emulsified isoflurane in beagle dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23015620/),[l] / [kg],0.809,213002,DB00753,Isoflurane
,23015620,total body clearance [Cl,"The total body clearance [Cl, 0.043 (0.032) litre kg(-1) min(-1)] in the bolus group was greater than that in the infusion group [0.028 (0.008) litre kg(-1) min(-1)].",Pharmacokinetics of intravenous emulsified isoflurane in beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23015620/),[l] / [kg·min],0.043,213003,DB00753,Isoflurane
,23015620,total body clearance [Cl,"The total body clearance [Cl, 0.043 (0.032) litre kg(-1) min(-1)] in the bolus group was greater than that in the infusion group [0.028 (0.008) litre kg(-1) min(-1)].",Pharmacokinetics of intravenous emulsified isoflurane in beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23015620/),[l] / [kg·min],0.028,213004,DB00753,Isoflurane
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,83,215807,DB00753,Isoflurane
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,82,215808,DB00753,Isoflurane
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,81,215809,DB00753,Isoflurane
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,77,215810,DB00753,Isoflurane
,2888422,heart rate,"In awake dogs, verapamil induced an increase in heart rate (24 +/- 5 bpm) and PR interval (35 +/- 9 msec) and a decrease in mean arterial pressure (-5 +/- 2 mmHg) and dP/dt (-494 +/- 116 mmHg/s).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),bpm,24,215811,DB00753,Isoflurane
,7997393,clearance,"However, clearance was significantly higher and elimination half-life lower in the group taking long-term drugs: clearance 6.94 +/- 4.64 versus 3.47 +/- 0.16 ml.kg-1.min-1, and elimination half-life 50.6 +/- 13.9 versus 90.7 +/- 22.4 minutes, respectively (p < 0.05).",Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997393/),[ml] / [kg·min],6.94,215860,DB00753,Isoflurane
,7997393,clearance,"However, clearance was significantly higher and elimination half-life lower in the group taking long-term drugs: clearance 6.94 +/- 4.64 versus 3.47 +/- 0.16 ml.kg-1.min-1, and elimination half-life 50.6 +/- 13.9 versus 90.7 +/- 22.4 minutes, respectively (p < 0.05).",Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997393/),[ml] / [kg·min],3.47,215861,DB00753,Isoflurane
,7997393,elimination half-life,"However, clearance was significantly higher and elimination half-life lower in the group taking long-term drugs: clearance 6.94 +/- 4.64 versus 3.47 +/- 0.16 ml.kg-1.min-1, and elimination half-life 50.6 +/- 13.9 versus 90.7 +/- 22.4 minutes, respectively (p < 0.05).",Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997393/),min,50.6,215862,DB00753,Isoflurane
,7997393,elimination half-life,"However, clearance was significantly higher and elimination half-life lower in the group taking long-term drugs: clearance 6.94 +/- 4.64 versus 3.47 +/- 0.16 ml.kg-1.min-1, and elimination half-life 50.6 +/- 13.9 versus 90.7 +/- 22.4 minutes, respectively (p < 0.05).",Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997393/),min,90.7,215863,DB00753,Isoflurane
,9840210,Cl,"Mean Cl for the cis-trans, trans-trans and cis-cis isomers were 19.98, 13.53 and 3.47 mL min(-1) kg(-1) respectively and the corresponding mean Vdss were 0.29, 0.24 and 1.00 L kg(-1).",Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-four response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840210/),[ml] / [kg·min],19.98,217066,DB00753,Isoflurane
,9840210,Cl,"Mean Cl for the cis-trans, trans-trans and cis-cis isomers were 19.98, 13.53 and 3.47 mL min(-1) kg(-1) respectively and the corresponding mean Vdss were 0.29, 0.24 and 1.00 L kg(-1).",Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-four response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840210/),[ml] / [kg·min],13.53,217067,DB00753,Isoflurane
,9840210,Cl,"Mean Cl for the cis-trans, trans-trans and cis-cis isomers were 19.98, 13.53 and 3.47 mL min(-1) kg(-1) respectively and the corresponding mean Vdss were 0.29, 0.24 and 1.00 L kg(-1).",Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-four response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840210/),[ml] / [kg·min],3.47,217068,DB00753,Isoflurane
,9840210,Vdss,"Mean Cl for the cis-trans, trans-trans and cis-cis isomers were 19.98, 13.53 and 3.47 mL min(-1) kg(-1) respectively and the corresponding mean Vdss were 0.29, 0.24 and 1.00 L kg(-1).",Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-four response. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840210/),,0.29,217069,DB00753,Isoflurane
,9840210,Vdss,"Mean Cl for the cis-trans, trans-trans and cis-cis isomers were 19.98, 13.53 and 3.47 mL min(-1) kg(-1) respectively and the corresponding mean Vdss were 0.29, 0.24 and 1.00 L kg(-1).",Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-four response. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840210/),,0.24,217070,DB00753,Isoflurane
,9840210,Vdss,"Mean Cl for the cis-trans, trans-trans and cis-cis isomers were 19.98, 13.53 and 3.47 mL min(-1) kg(-1) respectively and the corresponding mean Vdss were 0.29, 0.24 and 1.00 L kg(-1).",Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-four response. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840210/),[l] / [kg],1.00,217071,DB00753,Isoflurane
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,65,221707,DB00753,Isoflurane
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,80,221708,DB00753,Isoflurane
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,93,221709,DB00753,Isoflurane
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,132,221710,DB00753,Isoflurane
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],37,221711,DB00753,Isoflurane
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],39,221712,DB00753,Isoflurane
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],41,221713,DB00753,Isoflurane
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],64,221714,DB00753,Isoflurane
,3752571,cardiac output,Verapamil administered to awake animals resulted in a decrease from baseline in mean arterial pressure; 95 +/- 8 mmHg versus 108 +/- 4 mmHg (P less than 0.05): and an increase in cardiac output; 2.60 +/- 0.33 1 X min-1 versus 1.93 +/- 0.22 1 X min-1 (P less than 0.05).,Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),[1] / [min],2.60,221715,DB00753,Isoflurane
,3752571,cardiac output,Verapamil administered to awake animals resulted in a decrease from baseline in mean arterial pressure; 95 +/- 8 mmHg versus 108 +/- 4 mmHg (P less than 0.05): and an increase in cardiac output; 2.60 +/- 0.33 1 X min-1 versus 1.93 +/- 0.22 1 X min-1 (P less than 0.05).,Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),[1] / [min],1.93,221716,DB00753,Isoflurane
,10839928,minimum alveolar concentration,"The dogs were studied while awake and while anesthetized with 1.7%, 2.6%, and 3.5% isoflurane (1.15, 1.7, and 2.3 minimum alveolar concentration, respectively) in a randomized order determined by a Latin square experimental design.",Isoflurane alters the recirculatory pharmacokinetics of physiologic markers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839928/),,1.15,222019,DB00753,Isoflurane
,10839928,minimum alveolar concentration,"The dogs were studied while awake and while anesthetized with 1.7%, 2.6%, and 3.5% isoflurane (1.15, 1.7, and 2.3 minimum alveolar concentration, respectively) in a randomized order determined by a Latin square experimental design.",Isoflurane alters the recirculatory pharmacokinetics of physiologic markers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839928/),,1.7,222020,DB00753,Isoflurane
,10839928,minimum alveolar concentration,"The dogs were studied while awake and while anesthetized with 1.7%, 2.6%, and 3.5% isoflurane (1.15, 1.7, and 2.3 minimum alveolar concentration, respectively) in a randomized order determined by a Latin square experimental design.",Isoflurane alters the recirculatory pharmacokinetics of physiologic markers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839928/),,2.3,222021,DB00753,Isoflurane
,31318080,intercompartment distribution clearances,"Typical value (% interindividual variability) for the three-compartment volumes (ml/kg), the metabolic clearance and the two intercompartment distribution clearances (ml min-1 kg-1 ) were 168 (259), 318 (35), 1,425 (18), 12.4 (31), 39.1 (18), and 29.6 (17), respectively.",Pharmacokinetics of dexmedetomidine during administration of vatinoxan in male neutered cats anesthetized with isoflurane. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31318080/),[ml] / [kg·min],12.4,222691,DB00753,Isoflurane
,31318080,intercompartment distribution clearances,"Typical value (% interindividual variability) for the three-compartment volumes (ml/kg), the metabolic clearance and the two intercompartment distribution clearances (ml min-1 kg-1 ) were 168 (259), 318 (35), 1,425 (18), 12.4 (31), 39.1 (18), and 29.6 (17), respectively.",Pharmacokinetics of dexmedetomidine during administration of vatinoxan in male neutered cats anesthetized with isoflurane. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31318080/),[ml] / [kg·min],39.1,222692,DB00753,Isoflurane
,31318080,intercompartment distribution clearances,"Typical value (% interindividual variability) for the three-compartment volumes (ml/kg), the metabolic clearance and the two intercompartment distribution clearances (ml min-1 kg-1 ) were 168 (259), 318 (35), 1,425 (18), 12.4 (31), 39.1 (18), and 29.6 (17), respectively.",Pharmacokinetics of dexmedetomidine during administration of vatinoxan in male neutered cats anesthetized with isoflurane. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31318080/),[ml] / [kg·min],29.6,222693,DB00753,Isoflurane
,31982339,volume of distribution,"Estimated typical population value (interindividual variability) for volume of distribution and clearance were 10.3 (232%) L kg-1 and 9.9 (508%) L minute-1 kg-1, respectively.",Plasma dopamine concentrations following dopamine infusion to isoflurane-anesthetized New Zealand White rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31982339/),,10.3,223401,DB00753,Isoflurane
,31982339,clearance,"Estimated typical population value (interindividual variability) for volume of distribution and clearance were 10.3 (232%) L kg-1 and 9.9 (508%) L minute-1 kg-1, respectively.",Plasma dopamine concentrations following dopamine infusion to isoflurane-anesthetized New Zealand White rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31982339/),,9.9,223402,DB00753,Isoflurane
,7954994,Times to awakening,"Times to awakening were longer in Group H: 3.1 +/- 3.4 hr, than in Group L: 1.1 +/- 0.8 h, P < 0.05.",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),h,3.1,224529,DB00753,Isoflurane
,7954994,Times to awakening,"Times to awakening were longer in Group H: 3.1 +/- 3.4 hr, than in Group L: 1.1 +/- 0.8 h, P < 0.05.",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),h,1.1,224530,DB00753,Isoflurane
,7954994,t1/2 beta,"Mean values were t1/2 beta = 4.4 +/- 1.5 hr, CL = 5.94 +/- 1.69 mL.min-1.kg-1, Vd = 3.13 +/- 1.07 L.kg-1.(ABSTRACT TRUNCATED AT 400 WORDS)",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),h,4.4,224531,DB00753,Isoflurane
,7954994,CL,"Mean values were t1/2 beta = 4.4 +/- 1.5 hr, CL = 5.94 +/- 1.69 mL.min-1.kg-1, Vd = 3.13 +/- 1.07 L.kg-1.(ABSTRACT TRUNCATED AT 400 WORDS)",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),[ml] / [kg·min],5.94,224532,DB00753,Isoflurane
,7954994,Vd,"Mean values were t1/2 beta = 4.4 +/- 1.5 hr, CL = 5.94 +/- 1.69 mL.min-1.kg-1, Vd = 3.13 +/- 1.07 L.kg-1.(ABSTRACT TRUNCATED AT 400 WORDS)",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),[l] / [kg],3.13,224533,DB00753,Isoflurane
,1282046,half-life,"Spectrophotometric analysis of rat serum showed rapid elimination of MB from the vascular system, with a half-life of 3.5 +/- 1.9 minutes.","Limitations of monastral blue as a vascular label: rapid rate of clearance is age-dependent, and interactions with anesthetics depress arterial blood pressure in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282046/),min,3.5,225221,DB00753,Isoflurane
,8610903,infusion rate requirements to achieve 90% muscle relaxation,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),1/[min·μgram-kg],0.42,227640,DB00753,Isoflurane
,8610903,infusion rate requirements to achieve 90% muscle relaxation,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),1/[min·μgram-kg],0.40,227641,DB00753,Isoflurane
,8610903,CVEC,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],144.4,227642,DB00753,Isoflurane
,8610903,CVEC,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],149.7,227643,DB00753,Isoflurane
,8610903,CDES,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],57.2,227644,DB00753,Isoflurane
,8610903,CDES,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],65.3,227645,DB00753,Isoflurane
,8610903,clearance,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ml] / [kg·min],2.85,227646,DB00753,Isoflurane
,8610903,clearance,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ml] / [kg·min],3.19,227647,DB00753,Isoflurane
,10551581,central volume of distribution,"The central volume of distribution was increased to 131 (104-141) ml/kg in patients with cirrhosis (P < 0.01), compared with 75 (47-146) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],131,237005,DB00753,Isoflurane
,10551581,central volume of distribution,"The central volume of distribution was increased to 131 (104-141) ml/kg in patients with cirrhosis (P < 0.01), compared with 75 (47-146) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],75,237006,DB00753,Isoflurane
,10551581,total apparent volume of distribution,"The total apparent volume of distribution was also increased (P < 0.05) to 331 (284-488) ml/kg in patients with cirrhosis, compared with 221 (124-285) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],331,237007,DB00753,Isoflurane
,10551581,total apparent volume of distribution,"The total apparent volume of distribution was also increased (P < 0.05) to 331 (284-488) ml/kg in patients with cirrhosis, compared with 221 (124-285) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],221,237008,DB00753,Isoflurane
,10551581,elimination half-life,The elimination half-life was 88 (77-102) min in controls and 90 (76-117) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,88,237009,DB00753,Isoflurane
,10551581,elimination half-life,The elimination half-life was 88 (77-102) min in controls and 90 (76-117) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,90,237010,DB00753,Isoflurane
,10551581,Plasma clearance,"Plasma clearance was increased (P < 0.05) to 6.9 (6.1-8.9) ml x min(-1) x kg(-1) in patients with cirrhosis, compared with 5.3 (4.2-8.4) ml x min(-1) x kg(-1) in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg·min],6.9,237011,DB00753,Isoflurane
,10551581,Plasma clearance,"Plasma clearance was increased (P < 0.05) to 6.9 (6.1-8.9) ml x min(-1) x kg(-1) in patients with cirrhosis, compared with 5.3 (4.2-8.4) ml x min(-1) x kg(-1) in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg·min],5.3,237012,DB00753,Isoflurane
,10551581,Onset time,Onset time was 65 (40-110) s in controls and of 60 (52-240) s in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),s,65,237013,DB00753,Isoflurane
,10551581,Onset time,Onset time was 65 (40-110) s in controls and of 60 (52-240) s in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),s,60,237014,DB00753,Isoflurane
,10551581,Time to return to 90%,Time to return to 90% of thumb adduction force control value was of 49 (28-80) min in controls and 47 (28-71) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,49,237015,DB00753,Isoflurane
,10551581,Time to return to 90%,Time to return to 90% of thumb adduction force control value was of 49 (28-80) min in controls and 47 (28-71) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,47,237016,DB00753,Isoflurane
,9229987,recovery score,"Recovery times were significantly shorter for remifentanil-isoflurane than for remifentanil-propofol (Table 3): spontaneous ventilation 5.1 vs 8.1 min (P < 0.05), extubation 5.5 vs 8.6 min (P < 0.02), post-anaesthesia recovery score > or = 9 of 10 points 6.2 vs 11.3 min (P < 0.01), and arrival at PACU 16.2 vs 19.2 min (P < 0.01).",[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229987/),min,6.2,237367,DB00753,Isoflurane
,9229987,recovery score,"Recovery times were significantly shorter for remifentanil-isoflurane than for remifentanil-propofol (Table 3): spontaneous ventilation 5.1 vs 8.1 min (P < 0.05), extubation 5.5 vs 8.6 min (P < 0.02), post-anaesthesia recovery score > or = 9 of 10 points 6.2 vs 11.3 min (P < 0.01), and arrival at PACU 16.2 vs 19.2 min (P < 0.01).",[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229987/),min,11.3,237368,DB00753,Isoflurane
,9229987,recovery score,"Recovery times were significantly shorter for remifentanil-isoflurane than for remifentanil-propofol (Table 3): spontaneous ventilation 5.1 vs 8.1 min (P < 0.05), extubation 5.5 vs 8.6 min (P < 0.02), post-anaesthesia recovery score > or = 9 of 10 points 6.2 vs 11.3 min (P < 0.01), and arrival at PACU 16.2 vs 19.2 min (P < 0.01).",[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229987/),min,16.2,237369,DB00753,Isoflurane
,9229987,recovery score,"Recovery times were significantly shorter for remifentanil-isoflurane than for remifentanil-propofol (Table 3): spontaneous ventilation 5.1 vs 8.1 min (P < 0.05), extubation 5.5 vs 8.6 min (P < 0.02), post-anaesthesia recovery score > or = 9 of 10 points 6.2 vs 11.3 min (P < 0.01), and arrival at PACU 16.2 vs 19.2 min (P < 0.01).",[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229987/),min,19.2,237370,DB00753,Isoflurane
,16269600,tumor-to-ipsilateral brain ratio,The high boron concentration in brain tumor (76.6 mug/g) and the high tumor-to-ipsilateral brain ratio (6.3) may afford enough radiation doses to destroy the tumor cells while sparing the normal tissues in boron neutron capture therapy.,Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),,6.3,237761,DB00753,Isoflurane
,16269600,k(el),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),1/[min],0.0206,237762,DB00753,Isoflurane
,16269600,k(12),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),1/[min],0.0260,237763,DB00753,Isoflurane
,16269600,k(12),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),1/[min],0.0039,237764,DB00753,Isoflurane
,16269600,k(21),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),1/[min],0.0260,237765,DB00753,Isoflurane
,16269600,V(1),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),ml,3.1,237766,DB00753,Isoflurane
,12221061,ED50,"In sinus rhythm dogs, peak AERP changes resulting from intravenous KB infusion ranged from (mean+/-SEM) 4.4+/-0.4% (1 mg/kg) to 14.8+/-2.6% (5 mg/kg; ED50=1.9 mg/kg).","Kb-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12221061/),[mg] / [kg],1.9,238470,DB00753,Isoflurane
,12221061,Plasma drug concentration,Plasma drug concentration peaked at the end of KB infusions (30.86+/-3.26 nmol/L; n=4 dogs) and declined to 0.56+/-0.19 nmol/L after 100 minutes.,"Kb-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12221061/),[nM] / [l],30.86,238471,DB00753,Isoflurane
,12221061,Plasma drug concentration,Plasma drug concentration peaked at the end of KB infusions (30.86+/-3.26 nmol/L; n=4 dogs) and declined to 0.56+/-0.19 nmol/L after 100 minutes.,"Kb-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12221061/),[nM] / [l],0.56,238472,DB00753,Isoflurane
,12221061,tissue-to-plasma drug concentration gradient,The cardiac tissue-to-plasma drug concentration gradient averaged approximately 40 at 100 minutes after start of KB infusion.,"Kb-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12221061/),,40,238473,DB00753,Isoflurane
,8447208,elimination half-life,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),min,182,240009,DB00753,Isoflurane
,8447208,Vdss,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),l,169,240010,DB00753,Isoflurane
,8447208,plasma clearance,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),[ml] / [min],910,240011,DB00753,Isoflurane
,33629899,volumes of distribution,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg],692,244692,DB00753,Isoflurane
,33629899,volumes of distribution,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg],"2,439",244693,DB00753,Isoflurane
,33629899,volumes of distribution,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg],"2,293",244694,DB00753,Isoflurane
,33629899,metabolic clearance,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg·min],23.3,244695,DB00753,Isoflurane
,33629899,first,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg·min],556.4,244696,DB00753,Isoflurane
,33629899,second,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg·min],556.4,244697,DB00753,Isoflurane
,33629899,distributional clearances,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg·min],556.4,244698,DB00753,Isoflurane
,33629899,distributional clearances,"Estimated typical values for volumes of distribution were 692 mL/kg for the central compartment and 2,439 and 2,293 mL/kg for the first and second peripheral compartments, respectively, with metabolic clearance of 23.3 mL/kg/min and first and second distributional clearances of 556.4 and 51.8 mL/kg/min, respectively.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ml] / [kg·min],51.8,244699,DB00753,Isoflurane
,33629899,bioavailability,Typical bioavailability after IM administration was 79%.,Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),%,79,244700,DB00753,Isoflurane
,33629899,Elimination half-life,"Elimination half-life was 177 minutes, and maximum plasma concentration after IM administration was 950 ng/mL.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),min,177,244701,DB00753,Isoflurane
,33629899,maximum plasma concentration,"Elimination half-life was 177 minutes, and maximum plasma concentration after IM administration was 950 ng/mL.",Pharmacokinetics and pharmacodynamics of methadone administered intravenously and intramuscularly to isoflurane-anesthetized chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629899/),[ng] / [ml],950,244702,DB00753,Isoflurane
,30085862,target plasma concentrations,"In phase 2, pharmacokinetic values for individual birds were used for administration of fentanyl to achieve target plasma concentrations of 8, 16, and 32 ng/mL.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],8,245487,DB00753,Isoflurane
,30085862,target plasma concentrations,"In phase 2, pharmacokinetic values for individual birds were used for administration of fentanyl to achieve target plasma concentrations of 8, 16, and 32 ng/mL.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],16,245488,DB00753,Isoflurane
,30085862,target plasma concentrations,"In phase 2, pharmacokinetic values for individual birds were used for administration of fentanyl to achieve target plasma concentrations of 8, 16, and 32 ng/mL.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],32,245489,DB00753,Isoflurane
,30085862,plasma concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],0,245490,DB00753,Isoflurane
,30085862,plasma concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],5.01,245491,DB00753,Isoflurane
,30085862,plasma concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],12.12,245492,DB00753,Isoflurane
,30085862,plasma concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],24.93,245493,DB00753,Isoflurane
,30085862,MACiso,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),%,2.09,245494,DB00753,Isoflurane
,30085862,MACiso,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),%,1.45,245495,DB00753,Isoflurane
,30085862,MACiso,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),%,1.34,245496,DB00753,Isoflurane
,30085862,MACiso,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),%,0.95,245497,DB00753,Isoflurane
,30085862,target concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],0,245498,DB00753,Isoflurane
,30085862,target concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],8,245499,DB00753,Isoflurane
,30085862,target concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],16,245500,DB00753,Isoflurane
,30085862,target concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],32,245501,DB00753,Isoflurane
,8123396,Onset time for maximum block,"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),s,61,246879,DB00753,Isoflurane
,8123396,duration of clinical relaxation (T1(25)),"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),s,65,246880,DB00753,Isoflurane
,8123396,duration of clinical relaxation (T1(25)),"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,55,246881,DB00753,Isoflurane
,8123396,duration of clinical relaxation (T1(25)),"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,42,246882,DB00753,Isoflurane
,8123396,duration of clinical relaxation (T1(25)),"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,28,246883,DB00753,Isoflurane
,8123396,recovery index,"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,55,246884,DB00753,Isoflurane
,8123396,recovery index,"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,42,246885,DB00753,Isoflurane
,8123396,recovery index,"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,19,246886,DB00753,Isoflurane
,8123396,time for TOF ratio to,"The time for TOF ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,0,246887,DB00753,Isoflurane
,8123396,time for TOF ratio to,"The time for TOF ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,99,246888,DB00753,Isoflurane
,8123396,time for TOF ratio to,"The time for TOF ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,73,246889,DB00753,Isoflurane
,8123396,rates of clearance,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) ml kg-1 min-1 and 3.7 (1.4) ml kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) P < 0.05).",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),[ml] / [kg·min],2.5,246890,DB00753,Isoflurane
,8123396,rates of clearance,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) ml kg-1 min-1 and 3.7 (1.4) ml kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) P < 0.05).",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),[ml] / [kg·min],3.7,246891,DB00753,Isoflurane
,8123396,mean residence times,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) ml kg-1 min-1 and 3.7 (1.4) ml kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) P < 0.05).",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,97.1,246892,DB00753,Isoflurane
,8123396,mean residence times,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) ml kg-1 min-1 and 3.7 (1.4) ml kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) P < 0.05).",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,58.3,246893,DB00753,Isoflurane
,12602585,half-life,Typical half-life of MOR in plasma was 40 to 60 minutes and related to dose.,Interactions of morphine and isoflurane in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602585/),min,40 to 60,247028,DB00753,Isoflurane
,12602585,PaCO2,Mean PaCO2 increased from 70 mm Hg before MOR to 88 to 102 mm Hg for 30 to 240 minutes after the high dose of MOR.,Interactions of morphine and isoflurane in horses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602585/),hg·mm,70,247029,DB00753,Isoflurane
,12602585,PaCO2,Mean PaCO2 increased from 70 mm Hg before MOR to 88 to 102 mm Hg for 30 to 240 minutes after the high dose of MOR.,Interactions of morphine and isoflurane in horses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602585/),hg·mm,88,247030,DB00753,Isoflurane
,12602585,PaCO2,Mean PaCO2 increased from 70 mm Hg before MOR to 88 to 102 mm Hg for 30 to 240 minutes after the high dose of MOR.,Interactions of morphine and isoflurane in horses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602585/),hg·mm,102,247031,DB00753,Isoflurane
,26752560,clearance,"Mean population parameter estimates for maternal propofol clearance and central volume of distribution were 4.17 L/min and 37.7 L, respectively, in a typical ewe with a median heart rate of 135 beats/min.",Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26752560/),[l] / [min],4.17,250722,DB00753,Isoflurane
,26752560,central volume of distribution,"Mean population parameter estimates for maternal propofol clearance and central volume of distribution were 4.17 L/min and 37.7 L, respectively, in a typical ewe with a median heart rate of 135 beats/min.",Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26752560/),l,37.7,250723,DB00753,Isoflurane
,26752560,inter-compartment clearance,The estimated population maternal-fetal inter-compartment clearance was 0.0138 L/min and the volume of distribution of propofol in the fetus was 0.144 L.,Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26752560/),[l] / [min],0.0138,250724,DB00753,Isoflurane
,26752560,volume of distribution,The estimated population maternal-fetal inter-compartment clearance was 0.0138 L/min and the volume of distribution of propofol in the fetus was 0.144 L.,Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26752560/),l,0.144,250725,DB00753,Isoflurane
,7893030,plasma clearance,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),[ml] / [min],217,252827,DB00753,Isoflurane
,7893030,volume of the central compartment,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),l,5.96,252828,DB00753,Isoflurane
,7893030,volume of the central compartment,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),l,7.87,252829,DB00753,Isoflurane
,7893030,volume of distribution at steady state,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),l,16.4,252830,DB00753,Isoflurane
,7893030,volume of distribution at steady state,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),l,23.4,252831,DB00753,Isoflurane
,7893030,elimination half-life,"In turn, elimination half-life was longer in patients with liver disease (111 min) compared to controls (75.4 min).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),min,111,252832,DB00753,Isoflurane
,7893030,elimination half-life,"In turn, elimination half-life was longer in patients with liver disease (111 min) compared to controls (75.4 min).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),min,75.4,252833,DB00753,Isoflurane
,19795933,plasma concentrations,"Mean + or - SD fentanyl plasma concentrations were 13.9 + or - 2.6 ng/mL, 20.1 + or - 3.6 ng/mL, and 24.1 + or - 2.4 ng/mL for target concentrations of 16, 24, and 32 ng/mL, respectively.",Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],13.9,253465,DB00753,Isoflurane
,19795933,plasma concentrations,"Mean + or - SD fentanyl plasma concentrations were 13.9 + or - 2.6 ng/mL, 20.1 + or - 3.6 ng/mL, and 24.1 + or - 2.4 ng/mL for target concentrations of 16, 24, and 32 ng/mL, respectively.",Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],20.1,253466,DB00753,Isoflurane
,19795933,plasma concentrations,"Mean + or - SD fentanyl plasma concentrations were 13.9 + or - 2.6 ng/mL, 20.1 + or - 3.6 ng/mL, and 24.1 + or - 2.4 ng/mL for target concentrations of 16, 24, and 32 ng/mL, respectively.",Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],24.1,253467,DB00753,Isoflurane
,19795933,target concentrations,"Mean + or - SD fentanyl plasma concentrations were 13.9 + or - 2.6 ng/mL, 20.1 + or - 3.6 ng/mL, and 24.1 + or - 2.4 ng/mL for target concentrations of 16, 24, and 32 ng/mL, respectively.",Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],16,253468,DB00753,Isoflurane
,19795933,target concentrations,"Mean + or - SD fentanyl plasma concentrations were 13.9 + or - 2.6 ng/mL, 20.1 + or - 3.6 ng/mL, and 24.1 + or - 2.4 ng/mL for target concentrations of 16, 24, and 32 ng/mL, respectively.",Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],24,253469,DB00753,Isoflurane
,19795933,target concentrations,"Mean + or - SD fentanyl plasma concentrations were 13.9 + or - 2.6 ng/mL, 20.1 + or - 3.6 ng/mL, and 24.1 + or - 2.4 ng/mL for target concentrations of 16, 24, and 32 ng/mL, respectively.",Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],32,253470,DB00753,Isoflurane
,19795933,plasma target concentration,Results of the study did not verify an isoflurane-sparing effect of fentanyl at a plasma target concentration of 16 ng/mL.,Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],16,253471,DB00753,Isoflurane
,7734250,Apparent steady state blood propofol concentrations,Apparent steady state blood propofol concentrations were 3.41 (SD 0.69) micrograms ml-1 in the weight-corrected group and 3.46 (0.79) microgram ml-1 in the standard dose group.,Propofol administered by a manual infusion regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7734250/),[μg] / [ml],3.41,255240,DB00753,Isoflurane
,7734250,Apparent steady state blood propofol concentrations,Apparent steady state blood propofol concentrations were 3.41 (SD 0.69) micrograms ml-1 in the weight-corrected group and 3.46 (0.79) microgram ml-1 in the standard dose group.,Propofol administered by a manual infusion regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7734250/),[μg] / [ml],3.46,255241,DB00753,Isoflurane
,9278198,25% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,53.7,258187,DB00753,Isoflurane
,9278198,25% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,42.3,258188,DB00753,Isoflurane
,9278198,50% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,73.9,258189,DB00753,Isoflurane
,9278198,50% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,52.6,258190,DB00753,Isoflurane
,9278198,75% recovery,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,84.2,258191,DB00753,Isoflurane
,9278198,T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,84.2,258192,DB00753,Isoflurane
,9278198,T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,66.8,258193,DB00753,Isoflurane
,9278198,recovery of T4:T1,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,114.9,258194,DB00753,Isoflurane
,9278198,recovery of T4:T1,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,76.1,258195,DB00753,Isoflurane
,9278198,Plasma clearance,Plasma clearance was significantly reduced in the cirrhotic group (2.66 (0.60) vs 3.70 (1.03) ml kg(-1) min (-1); P<0.005).,The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),[-1·min·ml] / [kg],2.66,258196,DB00753,Isoflurane
,9278198,Plasma clearance,Plasma clearance was significantly reduced in the cirrhotic group (2.66 (0.60) vs 3.70 (1.03) ml kg(-1) min (-1); P<0.005).,The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),[-1·min·ml] / [kg],3.70,258197,DB00753,Isoflurane
,9278198,redistribution (,"The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,28.3,258198,DB00753,Isoflurane
,9278198,"t1/2,lambda1","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,28.3,258199,DB00753,Isoflurane
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,16.8,258200,DB00753,Isoflurane
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,143,258201,DB00753,Isoflurane
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,92,258202,DB00753,Isoflurane
,9278198,exit rate constant for,"The exit rate constant for the effect compartment k(eo) was significantly increased in the cirrhotic group (0.25 (0.18) vs 0.16 (0.06) min(-1); P < 0.05), but cirrhosis had no significant effect on the parameters of the concentration-effect relationship Cp(ss)(50) and gamma.",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),1/[min],0.25,258203,DB00753,Isoflurane
,9278198,exit rate constant for,"The exit rate constant for the effect compartment k(eo) was significantly increased in the cirrhotic group (0.25 (0.18) vs 0.16 (0.06) min(-1); P < 0.05), but cirrhosis had no significant effect on the parameters of the concentration-effect relationship Cp(ss)(50) and gamma.",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),1/[min],0.16,258204,DB00753,Isoflurane
,7826789,Clearance,Clearance of the cis-trans and trans-trans isomers was reduced significantly in the cirrhotic compared with the healthy group: cis-trans (median (range)) 44 (15-121) ml kg-1 min-1 vs 95 (57-213) ml kg-1 min-1 (P < 0.05); trans-trans 32 (12-64) ml kg-1 min-1 vs 70 (34-101) ml kg-1 min-1 (P < 0.05).,Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826789/),[ml] / [kg·min],44,258563,DB00753,Isoflurane
,7826789,Clearance,Clearance of the cis-trans and trans-trans isomers was reduced significantly in the cirrhotic compared with the healthy group: cis-trans (median (range)) 44 (15-121) ml kg-1 min-1 vs 95 (57-213) ml kg-1 min-1 (P < 0.05); trans-trans 32 (12-64) ml kg-1 min-1 vs 70 (34-101) ml kg-1 min-1 (P < 0.05).,Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826789/),[ml] / [kg·min],95,258564,DB00753,Isoflurane
,7826789,Clearance,Clearance of the cis-trans and trans-trans isomers was reduced significantly in the cirrhotic compared with the healthy group: cis-trans (median (range)) 44 (15-121) ml kg-1 min-1 vs 95 (57-213) ml kg-1 min-1 (P < 0.05); trans-trans 32 (12-64) ml kg-1 min-1 vs 70 (34-101) ml kg-1 min-1 (P < 0.05).,Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826789/),[ml] / [kg·min],32,258565,DB00753,Isoflurane
,7826789,Clearance,Clearance of the cis-trans and trans-trans isomers was reduced significantly in the cirrhotic compared with the healthy group: cis-trans (median (range)) 44 (15-121) ml kg-1 min-1 vs 95 (57-213) ml kg-1 min-1 (P < 0.05); trans-trans 32 (12-64) ml kg-1 min-1 vs 70 (34-101) ml kg-1 min-1 (P < 0.05).,Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826789/),[ml] / [kg·min],70,258566,DB00753,Isoflurane
,7826789,clearance,The difference in the clearance of the cis-cis isomer in the cirrhotic (4.2 (2.9-12.1) ml kg-1 min-1) compared with the healthy group (5.2 (2.9-8.9) ml kg-1 min-1) was not significant with this sample size.,Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826789/),[ml] / [kg·min],4.2,258567,DB00753,Isoflurane
,7826789,clearance,The difference in the clearance of the cis-cis isomer in the cirrhotic (4.2 (2.9-12.1) ml kg-1 min-1) compared with the healthy group (5.2 (2.9-8.9) ml kg-1 min-1) was not significant with this sample size.,Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826789/),[ml] / [kg·min],5.2,258568,DB00753,Isoflurane
,2363549,Vdc,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),[l] / [kg],0.66,258834,DB00753,Isoflurane
,2363549,Vdc,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),[l] / [kg],0.27,258835,DB00753,Isoflurane
,2363549,t1/2 pi,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,5.4,258836,DB00753,Isoflurane
,2363549,t1/2 pi,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,2.7,258837,DB00753,Isoflurane
,2363549,plasma clearance,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),[ml] / [kg·min],17.2,258838,DB00753,Isoflurane
,2363549,plasma clearance,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),[ml] / [kg·min],10.9,258839,DB00753,Isoflurane
,2363549,t1/2 alpha,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,37.1,258840,DB00753,Isoflurane
,2363549,t1/2 alpha,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,26.8,258841,DB00753,Isoflurane
,2363549,t1/2 beta,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,260,258842,DB00753,Isoflurane
,2363549,t1/2 beta,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,175,258843,DB00753,Isoflurane
,2363549,Vdss,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),1/[kg],2.5,258844,DB00753,Isoflurane
,2363549,Vdss,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),1/[kg],2.8,258845,DB00753,Isoflurane
,2363549,Vd beta,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),1/[kg],4.1,258846,DB00753,Isoflurane
,2363549,Vd beta,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),1/[kg],4.0,258847,DB00753,Isoflurane
,2363549,MRT,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,228,258848,DB00753,Isoflurane
,2363549,MRT,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,172,258849,DB00753,Isoflurane
,11927473,clinical duration,"After the second bolus, clinical duration was 20 +/- 6 min in the propofol group vs 39 +/- 8 min in the isoflurane group (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),min,20,260546,DB00753,Isoflurane
,11927473,clinical duration,"After the second bolus, clinical duration was 20 +/- 6 min in the propofol group vs 39 +/- 8 min in the isoflurane group (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),min,39,260547,DB00753,Isoflurane
,11927473,effect compartment concentration corresponding to 50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],1008,260548,DB00753,Isoflurane
,11927473,effect compartment concentration corresponding to 50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],592,260549,DB00753,Isoflurane
,11927473,EC50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],1008,260550,DB00753,Isoflurane
,11927473,EC50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],592,260551,DB00753,Isoflurane
,27692704,wash-in (,"The pharmacokinetics of isoflurane and sevoflurane were almost identical, with a rapid wash-in (time to reach 50% of arterial steady state) concentration of 0.87±0.97 minutes and 1.14±0.35 minutes for isoflurane and sevoflurane, respectively, and a biphasic venous elimination with a terminal half-life of approximately 10 minutes for both compounds.","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),min,0.87,263710,DB00753,Isoflurane
,27692704,wash-in (,"The pharmacokinetics of isoflurane and sevoflurane were almost identical, with a rapid wash-in (time to reach 50% of arterial steady state) concentration of 0.87±0.97 minutes and 1.14±0.35 minutes for isoflurane and sevoflurane, respectively, and a biphasic venous elimination with a terminal half-life of approximately 10 minutes for both compounds.","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),min,1.14,263711,DB00753,Isoflurane
,27692704,time to reach 50% of arterial steady state) concentration,"The pharmacokinetics of isoflurane and sevoflurane were almost identical, with a rapid wash-in (time to reach 50% of arterial steady state) concentration of 0.87±0.97 minutes and 1.14±0.35 minutes for isoflurane and sevoflurane, respectively, and a biphasic venous elimination with a terminal half-life of approximately 10 minutes for both compounds.","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),min,0.87,263712,DB00753,Isoflurane
,27692704,time to reach 50% of arterial steady state) concentration,"The pharmacokinetics of isoflurane and sevoflurane were almost identical, with a rapid wash-in (time to reach 50% of arterial steady state) concentration of 0.87±0.97 minutes and 1.14±0.35 minutes for isoflurane and sevoflurane, respectively, and a biphasic venous elimination with a terminal half-life of approximately 10 minutes for both compounds.","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),min,1.14,263713,DB00753,Isoflurane
,27692704,terminal half-life,"The pharmacokinetics of isoflurane and sevoflurane were almost identical, with a rapid wash-in (time to reach 50% of arterial steady state) concentration of 0.87±0.97 minutes and 1.14±0.35 minutes for isoflurane and sevoflurane, respectively, and a biphasic venous elimination with a terminal half-life of approximately 10 minutes for both compounds.","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),min,10,263714,DB00753,Isoflurane
,27692704,High-sensitivity troponin concentrations,"High-sensitivity troponin concentrations on the first postoperative morning were 0.355±0.312 µg/mL and 0.225±0.111 µg/mL in the isoflurane and sevoflurane groups, respectively (p = 0.147).","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),[μg] / [ml],0.355,263715,DB00753,Isoflurane
,27692704,High-sensitivity troponin concentrations,"High-sensitivity troponin concentrations on the first postoperative morning were 0.355±0.312 µg/mL and 0.225±0.111 µg/mL in the isoflurane and sevoflurane groups, respectively (p = 0.147).","Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692704/),[μg] / [ml],0.225,263716,DB00753,Isoflurane
,7940538,blood,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,0.65,265020,DB00753,Isoflurane
,7940538,blood,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,3.0,265021,DB00753,Isoflurane
,7940538,blood,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,21,265022,DB00753,Isoflurane
,7940538,blood,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,106,265023,DB00753,Isoflurane
,7940538,concentrations,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,0.65,265024,DB00753,Isoflurane
,7940538,concentrations,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,3.0,265025,DB00753,Isoflurane
,7940538,concentrations,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,21,265026,DB00753,Isoflurane
,7940538,concentrations,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,106,265027,DB00753,Isoflurane
,7940538,concentrations,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,211,265028,DB00753,Isoflurane
,7940538,peak blood [14C]formate concentrations,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,0.07,265029,DB00753,Isoflurane
,7940538,peak blood [14C]formate concentrations,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,0.25,265030,DB00753,Isoflurane
,7940538,peak blood [14C]formate concentrations,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,2.3,265031,DB00753,Isoflurane
,7940538,peak blood [14C]formate concentrations,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,2.8,265032,DB00753,Isoflurane
,7940538,peak blood [14C]formate concentrations,"Average (+/- SD) end-of-exposure blood [14C]MeOH concentrations were 0.65 +/- 0.3, 3.0 +/- 0.8, 21 +/- 16, 106 +/- 84, and 211 +/- 71 microM, while average (+/- SD) peak blood [14C]formate concentrations were 0.07 +/- 0.02, 0.25 +/- 0.09, 2.3 +/- 2.9, 2.8 +/- 1.7, and 9.5 +/- 4.7 microM following MeOH inhalation at 10, 45, 200, 900, and 900-FD ppm, respectively.",Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940538/),μM,9.5,265033,DB00753,Isoflurane
,7743571,K,"The ICG clearance was less (P < 0.05) in the 2 MAC HAL-N2O group (K, 0.087 min-1) than with either awake (K, 0.131 min-1) or other groups (K, 0.114 and 0.144 min-1, in the 1 MAC HAL and ISO-N2O groups, respectively) in spite of a similar degree of the depletion of MAP in 2 MAC ISO-N2O group (K, 0.124 min-1).",Noninvasive ICG clearance test for estimating hepatic blood flow during halothane and isoflurane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7743571/),1/[min],0.087,270709,DB00753,Isoflurane
,7743571,K,"The ICG clearance was less (P < 0.05) in the 2 MAC HAL-N2O group (K, 0.087 min-1) than with either awake (K, 0.131 min-1) or other groups (K, 0.114 and 0.144 min-1, in the 1 MAC HAL and ISO-N2O groups, respectively) in spite of a similar degree of the depletion of MAP in 2 MAC ISO-N2O group (K, 0.124 min-1).",Noninvasive ICG clearance test for estimating hepatic blood flow during halothane and isoflurane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7743571/),1/[min],0.131,270710,DB00753,Isoflurane
,7743571,K,"The ICG clearance was less (P < 0.05) in the 2 MAC HAL-N2O group (K, 0.087 min-1) than with either awake (K, 0.131 min-1) or other groups (K, 0.114 and 0.144 min-1, in the 1 MAC HAL and ISO-N2O groups, respectively) in spite of a similar degree of the depletion of MAP in 2 MAC ISO-N2O group (K, 0.124 min-1).",Noninvasive ICG clearance test for estimating hepatic blood flow during halothane and isoflurane anaesthesia. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7743571/),1/[min],0.114,270711,DB00753,Isoflurane
,7743571,K,"The ICG clearance was less (P < 0.05) in the 2 MAC HAL-N2O group (K, 0.087 min-1) than with either awake (K, 0.131 min-1) or other groups (K, 0.114 and 0.144 min-1, in the 1 MAC HAL and ISO-N2O groups, respectively) in spite of a similar degree of the depletion of MAP in 2 MAC ISO-N2O group (K, 0.124 min-1).",Noninvasive ICG clearance test for estimating hepatic blood flow during halothane and isoflurane anaesthesia. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7743571/),1/[min],0.144,270712,DB00753,Isoflurane
,7743571,K,"The ICG clearance was less (P < 0.05) in the 2 MAC HAL-N2O group (K, 0.087 min-1) than with either awake (K, 0.131 min-1) or other groups (K, 0.114 and 0.144 min-1, in the 1 MAC HAL and ISO-N2O groups, respectively) in spite of a similar degree of the depletion of MAP in 2 MAC ISO-N2O group (K, 0.124 min-1).",Noninvasive ICG clearance test for estimating hepatic blood flow during halothane and isoflurane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7743571/),1/[min],0.124,270713,DB00753,Isoflurane
,32222343,volume of distribution at steady state (Vss),"For the ketamine only model, the volume of distribution at steady state (Vss) was 3217 mL kg-1, metabolic clearance was 88 mL minute-1 kg-1 and the terminal half-life was 59 minutes.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),[ml] / [kg],3217,271010,DB00753,Isoflurane
,32222343,metabolic clearance,"For the ketamine only model, the volume of distribution at steady state (Vss) was 3217 mL kg-1, metabolic clearance was 88 mL minute-1 kg-1 and the terminal half-life was 59 minutes.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),[ml] / [kg·min],88,271011,DB00753,Isoflurane
,32222343,terminal half-life,"For the ketamine only model, the volume of distribution at steady state (Vss) was 3217 mL kg-1, metabolic clearance was 88 mL minute-1 kg-1 and the terminal half-life was 59 minutes.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),min,59,271012,DB00753,Isoflurane
,32222343,Vss,"For the model including both ketamine and norketamine, Vss were 3224 and 2073 mL kg-1, total metabolic clearance was 107 and 52 mL minute-1 kg-1 and terminal half-lives were 52 and 55 minutes for the parent drug and its metabolite, respectively.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),[ml] / [kg],3224,271013,DB00753,Isoflurane
,32222343,Vss,"For the model including both ketamine and norketamine, Vss were 3224 and 2073 mL kg-1, total metabolic clearance was 107 and 52 mL minute-1 kg-1 and terminal half-lives were 52 and 55 minutes for the parent drug and its metabolite, respectively.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),[ml] / [kg],2073,271014,DB00753,Isoflurane
,32222343,total metabolic clearance,"For the model including both ketamine and norketamine, Vss were 3224 and 2073 mL kg-1, total metabolic clearance was 107 and 52 mL minute-1 kg-1 and terminal half-lives were 52 and 55 minutes for the parent drug and its metabolite, respectively.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),[ml] / [kg·min],107,271015,DB00753,Isoflurane
,32222343,total metabolic clearance,"For the model including both ketamine and norketamine, Vss were 3224 and 2073 mL kg-1, total metabolic clearance was 107 and 52 mL minute-1 kg-1 and terminal half-lives were 52 and 55 minutes for the parent drug and its metabolite, respectively.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),[ml] / [kg·min],52,271016,DB00753,Isoflurane
,32222343,terminal half-lives,"For the model including both ketamine and norketamine, Vss were 3224 and 2073 mL kg-1, total metabolic clearance was 107 and 52 mL minute-1 kg-1 and terminal half-lives were 52 and 55 minutes for the parent drug and its metabolite, respectively.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),min,52,271017,DB00753,Isoflurane
,32222343,terminal half-lives,"For the model including both ketamine and norketamine, Vss were 3224 and 2073 mL kg-1, total metabolic clearance was 107 and 52 mL minute-1 kg-1 and terminal half-lives were 52 and 55 minutes for the parent drug and its metabolite, respectively.",Pharmacokinetics of ketamine following a short intravenous infusion to isoflurane-anesthetized New Zealand White rabbits (Oryctolagus cuniculus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222343/),min,55,271018,DB00753,Isoflurane
